Abstract Titles

Poster Presentation Dates

All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.

Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.


Search word or phrase:

# Type Title Authors Category Keywords
1 Poster Presentation Tumour associated macrophages in HPV-related carcinoma with adenoid cystic like features of the sinonasal tract; a review of three cases Kasimu U. Adoke, MBBS, FMCPath; Jonathan Madukwe; Faruk Mohammed, Msc; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma
2 Poster Presentation The Multi-physics Automated Reconfigurable Separation (MARS®) System Provides High Purity, High Recovery and High Throughput Enrichment of Immune Cells for Immunotherapy Liping Yu, MD Ph.D.; Gregory Schneider, Ph.D.; Alice Wang, Ph.D.; Biomarkers, Immune Monitoring and Novel Technologies CAR T cells; Immune monitoring; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
3 Poster Presentation Butyrophilin-3A is Expressed in Multiple Solid Tumors: Translational Research Supporting the EVICTION Study with ICT01, an Anti-BTN3A mAb activating Vg9Vd2 T-Cells Clement Ghigo; Aude de Gassard; Patrick Brune; Caroline Imbert; Clemence Demerle; Marie-Sarah Rouviere; René Hoet; Daniel Olive; Emmanuel Valentin, PhD; Emmanuel Valentin, PhD; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Biomarkers; Immune monitoring; T cell; Targeted therapy
4 Poster Presentation Molecularly guided multiplexed digital spatial analysis reveals differential gene expression profiles in the WNT-β-catenin pathway between melanoma and prostate tumors Anushka Dikshit, PhD; Dan Zollinger; Karen Nguyen; Jill McKay-Fleisch; Kit Fuhrman, MS PhD; Xiao-jun Ma, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; RNA; Solid tumors; Tumor microenvironment
5 Poster Presentation Multiple Myeloma Flow Cytometry Panel Validated for Clinical Monitoring of Patients Bevan Gang, PhD; Vicky Sgouroudis, PhD; Virginia Litwin; Anita Boyapati; Biomarkers, Immune Monitoring and Novel Technologies Antibody; B cell; Biomarkers; Immune monitoring; Tumor antigens
6 Poster Presentation Pre-clinical pharmacodynamic biomarker assays of immune modulation can translate to inform exploratory endpoints of target engagement in first-in-human clinical trial stages of drug discovery Russell J. Garland, PhD; Christopher Kirkham, PhD; Michelle Yap, PhD; Louise S. Brackenbury, PhD; Tommaso Iannitti, PhD; Robert Nunan; S R. Jenkinson; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation; T cell; T cell lineages
7 Poster Presentation Prognostic Factors for Overall Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Therapy – The MELimmune Score Soraia Lobo-Martins, MD; Diogo Martins-Branco; Patrícia Miguel Semedo; Cecília Melo Alvim; Ana Maria Monteiro; Inês Vendrell; Emanuel Gouveia; Maria José Passos; Luís Costa; André Mansinho; Rita Teixeira de Sousa; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Inflammation; Solid tumors
8 Poster Presentation Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist Aung Naing, MD, FACP; Daniel D. Karp, MD; Sarina A. Piha-Paul, MD; Cara Haymaker, PhD; Edwin R. Parra, MD, PhD; Fei Yang, MD, Ph.D.; Shubham Pant, MD; David S. Hong, MD; Siqing Fu, MD, PhD; Timothy A. Yap, MD, PhD; Bettzy Stephen, MBBS; Yali Yang, PhD; Heather Lin, MS, PhD; Cheuk Hong Leung, MS; Naval Daver, MD; Yeonjoo Choi, MD; Joud Hajjar, MD; Ignacio Wistuba, MD; Patrick M. Hwu, MD; Funda Meric-Bernstam, MD; Jordi Rodon; Biomarkers, Immune Monitoring and Novel Technologies Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors
9 Poster Presentation Mesenchymal Features of a Novel 27-Gene Algorithm Associate with Canonical Tumor Promoting Signaling Pathways which may Identify Therapeutic Options for Immunotherapy Resistant Patients Tyler J. Nielsen, MS; Rob S. Seitz; Douglas T. Ross, MD, PhD; David R. Hout, PhD; Brock L. Schweitzer, PhD; Biomarkers, Immune Monitoring and Novel Technologies Angiogenesis; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
10 Poster Presentation A multiparameter flow cytometry assay to monitor natural killer cell proliferation and activation in immuno-oncology clinical trials Jennifer Tsau, PhD; Brittney Atzmiller; David Quinn, PhD; Tanya Mulvey; Sema Kurtulus, PhD; Jennifer Mataraza, PhD; Shabnam Tangri, PhD; Naveen Dakappagari, PhD; Ghanashyam Sarikonda, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Clinical trial; Monocyte/Macrophage; NK/NK T cell; T cell
11 Poster Presentation A Multi-physics Approach Enabling Rare Cell Isolation with High Recovery and High Purity Liping Yu; Silin Sa, PhD; Alice Wang, Ph.D.; Biomarkers, Immune Monitoring and Novel Technologies B cell; Biomarkers; Gene expression; NK/NK T cell; Proteomics; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
12 Poster Presentation Development of an in vitro assay to assess bispecific T cell engager using T cells from CD3e humanized mice Jun Zhou; Shuang Zhu; Hongjuan Zhang, PhD; Lei Zheng; Mingfa Zang; Annie Xiaoyu An; Shuzong Wang; Davy Xuesong Ouyang; Henry Q. Li; Yujun Huang; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Bispecifics; T cell
13 Poster Presentation Use of anti-viral T cells to model HLA-restricted anti-tumor cytotoxic lymphocyte responses Michael Overstreet, PhD; Vanessa M. Muniz-Medina; Ruoyan Chen; James Kurasawa; Stacy R. Kentner; Deepali Malhotra, PhD; Jane Osbourn; Jill Walker; Gordon Moody; Michael Overstreet, PhD; Michael Overstreet, PhD; Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy; Checkpoint blockade; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs)
14 Poster Presentation Novel CD3 epsilon humanized N-terminal epitope model for assessment of efficacy of T-cell engagers Gaëlle Martin; Fabiane Sonego; Audrey Beringer; Chloé Beuraud; Yacine Cherifi; Alexandre Fraichard; Patricia Isnard-Petit; Kader Thiam, PhD; Fabiane Sônego, PhD, MS; Biomarkers, Immune Monitoring and Novel Technologies Bispecifics; Inflammation; T cell; Targeted therapy
15 Poster Presentation A novel CD28 humanized mouse model for efficacy assessment of CD28-targeting therapies Fabiane Sônego, PhD, MS; Gaelle Martin, PhD; Chloé Beuraud; Audrey Beringer; Yacine Cherifi; Alexandre Fraichard; Patricia Isnard-Petit; Kader Thiam; Biomarkers, Immune Monitoring and Novel Technologies Costimulation; Inflammation; T cell; Targeted therapy
16 Poster Presentation Antibody profiling of prostate cancer patients reveals differences in antibody signatures among disease stages and following treatment Hemanth K. Potluri, BA; Hemanth K. Potluri, BA; Tun Lee Ng; Michael A. Newton, PhD; Jin Zhang, PhD; Christopher A. Maher, PhD; Peter S. Nelson, MD; Douglas G. McNeel, MD, PhD; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Autoimmunity; Bioinformatics; Biomarkers; Vaccine
17 Poster Presentation Activity sensors for noninvasive monitoring of immune response and tumor resistance during immune checkpoint blockade therapy Quoc Mac, BS; James Bowen; Hathaichanok Phuengkham; Anirudh Sivakumar; Congmin Xu; Fang-Yi Su; Samuel Z. Stentz; Hyoung Sim; Adrian Harris; Tonia Li; Peng Qiu; Gabriel Kwong; Quoc Mac, BS; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
18 Poster Presentation New method of assessing tumor heterogeneity utilizing both circulating tumor DNA and tissue DNA to predict the response to immunotherapy Jaeyoun Choi, M.D.; Myungwoo Nam, MD; Stanislav Fridland; Jinyoung Hwang; Chan Mi Jung; Christmann Low; Young Kwang Chae, MD, MPH, MBA; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade
19 Poster Presentation Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients Zheng Feng; Juergen Scheuenpflug, PhD; Mengyao Tan; Danyi Wang; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; Regulatory T cell (Treg cell); RNA; Solid tumors; T cell; Tumor microenvironment
20 Poster Presentation Quantification of sBCMA in Human Plasma using a High-Throughput Mass Spectrometry Workflow for Exploratory, CAP/CLIA or Regulated Studies Luca Genovesi, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Clinical trial; Leukemia/Lymphoma; Proteomics
21 Oral Presentation Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients Michal Harel, PhD; Coren Lahav, MSc; Eyal Jacob, PhD; Eran Issler, MSc; Haim Bar, PhD; Adam P. Dicker, MD, PhD; Ofer Sharon, MD; Antonietta Bacchiocchi, MSc; Ruth Halaban, PhD; Mario Sznol, MD; Yuval Shaked, PhD; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Checkpoint blockade; Clinical trial; Immune suppression; Proteomics; Solid tumors; Systems biology
23 Poster Presentation Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer Pashtoon M. Kasi, MD, MS; Carlos HF. Chan, MD, PhD; Pashtoon M. Kasi, MD, MS; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; Tumor antigens; Tumor evasion
24 Poster Presentation Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade Pashtoon M. Kasi, MD, MS; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Clinical study; Neoantigens; Solid tumors
25 Poster Presentation Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring Georges Azzi, MD; Shifra Krinshpun, MS, LCGC; Antony Tin, PhD; Allyson K. Malashevich, PhD; Meenakshi Malhotra; Paul Billings, MD, PhD; Angel Rodriguez, MD; Alexey Aleshin, MD, MBA; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant
26 Poster Presentation ctDNA clearance and radiographic resolution of lymph node metastasis in a patient with metastatic microsatellite stable colorectal cancer on immunotherapy Charles J. Schneider, MD, FACP; Michael Krainock, MD; Meenakshi Malhotra; Paul Billings, MD, PhD; Alexey Aleshin, MD, MBA; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Chemotherapy; Immune adjuvant; Solid tumors
27 Poster Presentation The role of ligands of activatory receptor NKG2D in the immune-dependent pathogenesis and evolution of inflammatory bowel disease (IBD) Heba Sidahmed; Shilpa Ravindran, MSc; Harshitha S. Manjunath; William Mifsud; Adrian Charles; Adham A. Ammar; Muhammad U. Khan; Saad Al-Kaabi; Anthony Akobeng; Muneera J. Al-Mohannadi; Mamoun Elawad; Sara Tomei, PhD; Cristina Maccalli, PhD; Biomarkers, Immune Monitoring and Novel Technologies Autoimmunity; Biomarkers; Gene expression; Genetic polymorphism; Inflammation
28 Poster Presentation Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies Michael Smith, PhD; Robert C. Newton; Sherry Owens; Xiaohua Gong, PhD; Chuan Tian, PhD; Janet Maleski, RN, BSN; Lance Leopold, MD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Coinhibition; Inflammation; Tumor microenvironment
29 Poster Presentation Profiling Tumor Circulating Cell-Free DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of Somatic Mutations Simo V. Zhang, PhD; Mengyao Tan; Fabio C. P. Navarro; Josette M. Northcott; Shuyuan Ma; Christopher S. Nelson; Devayani P. Bhave, PhD; L. Gordon Bentley; Manju Chinnappa; Dan Norton; Gabor Bartha, PhD; Jason Harris; John Lyle, PhD; Sean M. Boyle, PhD, MS; John S. West, MBA; Richard Chen, MD, MS; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune monitoring
30 Poster Presentation NLR (Neutrophil Lymphocyte Ratio) and PLR (Platelet Lymphocyte Ratio) Changes as a Predictor of Eventual Treatment Failure and Death on Nivolumab Therapy in Renal Cell Carcinoma Arnab Basu, MD, MPh, FACP; yash Suri; Lakshminarayan Nandagopal; Mollie R. Deshazo, MD; Lyse A. Norian, PhD; Eddy Yang; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Immune monitoring
31 Oral Presentation Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients. Diego de Miguel Perez, PhD, MSc; Alessandro Russo, MD, PhD; Muthukumar Gunasekaran, PhD; Andrés F. Cardona, MD, PhD; Rena Lapidus, PhD; Brandon Cooper, MSc; Sunjay Kaushal; Christine B. Peterson, PhD; Rivka Colen, MD; Aung Naing, MD, FACP; Vincenzo Adamo, MD, PhD; Christian Rolfo, M.D, PhD, MBA; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Solid tumors; Extracellular vesicles/exosomes
32 Poster Presentation C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with Immune Checkpoint Inhibitors. Results from a multi-center international observational study Abdul Rafeh Naqash, MD; Alessio Cortellini, MD; Emma Mi; Sanna M. Livanainen; Daria Gramenitskaya; James Clark; Kevin O'Brien; Jussi P. Koivunen; Shravanti Macherla; Sweta Jonnalagadda; Shanker R. Polsani; Rahim A. Jiwani, MD; Nitika Sharma, MD; Chipman RG. Stroud; Mahvish Muzaffar, MD; Paul R. Walker, MD; David J. Pinato, MD, MRes, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Immune suppression; Inflammation; T cell
33 Poster Presentation Dynamic monitoring of response to immune checkpoint blockade through deep-learning empowered ultra-sensitive liquid biopsy in melanoma Adam J. Widman, MD; Cole Khamnei; Jake Bass; Will Liao, PhD; Minita Shah; Nicolas Robine, PhD; Jedd D. Wolchok, MD, PhD; Margaret K. Callahan, MD, PhD; Dan A. Landau, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Checkpoint blockade; Immune monitoring
34 Poster Presentation Multi-step antibody validation for the GeoMx® Digital Spatial Profiler Alyssa Rosenbloom; Jenny Cronin; Shilah A. Bonnett, PhD; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Biomarkers; Immune monitoring; Proteomics
35 Poster Presentation Targeted non-viral integration of large cargo in primary human T cells by CRISPR/Cas9 guided homology mediated end joining Beau R. Webber, PhD; Matthew J. Johnson, PhD; Nicholas J. Slipek; Walker S. Lahr; Xiaohong Qiu; Blaine Rathmann; Miechaleen D. Diers; Bryce Wick; R. Scott McIvor, PhD; Branden S. Moriarity, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy; CAR T cells; T cell
36 Oral Presentation Molecular events regulating solid tumor cell responses to natural killer cells Michal Sheffer, PhD; Constantine S. Mitsiades; Michal Sheffer, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Immune suppression; NK/NKT cell; Solid tumors; Systems biology; Tumor evasion
37 Poster Presentation Monitoring the evolution of inflammatory bowel disease (IBD) in pediatric and adult cohorts of patients to identify biomarkers to predict cancer risk Shilpa Ravindran, MSc; Heba Sidahmed; Harshitha S. Manjunath; Rebecca A. Mathew, MSc; Tanwir Habib; William Mifsud; Adrian Charles; Adham A. Ammar; Muhammad U. Khan; Saad Al-Kaabi; Anthony Akobeng; Muneera J. Al-Mohannadi; Mamoun Elawad; Sara Tomei, PhD; Cristina Maccalli, PhD; Biomarkers, Immune Monitoring and Novel Technologies Autoimmunity; Biomarkers; Epigenetics; Gene expression; Inflammation; RNA; Stem cell/cancer-initiating cell
38 Poster Presentation Clinical validation of an image analysis assay for determining programmed death-ligand 1 (22C3) in non-small cell lung cancer Roberto Gianani, MD, FCAP; Will Paces, MEng; Elliott Ergon, BS; Kristin Shotts, PhD; Vitria Adisetiyo, PhD; Vitria Adisetiyo, PhD; Charles Caldwell, Jr., PhD; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Biomarkers; Clinical study; Solid tumors
39 Poster Presentation Spatial single-cell quantitative analyses of human head and neck squamous cell carcinomas Katie E. Blise, BA; Shamilene Sivagnanam, MS; Lisa M. Coussens, PhD; Jeremy Goecks, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Immune contexture; Solid tumors; Systems biology; Tumor microenvironment
40 Poster Presentation The Orion™ platform from RareCyte® enables same-day 21-plex fluorescence tissue analysis Daniel Campton; Jeremy Cooper; Steven Reese; Kyla Teplitz; Jeffrey Werbin; Joshua Nordberg; Eric P. Kaldjian, MD; Tad George, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
41 Poster Presentation Optimization of an ultrasensitive, quantitative immunoassay for detection of CD20 in Non-Hodgkin's Lymphoma (NHL) FFPE samples Apollina Goel, PhD; Michael Ross; Jeanette Rheinhardt; Peter Duval; Michael Maker; Hiroyuki Yokota; Kenneth Bloom; George Abe; Ann Ranger; Joseph S. Krueger, BS PhD; Biomarkers, Immune Monitoring and Novel Technologies Antibody; B cell; Biomarkers; Bispecifics; Leukemia/Lymphoma; Tumor antigens
42 Poster Presentation Intravital multiphoton microscopy of infiltrating T cell and tumor cell metabolism in a murine melanoma model Alexa R. Heaton, PhD; Tiffany M. Heaster, PhD; Anna Hoefges, MS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD; Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy; Checkpoint blockade; Cytokine; Metabolism; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
43 Poster Presentation Highly multiplexed digital spatial profiling of the tumor microenvironment of non-small-cell lung cancer (NSCLC) Arutha J. Kulasinghe, PhD; Connor O'Leary; Rahul Ladwa; Majid Warkiani, PhD; Kenneth J. O'byrne, MD; Arutha J. Kulasinghe, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
44 Poster Presentation Body composition may be prognostic and predictive of clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) Dylan J. Martini, BA; Dylan J. Martini, BA; T. Anders Olsen, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; Sean T. Evans, BS; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Viraj A. Master, MD Ph.D; Mehmet A. Bilen, MD; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Clinical study; Metabolism; Solid tumors
45 Poster Presentation Body composition as a predictive and prognostic biomarker in advanced urothelial carcinoma (UC) patients treated with immune checkpoint inhibitors (ICI) Dylan J. Martini, BA; Julie M. Shabto, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Sean T. Evans, BS; Benjamin L. Magod, BS; Deepak Ravindranathan, MD, MS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Shreyas S. Joshi, MD, MPH; Haydn T. Kissick, Ph.D; Kenneth Ogan, MD; Wayne B. Harris, MD; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Viraj A. Master, MD Ph.D; Mehmet A. Bilen, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Clinical study; Metabolism; Solid tumors
46 Poster Presentation A novel H&E-like staining method compatible with multiplexed IF on the same tissue section for integrated translational workflows Michael J. McLane, II; Glenn Milton; Linying Liu; Rachel Schaefer; Yi Zheng; Carla Coltharp, PhD; Peter Miller, MS; Clifford C. Hoyt, MS; Michael J. McLane, II, BS; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Immune contexture; Tumor microenvironment; Tumor stroma
47 Poster Presentation Pathologists enhance interpretation of automated multiplex immunohistochemistry assays in cancer immunotherapy trials Emmanuel Pacia; Ju Young Kim, PhD; Evelyn Diaz; Beiru Chen, MD; Nathan Roscoe; Jason Hughes; Thai Tran, PhD; Jennifer M. Bordeaux, PhD; Bashar Dabbas, MD; Shabnam Tangri, PhD; Margaret McLaughlin, MD; Alexander Savchenko, MD, PhD; Naveen Dakappagari, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Clinical study
48 Poster Presentation Advances in Multiplexed Ion Beam Imaging (MIBI) for immune profiling of the tumor microenvironment Jason Ptacek, PhD; Felipe C. Geyer, MD; Andre Mignault; James Deeds; Jimmy Giedt, Ph.D.; Jane Gu; Margaret McLaughlin, MD; Yari Sigal, Ph.D.; Jay G. Tarolli, Ph.D.; Murat Aksoy, Ph.D.; Yi Zhang; Monirath Hav, MD; Rachel Finck; Jessica Finn, MD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Dendritic cell; Immune contexture; Immune monitoring; Immune suppression; Solid tumors; Systems biology; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
49 Poster Presentation In situ phenotypic analysis of T cells in the tumor microenvironment of a pre-clinical model of non-small cell lung cancer (NSCLC) by tissue sectioning and whole-mount immunofluorescence imaging Elen Torres, PhD; Stefani Spranger, PhD; Biomarkers, Immune Monitoring and Novel Technologies Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
50 Poster Presentation Spatially Resolved Molecular Investigation of Triple Negative Breast Cancer and Its Immune Microenvironment Stephen R. Williams, PhD; Cedric R. Uytingco, PhD; Neil Weisenfeld, PhD; Nigel Delaney, PhD; Solongo Ziraldo, PhD; Yifeng Yin, PhD; Jennifer Chew, BS; Sharmila Chatterjee; Daniel P. Riordan, PhD; Zachary W. Bent, PhD; Biomarkers, Immune Monitoring and Novel Technologies B cell; Bioinformatics; Biomarkers; Gene expression; Genetic polymorphism; RNA; Stem cell/cancer-initiating cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
51 Poster Presentation Small cell/lymphohistiocytic morphology is associated with CD8 positivity, retained T cell markers, a trend of decreased PD-L1 expression, but not outcome in adults with ALK+ ALCL Mahsa Khanlari; Shaoying Li, MD; Roberto N. Miranda, MD; Swaminathan Iyer, MD; Cameron Yin, MD, PhD; Pei Lin, MD; Guilin Tang, MD, PhD; Sergej N. Konoplev, MD, PhD; L. Jeffrey Medeiros, MD; Jie Xu, MD, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Antibody; Epidemiology; Leukemia/Lymphoma; Targeted therapy
52 Poster Presentation Advanced T Lymphocyte Analysis System (ATLAS) for In-depth Immunological Interrogation in Real-World Conditions, a Methodological Strategy Stephanie Berg, DO; Stephanie Berg, DO; Cara Joyce, PhD; Michael Delos Reyes; Brianna Burke; Lourdes Plaza-Rojas, PhD; Kushal Prajapati; Cynthia Perez; Courtney Wagner, MD; Elizabeth Elliott, DO; Blaine Knox, MD; Daniel Linden, DO; Joseph I. Clark, MD; Jose Guevara, MD PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; T cell
53 Poster Presentation Predictors of response to Immune checkpoint inhibitor therapy in metastatic solid tumors: Real world evidence Aasems Jacob, MD; Jianrong Wu, PhD; Jill Kolesar, PharmD; Eric Durbin, MS, DrPH; Aju Mathew, MD, MPH; Susanne M. Arnold, MD; Aman Chauhan, MD; Aasems Jacob, MD; Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune tolerance; Immune toxicity; Solid tumors
54 Poster Presentation Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues Maxim Isabelle, PhD; Maxim Isabelle, PhD; Maxim Isabelle, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Clinical study; Proteomics
55 Poster Presentation Thousands of antigens are recognized in mice via endogenous antibodies after being cured of a B78 melanoma via immunotherapy Anna Hoefges, MS; Amy K. Erbe, PhD; Sean J. Mcilwain, PhD; Trang Q. Le; Angie Xu; Nicholas Mathers; Eric Zhang; Andrew S. Melby; Claire Baniel; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Richard Pinapati, PhD; Brad Garcia, PhD; Jigar Patel, PhD; Zachary S. Morris, MD, PhD; Irene M. Ong, PhD; Paul M. Sondel, MD, PhD; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Antigen presenting cells; B cell; Bioinformatics; Biomarkers; Neoantigens; Proteomics; Radiotherapy; Solid tumors; Tumor antigens
56 Poster Presentation Improved next generation sequencing based Class I HLA typing through exome enhancement Lee D. McDaniel, Jr., MD, MSE; Rachel M. Pyke, PhD; Charles Abbott, PhD; Gabor Bartha, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Neoantigens
57 Poster Presentation Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets Dattatreya M. Mellacheruvu, PhD; Rachel M. Pyke, PhD; Charles Abbott, PhD; Nick Phillips, MS; Sejal Desai, PhD; Rena McClory, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Neoantigens; Proteomics; Tumor antigens; Vaccine
58 Poster Presentation Excluding Treg epitopes and integrating CD8 and CD4 effector neoepitope content improves prognostic biomarker tool in bladder cancer Guilhem Richard, PhD; Gary D. Steinberg; Tzintzuni Garcia; Matthew Ardito, BA; William Martin, BA MD; Gad Berdugo, MBA, MSc.; Michael F. Princiotta, PhD; Arjun V. Balar, MD; Anne S. de Groot, MD; Randy F. Sweis, MD; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor antigens; Vaccine
59 Poster Presentation Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients Kamil Sklodowski, PhD; Vito Dozio, PhD; Silvia Lopez-Lastra, PhD; Andrés Lanzós, PhD; Kristina Beeler, Dr.; Emanuela Romano, MD, PhD; Kamil Sklodowski, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Targeted therapy
60 Poster Presentation Development and validation of blood tumor mutational burden reference standards Eun-Ang Rabier-Moreau, PhD; Guillem Portella, PhD; Matthew Butler, PhD; Yves Konigshofer, PhD; James Hadfield, PhD; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers
61 Poster Presentation Tumor mutational burden assessments by two commercial targeted sequencing assays Ruchi Chaudhary; Gitanjali Vaidya; Meeta Sunil; Sakthivel Murugan S.M; Ramprasad VL; Ravi Gupta; Eric Stawiski; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade
62 Oral Presentation Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing Jiamin Chen, PhD; Lance Pflieger, PhD; Sue M. Grimes, MSc; Tyler Baker, PhD; Michael Brems; Gail Fulde; Shawnee Snow; Parker Howe; Anuja Sathe, PhD; Bryce Christensen; Hanlee P. Ji, MD; Terence Rhodes, MD, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Gene expression; Immune toxicity; Inflammation; T cell
63 Poster Presentation Microsatellite instability/mismatch repair biomarker testing disparities in patients with advanced colorectal cancer: Implications for immune checkpoint inhibitors Bryan Iorgulescu, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade
64 Poster Presentation Cancer testis antigen co-expression landscape in solid tumors R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Jonathan Andreas, MS; Vincent Giamo, BS, MS; Blake Burgher, BS, RN; Felicia L. Lenzo; Mary K. Nesline, MS; Paul DePietro, PhD; Yirong Wang, M.S.; Sean T. Glenn, PhD; Shengle Zhang, MD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Solid tumors; Tumor antigens
65 Poster Presentation PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer. Yong Hee Lee; Grace K. Dy; Paul DePietro, PhD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; Mary K. Nesline, MS Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; RNA; Solid tumors; Tumor microenvironment
66 Poster Presentation Complex markers of survival from pembrolizumab: The potential predictive role of tumor mutational burden (TMB) and KRAS Yong Hee Lee; Carrie Hoefer; Paul DePietro, PhD; Mary K. Nesline, MS Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Tumor microenvironment
67 Poster Presentation B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Eric Levy, PhD; Pamela Milani, PhD; Gabor Bartha, PhD; Charles Abbott, PhD; Robert Power, MS; Rena McClory, PhD; Robin Li, MS; John S. West, MBA; John Lyle, PhD; Sean M. Boyle, PhD, MS; Richard Chen, MD, MS; Biomarkers, Immune Monitoring and Novel Technologies Antibody; B cell; Bioinformatics; Biomarkers; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
68 Poster Presentation The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer Roger Li, MD; Logan Zemp, MD; Anders E. Berglund, PhD; Jasreman Dhillon, MD; Ryan Putney, PhD; Youngchul Kim, PhD; Rohit K. Jain, MD; Daniel Grass, MD; Jingsong Zhang, MD, PhD; Michael A. Poch, MD; Julio M. Pow-Sang, MD; Wade J. Sexton, MD; Scott M. Gilbert, MD; Shari A. Pilon-Thomas, PhD; José Conejo-Garcia, MD, PhD; Colin P. Dinney, MD; James J. Mulé, PhD; Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade; Chemokine; Immune contexture; Tumor microenvironment
69 Poster Presentation Automated TRB locus haplotype analysis by long-amplicon TCRB chain sequencing for potential immune-related adverse events biomarker research Jennifer Burke; Frances Chen; Jiajie Huang; Geoffrey M. Lowman, PhD; Timothy Looney, PhD; Marina Sedova, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Immune monitoring; Immune toxicity; T cell
70 Poster Presentation Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro Simarjot Pabla, PhD; Tenzing Khendu; Simarjot Pabla, PhD; Dhan Chand, PhD; Bulent A. Aksoy, PhD; Benjamin Duckless, BS; Andrew Basinski; Cailin CJ. Joyce, PhD; Thomas Horn, PhD; Lukasz Swiech; Jeremy D. Waight, PhD; David Savitsky, PhD; Jennifer S. Buell, PhD; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; T cell; Tumor evasion; Tumor microenvironment
71 Poster Presentation Whole Exome Sequencing of individuals presenting extreme phenotypes of high and low-risk of developing tobacco-induced lung adenocarcinoma: relevance of immune and DNA-repair related pathways Jose Perez-Gracia, MD; Mapi Andueza; Ana Patiño-Garcia, PhD; Alfonso Gurpide; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Carcinogenesis; Epidemiology; Genetic polymorphism; Solid tumors
72 Poster Presentation Routine use of comprehensive genomic profiling to assess tumor mutational burden across a community health system Carlo B. Bifulco, MD; Roshanthi Weerasinghe; Bela Bapat; Alexa K. Dowdell; Shwetha Pindikuri; Sheila Reynolds; Nancy Biery; David Ball; Mary Campbell; Thomas R. Ward; Alisha Stein; Brock E. Schroeder; David A. Eberhard, MD PhD; Brian D. Piening; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors
73 Poster Presentation Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity Rachel M. Pyke, PhD; Dattatreya M. Mellacheruvu, PhD; Charles Abbott, PhD; Eric Levy, PhD; Simo V. Zhang, PhD; Devayani P. Bhave, PhD; Manjula Chinnappa, PhD; Gabor Bartha, PhD; John Lyle, PhD; John S. West, MBA; Richard Chen, MD, MS; Sean M. Boyle, PhD, MS; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Neoantigens; Tumor antigens; Tumor evasion; Vaccine
74 Poster Presentation Novel approach for profiling immune-tumor cell interactions and mutations in the same tumor section by multiplex immunohistochemistry and NGS in immuno-oncology trials Nathan Riccitelli; Jennifer M. Bordeaux, PhD; Nancy Valencia; Ju Young Kim, PhD; Sarah Johnson; Nathan Roscoe; James Santos; Justin Santos; Jacob Levy; Deepika Asnani; Tracie Cobb; Angela McIntosh; Xun Li, MD; Shabnam Tangri, PhD; Reinhold Pollner, PhD; Naveen Dakappagari, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
75 Poster Presentation Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer Dante S. Bortone; Steven Vensko; Sarah Entwistle; Alexandria P. Cogdill, MEng; Anne Monette, PhD; Yana G. Najjar, MD; Randy F. Sweis, MD; Nicholas Tschernia, MD; Erik Wennerberg, PhD; Praveen K. Bommareddy, MS, PhD; Cara Haymaker, PhD; Uqba Khan, MD; Heather M. McGee, MD, PhD; Wungki Park, MD; Houssein A. Sater; Christine Spencer; Maria L. Ascierto, PhD; Valentin Barsan, MD; Vinita Popat, BA; Sara Valpione, MD, PhD; Danny Wells, BA, PhD; Vésteinn Thorsson, PhD; Roberta Zappasodi, Phd; Nils Rudqvist, PhD; Benjamin G. Vincent, MD; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune monitoring; RNA; Systems biology; Tumor microenvironment
76 Poster Presentation Potential Mechanisms of Resistance Identified Through Analysis of Multiple Biomarkers in Immune Hot Non-Responders With Non-Small Cell Lung Cancer (NSCLC) Treated With Tislelizumab Jayesh Desai, MBBS FRACP; Qing Zhou; Sanjeev Deva; Jun Zhao; Jie Wang; Wei Tan; Xiaopeng Ma; Yun Zhang; Zhirong Shen; Xikun Wu; Shiangjiin Leaw; Juan Zhang; Yi-Long Wu, MD; Biomarkers, Immune Monitoring and Novel Technologies Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell lineages; Tumor microenvironment
77 Poster Presentation Association Between Programmed Death-Ligand 1 (PD-L1) Expression and Gene Signatures of Response or Resistance to Tislelizumab Monotherapy in Hepatocellular Carcinoma (HCC) Ming-Mo Hou; Kun-Ming Rau; Yoon-Koo Kang; Jong-Seok Lee; Hongming Pan; Ying Yuan; Cunjing Yu; Yun Zhang; Xiaopeng Ma; Xikun Wu; Xin Li; Katie Wood; Chia-Jui Yen, MD, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment
78 Poster Presentation T-Cell, MHC I, and Tumor Intrinsic Gene Signatures Predict Clinical Benefit and Resistance to Tislelizumab Monotherapy in Pretreated PD-L1+ Urothelial Carcinoma Dingwei Ye; Aiping Zhou; Qing Zou; Hanzhong Li; Cheng Fu; Hailong Hu; Jian Huang; Wei Shen; Yun Zhang; Xiaopeng Ma; Pei Zhang; Ruiqi Huang; Xiusong Qiu; Lilin Zhang; Feng Bi; Biomarkers, Immune Monitoring and Novel Technologies Angiogenesis; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
79 Poster Presentation Tumor-Immune Signatures Associated With Response or Resistance to Tislelizumab (Anti-PD-1) in Esophageal Squamous Cell Carcinoma (ESCC) Jianming Xu; Nong Xu; Yuxian Bai; Chia-Chi Lin, MD, PhD; Michael Millward; Jingwen Shi; Yun Zhang; Xiaopeng Ma; Zhirong Shen; Ruiqi Huang; Wei Huang; Lin Shen, MD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment
80 Poster Presentation Evaluation of the TruSight Oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab Bo Wei, MS; John Kang; Miho Kibukawa, MS; Gladys Arreaza; Maureen Maguire; Lei Chen; Ping Qiu, PhD; Lixin Lang, PhD; Deepti Aurora-Garg, PhD; Razvan Cristescu, PhD; Diane Levitan, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Checkpoint blockade; Solid tumors
81 Poster Presentation Inclusion of PD-L1-expressing tumor cells in the Combined Positive Score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications Jay Milo, MAS; Christopher LaPlaca; Julia Hand; Stephanie Hund; Angeliki Apostolaki; Lindsay Guerrero; Kenneth Emancipator, MD; Jonathan Juco, MD; Bryce Portier; Siena Tabuena-Frolli; Karina Kulangara; Biomarkers, Immune Monitoring and Novel Technologies Antibody; Antigen presenting cells; Bioinformatics; Biomarkers; Chemotherapy; Solid tumors; T cell
82 Poster Presentation SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses Sangeetha Srinivasan, PhD; Nathan A. Yee, PhD; Kui Wu, PhD; Amir Mahmoodi, MS; Michael Zakharian, MS; Maksim Royzen, PhD; Jose M. Mejia Oneto, MD, PhD; Biomarkers, Immune Monitoring and Novel Technologies Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
83 Poster Presentation The Prognostic Significance of Peripheral Blood Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab: A Clinical Study Kira MacDougall, MD; Muhammad Niazi, MD; Jeff Hosry, MD; Sylvester Homsy, MD; Alexander Bershadskiy, MD; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation; Targeted therapy
84 Poster Presentation Quantifying pharmacodynamic biomarker changes in immuno-oncology by mass spectrometry Joseph M. Eckenrode, PhD; Omar F. Laterza, PhD; Michael E. Lassman, PhD; Biomarkers, Immune Monitoring and Novel Technologies Biomarkers; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs)
85 Poster Presentation Spatial Heterogeneity of Tumor Associated Macrophages in the Tumor Immune Microenvironment in ccRCC Nicholas H. Chakiryan, MD; Gregory Kimmel; Youngchul Kim, PhD; Jonathan Nguyen; Jad Chahoud; Philippe Spiess; Jasreman Dhillon, MD; Liang Wang; Carlos Moran-Segura; James J. Mule, PhD; Philipp Altrock; Brandon J. Manley; Biomarkers, Immune Monitoring and Novel Technologies Monocyte/Macrophage; Myeloid cells; Solid tumors
86 Poster Presentation Co-detection of RNA and protein in FFPE tumor samples by combining RNAscope in situ hybridization and immunohistochemistry assays Anushka Dikshit, PhD; Xiao-jun Ma, PhD; Emerald Doolittle, PhD; Lydia Hernandez, PhD; Jyoti Sheldon; Siobhan Kernag, PhD; Helly Xiao Yan Pimentel; Hailing Zong, PhD; Bingqing Zhang, PhD; Biomarkers, Immune Monitoring and Novel Technologies Cytokine; Gene expression; RNA; Tumor microenvironment
87 Poster Presentation Transcription factor RUNX1 activates OPN to promote tumor progression via MAPK signaling in head and neck cancer Kai Liu, Ph.D; Huiying Hu; Zhenkun Yu; Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics; Biomarkers; Carcinogenesis; Gene expression; Solid tumors; Tumor evasion
88 Poster Presentation Development of a 3D organoid autologous TIL co-culture platform for high throughput immuno-oncology studies Garima Kaushik, PhD; Bhavna Verma, PhD; Amy K. Wesa, PhD; Biomarkers, Immune Monitoring and Novel Technologies Checkpoint blockade; Cytokine; Immune suppression; Immune tolerance; NK/NK T cell; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
89 Poster Presentation First-in-human CAR T targets cleaved MUC1, the growth factor receptor form Benoit J. Smagghe, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Tyler E. Swanson; Danica M. Page; Mark G. Carter; Trevor J. Grant, PhD; Jennifer Specht, MD; Cynthia C. Bamdad, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; Stem cell/cancer-initiating cell; T cell; Targeted therapy
90 Oral Presentation Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway Jonathan Boiarsky, BA; Ranjan Upadhyay, PhD; Judit Svensson-Arvelund, PhD; Aleksandra Wroblewska, PhD; Sherry Bhalla, PhD; Nathalie Scholler, MD, PhD; Adrian Bot, MD, PhD; John M. Rossi, MS; Samir Parekh, MD; Norah Sadek, BA; Alessia Baccarini, PhD; Miriam Merad, MD, PhD; Brian Brown, PhD; Joshua Brody, MD; Cellular Therapies Bispecifics; CAR T cells; Immune tolerance; Leukemia/Lymphoma; T cell; Tumor antigens; Tumor evasion
91 Poster Presentation Directly Link T Cell Phenotype and Function to Genotype with the Opto™ Cell Therapy Development 1.0 Workflow Yelena Bronevetsky, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Cytokine; T cell
92 Poster Presentation Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) slows high-risk neuroblastoma tumor growth Cheng Cui, Ph.D.; Theresa Barberi, PhD; Rahul Suresh, Ph.D.; Ludovic Zimmerlin, Ph.D.; Elias Zambidis, M.D., Ph.D.; Alan D. Friedman, MD; Cellular Therapies Adoptive immunotherapy; Monocyte/Macrophage; Myeloid cells; Pediatric tumors
93 Poster Presentation Targeting Sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment Imene Hamaidi, PhD; Lin Zhang, MD. Ph.D; Nayoung Kim, PhD; Min-Hsuan Wang; Cristina Iclozan, Ph.D.; Bin Fang, PhD; Min Liu, Ph.D.; John M. Koomen, PhD; Anders E. Berglund, PhD; Sean J. Yoder; Jiqiang Yao, PhD; Robert W. Engelman, PhD; Ben C. Creelan, MD, MS; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; James J. Mule, PhD; Sungjune Kim, MD PhD; Cellular Therapies Checkpoint blockade; Metabolism; Post-translational modifications; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
94 Poster Presentation The T cell Antigen Coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation Duane Moogk, PhD; Vivian W. Lau; Arya Afsahi, MSc; Anna Dvorkin-Gheva, PhD; Ksenia Bezverbnaya; Joanne A. Hammill, PhD; Jonathan L. Bramson, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Immune toxicity
95 Poster Presentation Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro Katerina Mardilovich; Lilli Wang; Rachel Kenneil; Gareth Betts, PhD; Natalie Bath, MSc; Will Spinner; Vanessa De Mello; Seint Lwin; Joseph P. Sanderson, PhD; Jonathan D. Silk, PhD; Alex J. Tipping, PhD; Andrew B. Gerry, PhD; Phil Bassett; Karen Miller, PhD; Mark Dudley; Emily Schmidt Cellular Therapies Adoptive immunotherapy; T cell; Targeted therapy
96 Poster Presentation Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo Dmitry Pankov; Ioanna S. Eleftheriadou; Anna Domogala; Sara J. Brett, PhD; Lea Patasic; Magdalena A. Kijewska; Gary Thripp; Jack Euesden; Jan Klapwijk; Katrina Soor; Miriam Damm; Mark D. W. Hill; Mirella Georgouli; Aiman Shalabi; Cedrik Britten; Cellular Therapies Adoptive immunotherapy; Cytokine; Epigenetics; Gene expression; Solid tumors; T cell; Tumor antigens
97 Poster Presentation Polyfunctional activity of GD3CAR T-cells against tumors in Tuberous Sclerosis Complex Ancy Thomas, PhD; Emilia Dellacecca; Rohan Shivde; Nicola Lanki; Levi Barse; Ancy Thomas, PhD; Agnes Lo; Denise M. M. Scholtens; Daniel F. Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; Cellular Therapies CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy
98 Poster Presentation ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors Jiangyue Liu, MS; Xianhui Chen, PhD; Jason Karlen; Alfonso Brito, MS; Tiffany Jheng, MS; Philippe Foubert, PhD; Janani Krishnamurthy, PhD; Yannick Bulliard, PhD; Blake T. Aftab, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor antigens; Tumor microenvironment
99 Poster Presentation Structural optimization of anti-CEA-GITR-CAR to reduce tonic signaling and improve antigen-specific reactivity Yasunori Amaishi; Yu Okubo, PhD; Yizheng Wang; Linan Wang, PhD; Takuma Kato, PhD; Sachiko Okamoto, PhD; Hiroshi Shiku, PhD; Junichi Mineno, PhD; Cellular Therapies CAR T cells; Solid tumors; T cell; Tumor antigens
100 Poster Presentation Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML Jacob S. Appelbaum, MD, PhD; Wai-Hang Leung; Unja Martin; Kaori Oda; Giacomo Tampella, PhD; Dong Xia; Joy Zhang; Anne-Rachael Krostag; Rachael Logan; Claudya Evandy; Quennie Vong; Kyle S. Jones; John C. Timmer, PhD; Brendan P. Eckelman, PhD; Jim Rottman; Danielle Montt; Bryan Peguero; Mark Pogson; Alexander Astrakhan; Jordan Jarjour, PhD; Joshua Gustafson, PhD; Michael C. Jensen, MD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Myeloid cells
101 Poster Presentation Engineering gamma/delta T cells with the T-Cell Antigen Coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo Sarah E. Asbury, BSc; Seung Mi Yoo, PhD; Jonathan L. Bramson, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell
102 Poster Presentation Cord-blood derived NK cells, and CAR-T cells, an attractive improved immunotherapy treatment to be considered for hematological malignancies Mireia Bachiller García, Pharm; Lorena Pérez-Amill; Anthony M. Battram, PhD; Alvaro Urbano-Ispizua; Beatriz Martín-Antonio; Mireia Bachiller García, Pharm; Cellular Therapies Adoptive immunotherapy; CAR T cells; Myeloid cells; NK/NK T cell; Targeted therapy
103 Poster Presentation Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors Amorette Barber, Ph.D.; Cellular Therapies Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Solid tumors
104 Poster Presentation BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7 Anthony M. Battram, PhD; Mireia Bachiller, Pharm; Álvaro Urbano-Ispizua; Beatriz Martin-Antonio, Jr.; Cellular Therapies Adoptive immunotherapy; CAR T cells; Cytokine; T cell
105 Poster Presentation A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy Trevor R. Baybutt, BA; Adam E. Snook, PhD; Scott A. Waldman, MD, PhD; Jonathan M. Stem, MD; Ellen Caparosa, MD; Alicja Zalewski, MD; Trevor R. Baybutt, BA; Cellular Therapies CAR T cells; Solid tumors; T cell
106 Poster Presentation Increasing AMPK activity in human T cells enhances memory subset formation without sacrificing in vitro expansion Erica Braverman, MD; Andrea Dobbs, MSc; Darlene A. Monlish, PhD; Craig Byersdorfer, MD, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Metabolism; T cell lineages
107 Poster Presentation Effects of IL-2 and IL-15 on the proliferative and antitumor capacities of allogeneic CD20 CAR-engineered γδ T cells in a 3D B cell lymphoma spheroid assay Lu Bai; Kevin Nishimoto; Mustafa Turkoz; Marissa Herrman; Jason Romero; Daulet Satpayev; Stewart Abbot; Sandra M. Hayes; Mary M. Brodey, Ph.D.; Cellular Therapies CAR T cells; Cytokine; Leukemia/Lymphoma; Tumor microenvironment
108 Poster Presentation MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro Sashi Kasimsetty, PhD; Himavanth Gatla, PhD; Dhana Chinnasamy, PhD; Cellular Therapies Antigen presenting cells; B cell; CAR T cells; Clinical study; Costimulation; Dendritic cell; Monocyte/Macrophage; NK/NK T cell; RNA; T cell
109 Poster Presentation Dominant-negative TGFβ receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma Nina J. Chu, PhD; Michael Overstreet, PhD; Ryan Gilbreth; Lori Clarke; Christina Gesse; Eric Tu; Letizia Giardino; Gordon Moody; Cellular Therapies Adoptive immunotherapy; CAR T cells; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
110 Poster Presentation In-depth characterization of variability in apheresis collections from normal donor populations for allogeneic cell therapy Shawn P. Fahl, PhD; Cellular Therapies B cell; Biomarkers; CAR T cells; Genetic polymorphism; Immune monitoring; NK/NK T cell; T cell; T cell lineages; Targeted therapy
111 Poster Presentation Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL Jason Gehrke, PhD; Aaron Edwards; Ryan Murray; Angelica Messana; Lindsey Coholan; Henry Poulin; Melissa Le; Alden Ladd; Mark Naniong; Faith Musenge; Adam Camblin; Yeh-Chuin Poh; Sarah Smith; Giuseppe Ciaramella; Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell
112 Poster Presentation Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy Letizia Giardino; Ryan Gilbreth; Cui Chen; Erin Sult; Noel Monks; Ravinder Tammali; Jon Chesebrough; Kevin Schifferli; Nina Chu; Jessica Tong; Lori Clarke,; Christina Gesse; Xiao-Tao Yao; Karma DaCosta; Kapil Vashisht; Gordon Moody; Letizia Giardino; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy
113 Poster Presentation Development of T cell-based immunotherapies to target dormant disseminated breast cancer cells Erica T. Goddard, PhD; Shivani Srivastava, PhD; Stanley R. Riddell, MD; Cyrus Ghajar, PhD; Erica T. Goddard, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Tumor microenvironment
114 Poster Presentation Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing John Goulding, PhD; John Goulding, PhD; Mochtar Pribadi, PhD; Robert Blum, MS; Wen-I Yeh, PhD; Yijia Pan, PhD; Svetlana Gaidarova, MS; Chia-Wei Chang, PhD; Hui-Yi Chu, PhD; Ellen Liu, MS; Shohreh Sikaroodi, PhD; Lucas Ferrari de Andrade, PhD; Lauren Fong, PhD; Janel Huffman, MS; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD; Cellular Therapies Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor evasion
115 Poster Presentation Engineered T cells directed at tumors with defined allelic loss Agi Hamburger, PhD; Breanna DiAndreth; Jiajia Cui; Mark Daris, PhD; Melanie Munguia; Kiran Deshmukh; Jee-Young Mock; Grace Asuelime; Emily Lim; Michelle Kreke; Talar Tokatlian; Alexander Kamb, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell
116 Poster Presentation Multi-antigen targeting of heterogenous solid tumors using CAR T cells secreting bi-specific T-cell engagers Martin Hosking, PhD; Bishwas Shrestha; Megan M. Boyett; Soheila Shirinbak; Angela Gentile; Eric Sung; Yijia Pan, PhD; Tom T. Lee, PhD; Jason ORourke; Dan Shoemaker, PhD; Cokey Nguyen; Bahram Valamehr, PhD; Cellular Therapies Adoptive immunotherapy; Bispecifics; CAR T cells; Solid tumors; Tumor evasion
117 Poster Presentation Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression Frederic Vigant, PhD; Qun He, PhD; Wei Zhang, PhD; Hongliang Zong, MD, PhD; Anirban Kundu; Ewa Jaruga-Killeen, PhD; Gregory Schreiber, PhD; Michelle Andraza; Alissa Kerner, PhD; Gregory I. Frost, PhD Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell; Targeted therapy
119 Poster Presentation IL-6 is critical for memory responses elicited by Th17 cells to tumors Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Aubrey S. Smith, BS; Megan Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Gregory B. Lesinski, PhD; Zihai Li, MD, PhD; Mark P. Rubinstein, PhD; Chrystal M. Paulos, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Cytokine; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
120 Poster Presentation P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications Anna K. Kozlowska, PhD; Yan Zhang, PhD; Jacqueline Fritz, BS; Steven Wang, PhD; Rebecca A. Codde, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Vanitra Richardson, MS; Sumiti Jain, PhD; Maximilian Richter, PhD; Deepak Patil, PhD; Yening Tan, MS; Min Tong, MS; Lu Yao, PhD; Majid Ghoddusi, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; T cell
122 Oral Presentation Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model Amanda N. Lisby, MS; Trevor R. Baybutt, BA; Megan Weindorfer, BS; Robert Carlson, BS; Alicja Zalewski, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; Cellular Therapies Adoptive immunotherapy; Antibody; Biomarkers; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens
123 Poster Presentation Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment Kyle B. Lupo, BS; Sandro Matosevic, PhD; Cellular Therapies Adoptive immunotherapy; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment
124 Poster Presentation Optimizing the Generation from Umbilical Cord Blood of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) expressing T cells Cristina Maccalli, PhD; Asma Al Sulaiti, Bachelor; Moza Al Khulaifi; Shilpa Ravindran, MSc; Mohammed El-Anbari; Mohammed Toufiq; Rebecca Mathew; Chiara Bonini; Monica Casucci, PhD; Chiara Cugno, MD; Suruchi Mohan; Sara Deola; Damien Chaussabel; Sara Tomei, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Leukemia/Lymphoma; T cell; T cell lineages
125 Poster Presentation Reexamination of MAGE-A3 as a T-cell Therapeutic Target Aaron D. Martin, M.A.; Xueyin Wang, PhD; Han Xu, PhD; Alexander S. Kamb; Mark Sandberg, PhD; Kathleen Negri; Ming Wu; Dora Toledo Warshaviak, PhD; Grant Gabrelow; Michele Mcelvain; Mark Daris, PhD; Bella Lee; Cellular Therapies Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy
126 Poster Presentation Early-phenotype Lewis Y CAR-T cells persist better in vivo and induce solid tumor regression in combination with anti-PD1. Deborah Meyran, MD; Joe Zhu; Jeanne Butler; Sean Macdonald; Daniela Tantalo; Niko Thio; Kevin Sek; Paul Ekert; Michael H. Kershaw, PhD; Joe Trapani; Phillip K. Darcy; Paul J. Neeson, PhD; Cellular Therapies CAR T cells; Checkpoint blockade
127 Poster Presentation Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell Nadege Morisot; Sarah Wadsworth; Tina Davis; Nicole Dailey; Kyle Hansen; Denise Gonzalez; Nafees Rahman; Alex Aronov; Y Fan; Chao Guo; Luxuan Buren; Anmol Vohra, MS; Kate Jamboretz; H Leman; Sasha Lazetic, BA; Ivan Chan, PhD; James T. Trager, PhD; Joanne BT. Tan; Cellular Therapies Adoptive immunotherapy; Leukemia/Lymphoma; NK/NK T cell
128 Poster Presentation Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy Yumi Ohtani, PhD; Kayleigh Ross; Aditya Dandekar; Rashid Gabbasov, PhD; Michael Klichinsky, PharmD, PhD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR; Tumor microenvironment
129 Poster Presentation A novel CAR conducting antigen-specific JAK-STAT signals demonstrates superior antitumor effects with minimal undesired non-specific activation Sachiko Okamoto, PhD; Sachiko Okamoto, PhD; Yasunori Amaishi; Mitsuki Shigeta, PhD; Yu Okubo, PhD; Yota Ohashi; Naoto Hirano, MD, PhD; Junichi Mineno, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; Solid tumors; T cell; Tumor antigens
130 Poster Presentation Immunogenic potential of chimeric antigen receptor (CAR)-engineered T cells expressing inducible nuclease-deactivated SpCas9 (dCas9) Dharmeshkumar Patel, PhD, MS; Angshumala Goswami; Vitaly Balan; Zhifen Yang, Dr.; Lingyu Li, PhD; Sowndharya Rajavel, Sr.; Alper Kearney, PhD; Rona Harari-Steinfeld; Maggie Bobbin; Bing C. Wang, PhD; Alessandra Cesano, MD, PhD; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune monitoring; Immune toxicity; Solid tumors; T cell; Targeted therapy
131 Poster Presentation CoupledCAR® Technology Strengthens Adoptive T Cell Therapy by Promoting Rapid Expansion Zhiyuan Cao; Chengfei Pu; Xianyang Jiang; Xiaogang Shen; Ruihong Zhu; Yuzhe Peng; Xi Huang; Zhao Wu; Lei Xiao, Ph.D.; Cellular Therapies Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens
132 Poster Presentation CAR macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors Stefano Pierini, PhD; Rashid Gabbasov, PhD; Linara Gabitova, PhD; Yumi Ohtani, PhD; Michael Klichinsky, PharmD, PhD; Cellular Therapies Monocyte/Macrophage; Myeloid cells; Solid tumors
133 Poster Presentation Development of novel cellular therapeutics for metastatic and primary CNS malignancies Paul D. Rennert, PhD; Alyssa Birt; Lihe Su, PhD; Lan Wu, PhD; Fay J. Dufort, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD; Cellular Therapies Adoptive immunotherapy; Antibody; Bispecifics; CAR T cells; Pediatric tumors; Solid tumors; Tumor antigens
134 Poster Presentation Tumor-responsive, multi-functional genetically-engineered natural killer cells for immunotherapy of glioblastoma Jiao Wang, PhD; Yeonhee I. Yun; Karen E Pollok; Anthony L. Sinn; Randy R Brutkiewicz; Michael C Veronesi; Sandro Matosevic, PhD; Jiao Wang, PhD; Cellular Therapies Adoptive immunotherapy; Chemokine; Immune suppression; Metabolism; NK/NKT cell; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment; Tumor stroma
136 Poster Presentation Targeting MET with Chimeric Antigen Receptor T cells in Hepatocellular Carcinoma Yuan Qin; Anna Qin; Anna Musket; Joseph Lee; Zhi Q. Yao; Giedre Krenciute, PhD; Qian Xie; Qian Xie Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy
137 Poster Presentation Genomics of multiple myeloma influences the expression of CAR T-cell targets Christina Y. Yu, BSc; Brian A. Walker, PhD; G. David Roodman, MD, PhD; Kun Huang, PhD; Michel Sadelain, MD PhD; Fabiana Perna, MD, PhD; Cellular Therapies B cell; Bioinformatics; CAR T cells; Gene expression; Targeted therapy
138 Poster Presentation In vivo localization of genetically engineered natural killer cells against glioblastoma using PET imaging Yeonhee I. Yun; Jiao Wang, PhD; Karen Pollok; Tony Sinn; Randy Brutkiewicz; Sandro Matosevic, PhD; Michael Veronesi; Cellular Therapies Chemokine; Immune suppression; Metabolism; NK/NKT cell; Radiotherapy; Solid tumors; Tumor antigens; Tumor evasion
139 Poster Presentation Establishment of canine CAR T cells treatment model for solid tumor immunotherapy development Shihong Zhang, Ph.D; Karan Kohli, Ph.D; R. Graeme Black; Brian J. Hayes, Ph.D; Cassandra Miller, DVM; Mari Maeda-Whitaker, PhD; Brett A. Schroeder, MD; Kraig Abrams; Bernard Seguin, DVM; Stephen Gottschalk, MD; Peter F. Moore, DVM, Ph.D.; Beverly J. Torok-Storb, Ph.D; Seth M. Pollack, MD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens
140 Poster Presentation Adoptive transfer of T cells surface-tethered with IL-12 promote antigen spreading for enhanced anti-tumor efficacy Ditte E. Jaehger, PhD; Kate L. Stokes, PhD; Hólmfridur R. Halldórsdóttir, MSc; Alvin Pratama, PhD; Gulzar Ahmad, PhD; Jonathan D. Nardozzi, PhD.; Katharine Sackton, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; Cellular Therapies Adoptive immunotherapy; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
141 Poster Presentation PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants Matthew G. Booty, PhD; Adam Stockmann; Olivia Pryor; Melissa Myint, PhD; Christine Trumpfheller, PhD; Valeria G. Nicolini; Christian Klein, Dr rer nat; Laura Codarri, Dr.; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine Seidl, PhD; Scott M. Loughhead, PhD; Cellular Therapies Adoptive immunotherapy; Antibody; Bispecifics; Checkpoint blockade; Cytokine; Tumor microenvironment; Vaccine
142 Poster Presentation Contextual reprogramming of CAR T cells for the treatment of HER2-expressing cancers Zhifen Yang, Dr.; Lingyu Li, PhD; Ahu Turkoz, Ph.D.; Pohan Chen, MS; Hana Choi, MS; Damla Inel, MS; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Costimulation; Immune contexture; Solid tumors; T cell lineages; Tumor microenvironment
144 Poster Presentation RTX-240, an Allogeneic Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes NK Cell Functionality In Vitro and In Vivo Anne-Sophie Dugast; Shannon L. McArdel; Enping Hong; Arjun Bollampalli; Maegan E. Hoover; Sneha Pawar; Viral Amin; Kangjian Qiao; Christopher Ta; Laurence A. Turka; Thomas J. Wickham, PhD; Sivan Elloul; Cellular Therapies Costimulation; Cytokine; Immune monitoring; NK/NK T cell
145 Poster Presentation Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cells Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment Karrie K. Wong, Ph.D.; Steven Sexton; Kelly Donahue; Lincy Prem Antony; Kevin Wasko; Jared Nasser, BS; Glenn Leary; Amanda Pfautz; Owen Porth; William Pierce; Patricia Sousa; Sean N. Scott; Aaron C. Wilson; Kai-Hsin Chang, Ph.D.; John A. Zuris, Ph.D.; Christopher J. Wilson, Ph.D.; Richard A. Morgan, Ph.D.; Christopher M. Borges, Ph.D.; Cellular Therapies NK/NK T cell; Solid tumors; Tumor microenvironment
146 Poster Presentation Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1 Alma-Martina Cepika; Pauline P. Chen; Molly J. Uyeda; Brandon Cieniewicz; Mansi Narula; Laura Amaya; David M. Louis; Liwen Xu; Xuhuai Ji; Alice Bertaina; Rajni Agarwal-Hashmi; Mark M. Davis; Everett Meyer; Rosa Bacchetta; Maria Grazia Roncarolo Cellular Therapies Adoptive immunotherapy; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell
147 Poster Presentation CD155 blockade boosts alloreactive natural killer cell antitumor effects against osteosarcoma Monica M. Cho, BSE; Monica M. Cho, BSE; Madison F. Phillips; Longzhen Song, Ph.D.; Amy K. Erbe, PhD; Christian M. Capitini, MD; Cellular Therapies Adoptive immunotherapy; NK/NKT cell; Pediatric tumors; Solid tumors
148 Poster Presentation Identification of prostate-restricted epithelial antigens for transgenic T cell adoptive therapy against prostate cancer Diana DeLucia, PhD; Tiffany Pariva; Roland Strong; Owen Witte; John Lee; Cellular Therapies Adoptive immunotherapy; Solid tumors; T cell; Tumor antigens
149 Poster Presentation GEN-011: An ATLASTM-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approaches Pranay D. Khare, PhD; Harshal Zope; James Perry; Victoria L. DeVault, PhD; Mercay R. Reuter; Adrienne Li, PhD; Daniel B. DeOliveira, PhD; Hubert Lam, PhD; Manish Jain, PhD; Jessica B. Flechtner, PhD; Pranay D. Khare, PhD; Cellular Therapies Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs)
150 Poster Presentation GAIA-102: a new class off-the-shelf allogeneic NK-like cells that can eliminate solid tumors Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; Cellular Therapies Adoptive immunotherapy; NK/NK T cell; Solid tumors
151 Poster Presentation Combination NK-92MICD64 cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer Hallie Hintz, BA; Bruce Walcheck; Aaron LeBeau; Cellular Therapies Antibody; NK/NKT cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment
152 Oral Presentation Adoptive T cell therapy targeting somatic p53 mutations Peter Kim, PhD; Parisa Malekzadeh, MD; Nolan Vale; Elizabeth Hedges; Nikolaos Zacharakis, PhD, MS; Steven A. Rosenberg, MD, PhD; Cellular Therapies Adoptive immunotherapy; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs)
153 Poster Presentation NEO-PTC-01 (BNT-221), an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic melanoma Divya R. Lenkala, MS; Jessica Kohler, PhD; Brian McCarthy; Michael Nelson; Jonathan McGee; Daniel Kallin; Janani Sridar; Paul Turcott; Dewi Harjanto; Cynthia Nijenhuis; Joost H. Van Den Berg, PharmD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Dendritic cell; Neoantigens; T cell
154 Poster Presentation Marrow-infiltrating Lymphocytes (MILs): A Novel Adoptive Immunotherapy for Hematological and Solid Tumors Eric R. Lutz, PhD; Lakshmi Rudraraju, MS; Elizabeth DeOliveira; Amanda L. Seiz; Monil Shah, PharmD; Celine Colmenares; Beverly Dan Fu; Daniela Bota, MD, PhD; Collin Brummel; Chad Brenner, PhD; Paul Swiecicki, MD; Nicole E. Fredrich; David B. Page, MD; Eleni Efstatihiou, MD, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD, MPH; Cellular Therapies Adoptive immunotherapy; Solid tumors; T cell
155 Poster Presentation iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma Jeff S. Miller, MD; Frank S. Cichocki, PhD; Jianfang Ning; Ryan Bjordahl, PhD; Zachary B. Davis, PhD; Katie Tuininga; Hongbo Wang; Paul Rogers; Moyar Ge; Tom T. Lee; Bob Valamehr, PhD; Clark C. Chen; Cellular Therapies Adoptive immunotherapy; NK/NK T cell; Solid tumors
156 Poster Presentation Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy Ribhu Nayar, Ph.D.; Sonal Jangalwe; Mollie M. Jurewicz; Antoine J. Boudot; Andrew S. Basinski; Robert Prenovitz; Elizabeth A. Olesin; Daniel C. Pollacksmith; Qikai Xu; Yifan Wang; Amy Virbasius; Jeffery Li; Holly Whitton; Garrett S. Dunlap; Alexander Cristofaro; Nancy Nabilsi; Ruan Zhang; Candace Perullo; Sida Liao; Kenneth L. Jahan; Kenneth Olivier; Gavin MacBeath, Ph.D.; Cellular Therapies Adoptive immunotherapy; Genetic polymorphism; Inflammation; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor antigens
157 Poster Presentation A critical role of CD40 and CD70 signaling in cDC1s in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells Takaaki Oba, MD,PhD; Toshifumi Hoki, MD,PhD; Takayoshi Yamauchi; Tibor Keler, PhD; Henry C. Marsh; Xuefang Cao; Fumito Ito; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Costimulation; Dendritic cell
158 Poster Presentation Inhibition of PI3Kδ improves tumor specific T cell immunity and metabolic fitness Guillermo O. Rangel RIvera, B.S.; Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Dimitrios C. Arhontoulis; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs)
159 Poster Presentation Adoptively transferred CD8+ T cells that target neoantigen persist and regress melanomas to a greater extent than those that target self/tumor-antigen Amalia M. Rivera Reyes, BS; Megan M. Wyatt, MS; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Chrystal M. Paulos, PhD; Cellular Therapies Adoptive immunotherapy; Neoantigens; Solid tumors
160 Poster Presentation TLR9-activated B cells imprint adoptively transferred CD8+ T cells with potent tumor immunity and persistence in vivo Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Chrystal M. Paulos, PhD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; B cell; Proteomics; T cell; TLR; Tumor infiltrating lymphocytes (TILs)
161 Poster Presentation Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy Kathrin Davari, PHD; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth Ganley; Lisa J. Pechilis; Iulia Diaconu; Prashant R. Nambiar; Mike S. Magee; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Christian Ellinger, Dr. Rer. Nat.; Cellular Therapies Adoptive immunotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens
163 Poster Presentation NICE: Neoantigen-Cytokine-Chemokine Multifunctional Engager for NK cell immunotherapy of solid tumors Xue Yao, MS; Sandro Matosevic, PhD; Cellular Therapies Adoptive immunotherapy; Bispecifics; Chemokine; Cytokine; Neoantigens; NK/NK T cell; Solid tumors; Tumor antigens; Tumor microenvironment
164 Poster Presentation AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing Burcu Yigit, PhD; Xavier Michelet, PhD; Shalu S. Kharkwal; Eleni Chantzoura, PhD; Jan Bergmann; Alvaro Sebastian Yague, Ph.D; Simon Yue; Darrian Moskowitz; Benjamin Wolf, PhD; Mark A. Exley, PhD; Dhan Chand, PhD; Marc A. Van Dijk, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; NK/NK T cell
165 Poster Presentation Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses Katarina Blagovic, PhD; Katarina Blagovic, PhD; Katarina Blagovic, PhD; Amritha K. Ramakrishnan, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine J. Seidl, PhD; Defne Yarar, PhD; Cellular Therapies Adoptive immunotherapy; Immune adjuvant; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine
166 Poster Presentation Mucosal-associated invariant T-cells (MAIT) in pancreatic cancer Jéssica O. Kamiki, Master's student; Patrícia A. António; Pedro Noronha; Carolina Condeço; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric De Sousa; Andreia Maia, PhD student; Mireia Castillo-Martin, MD, PhD; Antonio Beltran; Carlos Carvalho, MD; Joana Lérias, DVM; Markus J. Maeurer, MD, PhD, FRCP(London); Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Microbiome; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine
167 Poster Presentation B-cell-based vaccination elicit potent immunity against glioblastoma Catalina Lee-Chang, PhD; Jason Miska, PhD; David Hou; Aida Rashidi, MD; Peng Zhang, PhD; Rachel A. Burga, PhD; Crag M. Horbinski, MD, PhD; Roger Stupp, MD; Maciej S. Lesniak, MD; Cellular Therapies Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Solid tumors; Tumor microenvironment; Vaccine
168 Poster Presentation A Novel Prostate-Restricted Tumor-Associated Antigen: A Potential Therapeutic Target Zoila (Areli) A. Lopez Bujanda, MS; Aleksandar Obradovic; Thomas Nirschl; Timothy O’Donnell; Uri Laserson; Rodney Macedo-Gonzales; Ran Reshef, MD, MSc; Tiezheng Yuan; Mithil Soni; Emmanuel S. Antonarakis, MD; Benjamin Larman; Pawel Muranski; Charles G. Drake, MD, PhD; Cellular Therapies Antigen presenting cells; Dendritic cell; Neoantigens; Targeted therapy; Tumor antigens
169 Poster Presentation Microfluidics cell squeezing enables human PBMCs as drivers of antigen-specific CD8 T responses across broad range of antigens for diverse clinical applications Michael F. Maloney, PhD; Scott M. Loughhead, PhD; Amritha K. Ramakrishnan, PhD; Carolyne Smith, PhD; Anita Venkitaraman; Christian Yee; Miye Jacques, MSc; Defne Yarar, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Kelan A. Hlavaty, PhD; Melissa Myint, PhD; Katherine J. Seidl, PhD; Cellular Therapies Adoptive immunotherapy; Antigen presenting cells; Cytokine; T cell; Targeted therapy; Tumor antigens; Vaccine
170 Poster Presentation Microfluidics Cell Squeezing Enables Potent Cellular Vaccines in Murine Models Through Direct Cytosolic Loading and Direct CD8 T Cell Priming Emrah I. Ozay, PhD; Matthew G. Booty; Katarina Blagovic, PhD; David Soto; Olivia Pryor; Adam Stockmann; Disha Subramanya; Kelly Volk; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Defne Yarar, PhD; Katherine J. Seidl, PhD; Scott M. Loughhead, PhD; Cellular Therapies Antigen presenting cells; Chemotherapy; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine
171 Poster Presentation Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer Maho Nagasawa; Remco Bos; Haoxiao Zuo; Kiave Yune Ho Wang Yin, PhD; Marie-José van Lierop; Sebastien Tabruyn, PhD; Erik Manting; Marco de Bruyn; Hans Nijman; Satwinder Kaur SK. Singh, PhD; Cellular Therapies Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine
172 Poster Presentation Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM) Colin J. Thalhofer, PhD; Ryan D. Montler, MBA; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; Jacob Moses, B.S.; Joshua Rios, B.S.; Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Nick P. Morris, PhD; B R. Bell, M.D., DDS; Andrew D. Weinberg, PhD; Cellular Therapies Biomarkers; Immune contexture; Immune tolerance; Solid tumors; T cell; T cell lineages; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
173 Poster Presentation An In Vivo CRISPR/Cas9 Screening Platform to Identify T Cell Enhancing Edits in Distinct Solid Tumor Microenvironments Amy Becker, PhD; Troy Luster; Ishina Balwani; Nachiket Shevale; Jingwei Sun, PhD; Erica Del Aguila; Jeff Jones; Srijani Sridhar; Nishit Patel; Daniel O'Connell; Reynald Lescarbeau; Birgit C. Schultes; Cellular Therapies Adoptive immunotherapy; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
174 Poster Presentation An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology Stephen Iwanowycz, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Tina Pastoor; Jenny Kreahling, PhD; Soner Altiok, MD, PhD; Cellular Therapies Adoptive immunotherapy; Antibody; CAR T cells; Cytokine; Gene expression; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
175 Poster Presentation A Fas-4-1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer Shannon K. Oda, PhD; Shannon K. Oda, PhD; Kristin G. Anderson, PhD; Philip D. Greenberg, MD; Nicolas Garcia, BS; Pranali Ravikumar; Patrick Bonson; Cody Jenkins; Summer Zhuang; Andrew W. Daman; Shannon K. Oda, PhD; Cellular Therapies Adoptive immunotherapy; CAR T cells; Costimulation; Immune suppression; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor microenvironment
176 Poster Presentation Evaluating the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies Shiri Davidi; Roni Blat; Mijal Munster; Anna Shteingauz; Shay Cahal; Moshe Giladi; Uri Weinberg, MD PhD; Yoram Palti; Moshe Giladi, PhD; Cellular Therapies Solid tumors
177 Poster Presentation A severe cytokine release syndrome with respiratory failure in recurrent mesothelioma induced by EpCAM CAR-T cells infusion: a case report Sitong Wang, PG; Sitong Wang, PG; Juemin Fang; Hui Wang; Qing Xu; Cellular Therapies CAR T cells
179 Poster Presentation Immunotherapy trials lack a biomarker for inclusion: implications for drug development Jacob J. Adashek, DO; Alexey Goloubev; Shumei Kato, MD; Razelle Kurzrock, MD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Clinical study
180 Poster Presentation The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy Christopher D'Avella, MD; Karthik Devarajan, PhD; Martin Edelman, MD; Daniel M. Geynisman, MD; Checkpoint Blockade Therapy Checkpoint blockade; Immune suppression; Solid tumors
181 Poster Presentation Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors Haochuan Liu; Yaqiong Jie; Xinguang Han; Checkpoint Blockade Therapy Angiogenesis; Antibody; Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Immune contexture; Immune suppression; Surgery; T cell
182 Poster Presentation Highly Potent Fully Human Anti-VISTA Antibodies – A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells. Thierry Guillaudeux; Eric Tarcha; Robert Bader; Benjamin Dutzar; Nathan Eyde; Emily Frazier; David Jurchen; Remington Lance; Cristina Loomis; Kurt Lustig; Yulia Ovechkina; David Peckham; Shaarwari Sridhar; Mei Xu; Shawn Iadonato; Jeff Posakony; Checkpoint Blockade Therapy Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment
183 Poster Presentation Overcoming immunotherapy resistance in T cell-inflamed lung cancer Brendan L. Horton, PhD; Duncan Morgan; Noor Momin; Vidit Bhandarkar; Dane Wittrup, PhD; Chris Love, PhD; Stefani Spranger, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Cytokine; Immune contexture; Immune suppression; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
184 Poster Presentation Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities Tingting Zhong, MS; Xinghua Pang, BSc; Zhaoliang Huang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; Checkpoint Blockade Therapy Antibody; Checkpoint blockade
185 Poster Presentation Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma:a retrospective study Hong Liu, MD; Hong Liu, MD; Shuhuai Niu; Zhaohui Fang; Xi Chen; Qianying Zhang; Checkpoint Blockade Therapy Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Cytokine; Immune toxicity; Radiotherapy; Solid tumors; T cell
186 Poster Presentation Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. Yuki Muroyama, MD, PhD; Sasikanth Manne; Alexandar C. Huang, MD; Divij Mathew, PhD; Lakshmi Chilukuri; Allison R. Greenplate, PhD; Takuya Ohtani, PhD; Dmitriy Zamarin, MD, PhD; Claire F. Friedman, MD; John Wherry, PhD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
187 Poster Presentation Real-world treatment patterns and clinical predictors of overall survival among anti-PD-1 exposed advanced melanoma patients with documented evidence of disease progression. Cathy Anne Pinto, Ph.D.; Xinyue Liu; Xiaoyun Li; Emilie Scherrer; Mizuho Kalabis; Cathy Anne Pinto, Ph.D.; Checkpoint Blockade Therapy Checkpoint blockade; Epidemiology
188 Poster Presentation Novel Anti-SIRPalpha Antibodies with Differentiated Characteristics as Promising Cancer Therapeutics Swati Jalgaonkar; George Huang; Erin L. Filbert, PhD; Christine Tan; Ryan Alvarado; Sushma Krishnan, MSc in Biology; Rena Bahjat; Xiaodong Yang, MD, PhD; Checkpoint Blockade Therapy Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment
189 Poster Presentation A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice Suominen I. Suominen, PhD; Justyna Zdrojewska, PhD; Jenni Mäki-Jouppila, PhD; Philip Dube, PhD; Ivan Gladwyn-Ng, PhD; Paul Volden, PhD; Jukka Rissanen, PhD; Mari I. Suominen, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
190 Poster Presentation Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer Karine Tawagi, MD; Diana V. Maslov, MD, MS; Victoria Simenson, MD; Helen Yuan; Cameron Parent; Adi Bamnolker; Richa Goel; Zoe Blake; Madhav KC; Marc Matrana; Karine Tawagi, MD; Daniel Johnson, MD; Checkpoint Blockade Therapy Checkpoint blockade; Immune toxicity; Solid tumors
191 Poster Presentation Association of immune related adverse events with the efficacy of immune checkpoint inhibitors in metastatic renal cell carcinoma Vasilii Bushunow, MD; Leonard J. Appleman, MD, PhD; Roby Thomas, MD; Checkpoint Blockade Therapy Checkpoint blockade; Immune toxicity; Solid tumors
192 Poster Presentation 'Immune-Brain': A case series of cognitive dysfunction/decline in cancer patients on immunotherapy Sarah R. Gillett, MD, PhD; Ximena Jordan-Bruno, MD; Hibba Rehman, MD; Alissa Thomas, MD; Sarah R. Gillett, MD, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Immune toxicity; Solid tumors
193 Poster Presentation Differences In Thyroid Immune-Related Adverse Events Between Lung Cancer Types, A Retrospective Analysis Rahim A. Jiwani, MD; Heather Brody; Yuxuan Mao, MD, MS; Elisabeth Lee, PhD; Rita Rehana, MD; Cynthia Cherry; Hui Bian, PhD; Praveen Namireddy, MD; Checkpoint Blockade Therapy Checkpoint blockade; Immune toxicity
194 Poster Presentation A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma James R. Patrinely, Jr., BA; Rebecca Johnson, B.HlthSc, M.N; Aleigha R. Lawless, B.S.; Prachi Bhave, M.D.; Amelia Sawyers, B.S.; Maya Dimitrova, M.D.; Hui L. Yeoh, M.B.B.S., B.Med.Sc.; Marisa Palmeri, B.S.; Elizabeth J. Davis, M.D.; Suthee Rapisuwon, M.D.; Georgina V. Long, M.D., Ph.D.; Andrew Haydon, M.D., Ph.D.; Iman Osman, M.D.; Janice M. Mehnert, M.D.; Matteo S. Carlino, M.D., Ph.D.; Ryan J. Sullivan, M.D.; Alexander M. Menzies, M.D., Ph.D.; Douglas B. Johnson, M.D.; Checkpoint Blockade Therapy Checkpoint blockade; Clinical study; Immune adjuvant; Immune toxicity; Targeted therapy
195 Poster Presentation Avelumab internalization and lysosomal degradation by circulating immune cells in human is mediated by both Fc gamma Receptor (FcgR) and PD-L1 binding Hulin Jin, Ph.D; Vittorio D'Urso; Berend Neuteboom; Sean D. McKenna; Rene Schweickhardt; Alec W. Gross; Yves Fomekong Nanfack; Lars Toleikis; Markus Fluck; Juergen Scheuenpflug, PhD; Ti Cai; Checkpoint Blockade Therapy Antibody; Biomarkers; Checkpoint blockade
196 Poster Presentation Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data Nayan Lamba, MD; Bryan Iorgulescu, MD; Checkpoint Blockade Therapy Checkpoint blockade
197 Poster Presentation Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect? Nikolaos Andreatos, MD; Joanna Roopkumar, MBBS, MPH; Alok A. Khorana, MD; Neil M. Woody, MD, MS; Brian R. Gastman, MD; Pauline Funchain, MD; Checkpoint Blockade Therapy Autoimmunity; Checkpoint blockade; Immune toxicity; Radiotherapy; Solid tumors; Tumor antigens
198 Poster Presentation Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan; Andrej Jedinak, PhD; James Cardia, PhD; Simon P. Fricker, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Coinhibition; Gene expression; RNA; T cell; Targeted therapy; Tumor microenvironment
199 Poster Presentation Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ stem cell humanized NCG (HuCD34NCG) mouse model Christoph S. Eberle, PhD; Jenny Rowe, PhD; Ann Fiore, BS; Robert Mihalek, PhD; Stephen Festin, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
200 Oral Presentation NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model Yun Hu, PhD; James W. Welsh, MD; Sebastien Paris, PhD; Hampartsoum Barsoumian, PhD; Chike O. Abana; Saumil Gandhi; Quynh N. Nguyen; Maria A. Cortez, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
201 Poster Presentation Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma Angelica Valadez; Madeleine Welsh; Christine Kim; Angela Johns; Alain P. Algazi, MD; Hyunseok Kang, MD, MPH; Hyunseok Kang, MD, MPH; Checkpoint Blockade Therapy Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors
202 Poster Presentation In vitro and in vivo combination therapy of Low Molecular Weight Heparins, chemotherapy and immunotherapy, induce antitumor activity in Pancreatic Cancer Michalis Karamouzis; Panagiotis Sarantis, MD, PhD; Evangelos Koustas; Adriana Papadimitropoulou; Pavlos Papakotoulas; Alexandros Bokas; Dimitrios Schizas; Alexandros Papalampros; Evangelos Felekouras; Theodoros Liakakos; Athanasios Papavassiliou; Checkpoint Blockade Therapy Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
203 Poster Presentation Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients Jae-Chul Lee, MS; Woo Seok Yang; Hye-Young Park; Hye-mi Nam; Hyun-Jung Cho; Mi-Young Oh; Eun-Young Kwak; Jinhyun Park; Myeng Eun Jung; Hawook Chung; Minju Kim; Jae-Hwan Kim, PhD; Byoung Chul c. Cho, MD, PhD; Checkpoint Blockade Therapy Antibody; Biomarkers; Checkpoint blockade; Immune suppression; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
204 Poster Presentation The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer Ju Young Lee; Ju Young Lee, MD; Inae Park; Myungwoo Nam, MD; Christmann Low; Eugene Kim; Hansol Choi; Elena Vagia; Chan Mi Jung; Young Kwang Chae, MD, MPH, MBA; Checkpoint Blockade Therapy Checkpoint blockade; Clinical study; Clinical trial
205 Poster Presentation PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series Suresh Mukkamala, MD; Suresh Mukkamala, MD; Suresh Mukkamala, MD; Karine Tawagi, MD; Marc R. Matrana, MD; Checkpoint Blockade Therapy Checkpoint blockade; Clinical study; Immune toxicity; Tumor microenvironment
206 Oral Presentation An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer Elizabeth R. Stirling, MS; Ethan Willey-Shelkey; Adam Wilson; Aleksander Skardal, PhD; Pierre L. Triozzi, MD; Masaki Terabe, PhD; Lance D. Miller, MS, PhD; Shay Soker, PhD; David R. Soto-Pantoja, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Metabolism; Solid tumors; T cell; Tumor microenvironment
207 Poster Presentation Small molecule inhibitors of Sec61 cotranslational translocation regulate the phagocytosis checkpoint molecule CD47 Jennifer A. Whang, PhD; Jennifer A. Whang, PhD; Andrea Fan, PhD; Christopher J. Kirk, PhD; Eric Lowe, BS; Dustin McMinn, PhD; Beatriz Millare, BS; Meera Rao, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment
208 Poster Presentation E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 in syngeneic solid tumor models Mary Woodall-Jappe, Ph.D.; A. Raghav Chari; Anil N. Namboodiripad; Chandrasekhar Goda; Checkpoint Blockade Therapy Regulatory T cell (Treg cell); Solid tumors; T cell
209 Oral Presentation Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer Bryan Iorgulescu, MD; Prafulla C. Gokhale, PhD; Maria Speranza, PhD; Benjamin Eschle; Michael Poitras; Margaret Wilkens; Kara Soroko; Chhayheng Chhoeu; Aine Knott; Yan Gao; Mary Jane Lim-Fat; Gregory Baker; Dennis Bonal; Quang-Dé Nguyen; Gareth Grant; Keith Ligon; Peter K. Sorger; E Chiocca, MD; Ana C. Anderson, PhD; Paul T. Kirschmeier, PhD; Arlene H. Sharpe, MD, PhD; Gordon J. Freeman, PhD; David A. Reardon, MD; Checkpoint Blockade Therapy Checkpoint blockade; Clinical study; Immune suppression; Tumor infiltrating lymphocytes (TILs)
210 Poster Presentation Regulation of TIM-3 by phosphatidylserine Courtney M. Smith, BS; Alice Li; Nithya Krishnamurthy; Mark A. Lemmon, PhD, FRS; Checkpoint Blockade Therapy Antibody; Checkpoint blockade; Coinhibition; T cell
211 Poster Presentation Targeting BTN2A1 modulates anti-tumor activity of Vg9Vd2 T Cells Carla E. Cano, Ph.D.; Aude de Gassart, PhD; Christine Pasero, PhD; Melanie Gabriac; Marie Fullana; Emilie Granarolo; Rene Hoet; Caroline Imbert; Laurent Gorvel; Antoine Briantais; Anne-Charlotte Le Floch; Daniel Olive, Md, PhD; Checkpoint Blockade Therapy Checkpoint blockade; T cell; T cell lineages; Targeted therapy; Tumor microenvironment
212 Poster Presentation CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies. Vanessa Gauttier; Marion Drouin; Sabrina Pengam; Javier Saenz; Bérangère Evrard; Caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Emmanuelle Wilhelm; Elise Chiffoleau; Nicolas Poirier, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Dendritic cell; Myeloid cells; Tumor microenvironment
213 Poster Presentation Use of A novel peptide ligand targeting multiple immune checkpoints: A novel approach to immunotherapy against Central Nervous System Tumors Christopher Moertel; Zhengming Xiong; Michael Olin, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Immune suppression; Solid tumors
214 Poster Presentation The effect of Anti-PD-1 therapy on median Overall Survival and Progression Free Survival in Glioblastoma Multiforme Patients with certain tumor markers Awais Paracha, BA; Jian L. Campian, MD, PhD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Targeted therapy
215 Poster Presentation AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin Robyn J. Puro, Ph.D; Prabir Chakraborty, Ph.D; John O. Richards, Ph.D; Ronald R. Hiebsch; Michael J. Donio, MS; W. Casey Wilson, Ph.D; Benjamin J. Capoccia, Ph.D; Carrie B. Brachmann, Ph.D; Vicki Sung, Ph.D; Arun K. Kashyap, Ph.D; Daniel S. Pereira, Ph.D; Checkpoint Blockade Therapy Antibody; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor microenvironment
216 Poster Presentation Anti-tumor activity of iosH2 by blocking LILRB2 receptor signalling Osiris Marroquin Belaunzaran; Anahita Rafiei; Anil Kumar; Julia Kolibaba; Lorenz Vogt; Sean Smith; Christoph Renner; Checkpoint Blockade Therapy Checkpoint blockade; MDSC; Solid tumors; T cell
217 Poster Presentation Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development Yasmin L. Hashambhoy-Ramsay, PhD; Vikki Spaulding; Michelle Priess; Kristin O'Malley; Monica Gostissa, PhD; Edward C. Stack, PhD; Jeff Smith; Margaret Willer; Ben Umiker; Donald Shaffer, PhD; Checkpoint Blockade Therapy Antigen presenting cells; Biomarkers; Monocyte/Macrophage; Myeloid cells; RNA; Tumor evasion; Tumor microenvironment; Tumor stroma
218 Poster Presentation A preclinical study of IMC-002, a fully human therapeutic antibody safely targeting CD47 in cancer Hyeonseok Yoo, Ph.D.; Jeong Kook Kim, Ph.D.; Ji Yea Choi; Sun Kwang Song; Jihyun Park, Ph.D; Ara Jeon; Ji Hye Lee, MD; Sook Kyung Chang, Ph.D; Yun J. Song; Checkpoint Blockade Therapy Antibody; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors
219 Poster Presentation Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients Ahmad A. Tarhini, MD, PhD, MS; David F. McDermott, MD; Apoorva Ambavane, MPH; Agnes Benedict, MSc, MA; Cho-Han Lee; Corey Ritchings, PharmD; Brian Stwalley, PharmD; Meredith M. Regan, PhD; Michael B. Atkins, MD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Targeted therapy
220 Poster Presentation Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab Wolfram Samlowski, MD; Robert Nicholas, MD; Tayla Poretta, PharmD, MPH; Andriy Moshyk, MSc, MD; Jonathan Rajkumar, MPH; Anthony Salvatore, PharmD; Brian Stwalley, PharmD; Esmond D. Nwokeji, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Epidemiology; Immune adjuvant; Solid tumors
221 Poster Presentation Poor performance status negatively affects survival benefit of immunotherapy in non-small cell lung cancer Hameem I. Kawsar, MD, PhD; Pramod I. Gaudel, MD; Nahid Suleiman, MD, PharmaD; Mohammed Al-Jumayli, MD; Chao Huang, MD; Prakash Neupane, MD; Checkpoint Blockade Therapy Checkpoint blockade; Immune toxicity; Solid tumors
222 Poster Presentation Increased PD-L1 Tumor Expression Correlates with High Rate of Response to PD-1 Inhibitors in Patients with Unresectable, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma Nate Bowers, MD, PhD; Kimberly Burcher, MD; Jess Savas, MD; Phillip Williford, MD; Laura Doerfler, MD; Hafiz Shabbir Patwa, PharmD, MD; Joshua Waltonen, MD; Christopher Sullivan, MD; James Brown, MD; Mercedes Porosnicu, MD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Gene expression
223 Poster Presentation Racial differences in outcomes for metastatic Renal Cell Carcinoma (mRCC) patients managed on Immune-Checkpoint Inhibitor (ICI) therapy. T. Anders Olsen, BA; Dylan J. Martini, BA; Subir Goyal, Ph.D; Yuan Liu, Ph.D; Sean T. Evans, BS; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; Checkpoint Blockade Therapy Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors
224 Poster Presentation Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis Tamara A. Sussman, MD; Wei Wei, MS; Pauline Funchain, MD; Brian R. Gastman, MD; Checkpoint Blockade Therapy Checkpoint blockade; Solid tumors; T cell
226 Poster Presentation Checkpoint blockade hastens a switch from an NKT dominant, TNF-alpha-driven to a CD4+/CD8+ IFN-gamma-driven immune response within MC-38 tumor-infiltrating lymphocytes Shota Aoyama, MD; Ryosuke Nakagawa, MD; Satoshi Nemoto, MD; Patricio Perez Villarroel; James J. Mulé; Adam W. Mailloux, PhD; Checkpoint Blockade Therapy Tumor infiltrating lymphocytes (TILs)
227 Poster Presentation Using 3D spheroid cultures towards personalized ex vivo profiling of immune checkpoint inhibitor efficacy in melanoma and non-small cell lung cancer Kathryn Appleton, PhD; Katy A. Lassahn, MS; Ashley K. Elrod; Tessa DesRochers, PhD; Checkpoint Blockade Therapy Antibody; Biomarkers; Checkpoint blockade; Chemokine; Chemotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
228 Poster Presentation Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy Xue Bai, MD; Michelle Kim; Gyulnara Kasumova; Lu Si; Bixia Tang; Chuanliang Cui; Xiaoling Yang; Xiaoting Wei; Justine V. Cohen, DO; Donald P. Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, NP, MS; Tatyana Sharova; Dennie Frederick; Keith Flaherty, MD; Ryan J. Sullivan, MD; Jun Guo; Genevieve M. Boland, MD, PhD; Checkpoint Blockade Therapy Clinical study
229 Poster Presentation Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy Kristina Beeler, Dr.; Jakob Vowinckel, PhD; Martin Soste; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele, MD; Antonio Sorrentino, MD; Vito Vanella, MD; Kamil Sklodowski, PhD; Daniel Heinzmann, MSc; Paolo A. Ascierto, MD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Immune monitoring; Immune suppression; Metabolism; Proteomics; Tumor microenvironment
230 Poster Presentation Single cell PIK3 gene expression patterns support duvelisib (PI3K-delta, gamma inhibitor) treatment of melanoma and other tumors after checkpoint inhibitor therapy Samantha Hidy; David Weaver, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Gene expression; Targeted therapy
231 Poster Presentation A novel discovery pipeline identifies melanoma-specific antibodies in patients responding to immune checkpoint inhibitors Daniel Delitto, MD, PhD; Evan J. Lipson, MD; Daniel Delitto, MD, PhD; Laura Cappelli, MD; Klaus J. Busam, MD; Antony Rosen, MBChB, MS; Suzanne L. Topalian, MD; Livia Casciola-Rosen, PhD; Checkpoint Blockade Therapy Antibody; B cell; Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors; Tumor antigens
232 Poster Presentation The Epithelial-to-Mesenchymal Transition (EMT) contributes to Immunosuppression in Breast Carcinomas and regulates their response to Immune Checkpoint Blockade Anushka Dongre, PhD; Robert A. Weinberg, PhD; Mohammad Rashidian, PhD; Elinor Ng. Eaton; Ferenc Reinhardt; Prat Thiru; Maria Zagorulya; Sunita Nepal; Tuba Banaz; Anna Martner; Stefani Spranger, PhD; Checkpoint Blockade Therapy Biomarkers; Carcinogenesis; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
233 Poster Presentation Gene expression analysis of immune checkpoint therapy in mouse tumor models reveals similarities and differences in immune cell populations and functional processes that reflect response to treatment Dominic Pearce; Daniel Halligan; Patrick Fadden, PhD; Chassidy Hall; Amber Blackwell; Edgar R. Wood, Ph.D.; Checkpoint Blockade Therapy B cell; Gene expression; Monocyte/Macrophage; NK/NK T cell; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
235 Poster Presentation Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy Saurabh Garg, PhD; Eric A. Welsh; Bin Fang, PhD; Yuliana I. Hernandez; Trevor Rose; Jhanelle Gray; John M. Koomen, PhD; Anders E. Berglund, PhD; James J. Mule, PhD; Joseph Markowitz, MD, PhD; Checkpoint Blockade Therapy Antigen presenting cells; Biomarkers; Checkpoint blockade; Gene expression; Proteomics; RNA; Tumor microenvironment
236 Poster Presentation Evaluation of PD-L1 Expression in Primary Lung Tumor and Metastatic Lymph Nodes in the Presence of Immune Cells Chris Hansis; Xiaomei Wang, MD, PhD; Tao Wang; Gerald Feldman; Checkpoint Blockade Therapy Checkpoint blockade; Immune contexture; Solid tumors; Targeted therapy
237 Poster Presentation In vitro potency assays for immune checkpoint blockade using human primary cells, murine huGEMM immune cells and patient-derived tumor organoids Xuefei Yan, PhD; Hongjuan Zhang, PhD; Jun Zhou; Jia Zheng; Shuang Zhu; Rui Zhang; Mingfa Zang; Annie Xiaoyu An; Xiaoxi Xu; Shuzong Wang; Kevin Qijin Xu; Davy Xuesong Ouang; Henry Q. Li; Yujun Huang; Checkpoint Blockade Therapy Antibody; Checkpoint blockade; Costimulation; T cell
238 Poster Presentation Molecular dissection of tumor-immune microenvironment factors associated with response to checkpoint inhibitor therapy in non-small cell lung cancer patients using Nanostring Digital Spatial Profiling Omar J. Jabado, PhD; Suzana Couto, PhD, DVM pathologist; Jordan Blum, PhD; Patrick Franken; Patricia Coutinho de Souza, PhD; Maria N. Jure-Kunkel, PhD, DVM; Nora Pencheva, PhD; Brandon W. Higgs, PhD; Kate Sasser, PhD; Mark Fereshteh, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Chemotherapy; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
239 Poster Presentation Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis Thomas F. Gajewski, MD, PhD; Emily Higgs, BA; Shuyin Li, PhD; Shuyin Li, PhD; Blake Flood, BS; Ken Hatogai; Checkpoint Blockade Therapy Checkpoint blockade; Metabolism
240 Poster Presentation Identification of lung cancer mutational signatures and tumor drivers associated with specific bimodal PD-L1/TMB status. Fernando J. Lopez-Diaz, PhD.; Lauryn Keeler; Sally Agersborg, MD.; Lawrence Weiss, MD.; Vincent Funari, PhD (CGMBS); Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
241 Poster Presentation Clinical Outcomes of Metastatic Melanoma Patients with Liver Metastases Treated with Anti-PD-1 Monotherapy Versus Combination Ipilimumab/Nivolumab Vincent T. Ma, MD; Kent A. Griffith, MPH, MS; Jessica J. Waninger, BS; Stephanie Daignault-Newton, MS; Leslie A. Fecher, MD; Ajjai S. Alva, MBBS; Christopher D. Lao, MD, MPH; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Solid tumors
242 Poster Presentation Monitoring MDSC – A Hurdle to Immune Checkpoints Inhibitors Damien Montamat-Sicotte, PhD; Laetitia Cortes; Virginia Litwin; Henry Hepburne-Scott, PhD; Phoebe Bonner; Checkpoint Blockade Therapy Checkpoint blockade; Immune suppression; MDSC
243 Poster Presentation Real world exposure survival relationship of pembrolizumab in metastatic melanoma Vishal Navani, MA (Oxon) MBBS (Lon) MRCP (UK); Moira C. Graves, PhD; Giovana Marchett, MD, FRACP; Hiren Mandaliya, MD, FRACP; Nikola Bowden, BSc, PhD; Andre Van der Westhuizen, MBChB, MMed (Internal Medicine), FRACP, MSc (Med); Checkpoint Blockade Therapy Antibody; Biomarkers; Checkpoint blockade; Solid tumors
244 Poster Presentation Novel Respirable Antisense Oligonucleotide (RASON) approach to primary and metastatic human lung cancer: Preliminary results in a model system employing spontaneous lung tumors in dogs Jonathan W. Nyce, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Epigenetics; NK/NK T cell; Solid tumors; Tumor evasion
245 Poster Presentation Human TLR8 knock-in mice potentiate immunotherapy responses of MC38 syngeneic tumors Shanshan Qi, PhD; Hongjuan Zhang, PhD; Ruilin Sun; Annie X. An; Henry Q. Li; Davy X. Ouyang, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Dendritic cell; T cell; TLR
246 Poster Presentation Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups Biagio Ricciuti, MD; Navin R. Mahadevan; Renato Umeton; Joao V. Alessi; Andrew Polio; Natalie Vokes; Giulia C. Leonardi; Elizabeth J. Aguilar; Gonzalo Recondo, MD; Giuseppe Lamberti, MD; Marissa Lawrence; Pasi A. Janne, MD PhD; Eliezer Van Allen, MD; Lynette M. Sholl, MD; Mark Awad, MD, PhD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade
247 Poster Presentation Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34NCG mice Simon Tarpinian, BS; Jenny Rowe, PhD; Ruziboy Husanov, MS; Uma Saha, MS; Prabal Banerjee, PhD; Rukiye Eraslan, PhD; Beverly Jones, PhD; Stephen Festin, PhD; Vladimir Khazak, PhD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors; Stem cell/cancer-initiating cell
248 Oral Presentation Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing Kartik Sehgal, MD; Andrew Portell; Elena Ivanova; Patrick Lizotte, PhD; Navin R. Mahadevan; Jonathan R. Greene; Amir Vadji; Carino Gurjao; Tyler Teceno; Luke J. Taus; Tran C. Thai; Shunsuke Kitajima; Derek Liu; Tetsuo Tani; Moataz Noureddine; Christie J. Lau; Paul T. Kirschmeier, PhD; David Liu, MD, MPH, MS; Marios Giannakis, MD, PhD; Russell W. Jenkins; Prafulla C. Gokhale, PhD; Silvia Goldoni; Maria Pinzon-Ortiz, BS; William D. Hastings; Peter Hammerman; Juan Miret; Cloud P. Paweletz, Ph.D.; David A. Barbie, MD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade; Gene expression; Stem cell/cancer-initiating cell; Targeted therapy; Tumor evasion
249 Poster Presentation Targeting IFNβ-regulated secretory profiles to overcome acquired anti-PD-L1 resistance Yuhao Shi, B.S.; Melissa Dolan; Michalis Mastri, PhD; Kevin H. Eng, PhD; John ML. Ebos, PhD; Checkpoint Blockade Therapy Bioinformatics; Biomarkers; Checkpoint blockade; Cytokine; Gene expression; Immune suppression; Inflammation; Tumor microenvironment; Tumor stroma
250 Poster Presentation SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc?R engagement Alyson J. Smith, PhD; Weiping Zeng; William Siegall; Bryan Grogan; Jane Haass; Amber Blackmarr; Robert Thurman; Scott Peterson; Shyra J. Gardai, PhD; Checkpoint Blockade Therapy Antibody; Checkpoint blockade; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Targeted therapy
251 Poster Presentation Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer Alexander H. Song, MD; Ron Ng, MD; John Heller, MD; Robin Petro; Ralph B. D’Agostino, PhD; Thomas W. Lycan, Jr., DO; Mercedes Porosnicu, MD; Checkpoint Blockade Therapy Biomarkers; Checkpoint blockade
252 Poster Presentation Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence Eric J. Vick, MD, PhD; Inas Abuali, MD; Andrew Kelleher, MD; Sarah Ludvigsen, DO; Nathanael D. Moore, MD; Nicholas Arias; Shuchi Gulati, MD, FACP; Trisha M. Wise-Draper, MD, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Immune toxicity; Solid tumors
253 Poster Presentation Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity Rebecca Ward, MSc; Elena Paltrinieri, PhD; Marilyn Marques; Priyadarshini Iyer, MSc; Sylvia Dietrich, PhD; Jeremy D. Waight, PhD; Mark Bushell, PhD; Nicholas Wilson, PhD; Jennifer S. Buell, PhD; David Savitsky, PhD; Dhan Chand, PhD; Checkpoint Blockade Therapy Antibody; Checkpoint blockade; NK/NK T cell; T cell
254 Oral Presentation CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors. Roberta Zappasodi, PhD; Inna Serganova; Ivan Cohen; Masatomo Maeda; Yasin Senbabaoglu; Masahiro Shindo; Rachana Maniyar, PhD; Mayuresh Mane; Avigdor Leftin; McLane Watson, BS; Svena Verma, BS; Matthew Lubin; Myat Kyaw Ko; Arnab Ghosh, MD, PhD; Mohsen Abu-Akeel, BS; Ellen Ackerstaff; Jason Koutcher; Ping-Chih Ho, PhD; Greg M. Delgoffe, PhD; Ronald Blasberg; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; Checkpoint Blockade Therapy Checkpoint blockade; Immune suppression; Immune tolerance; Metabolism; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
255 Poster Presentation Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies Sean T. Evans, BS; Dylan J. Martini, BA; Benjamin L. Magod, BS; Timothy A. Olsen, BA; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Deepak Ravindranathan, MD, MS; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; Checkpoint Blockade Therapy Checkpoint blockade; Targeted therapy
256 Poster Presentation Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699). Cesar A. Perez, MD; Robert Wesolowski, MD; Breelyn A. Wilky, MD; Waldo Ortuzar Feliu, MD; Hong Zhang; irina shapiro, PhD; Anna Wijatyk, MD; Remigiusz Kaleta, MD; Jonathan C. Trent, MD; Checkpoint Blockade Therapy Solid tumors
257 Poster Presentation Development of a Diagnostic Platform Which Matches Therapies to the Tumor Microenvironment Dominant Biology Kristen Strand-Tibbitts, PhD; Completed Clinical Trials Angiogenesis; Bioinformatics; Tumor microenvironment; Tumor stroma
258 Poster Presentation Scientific correlatives from LCCC 1525: A Phase II Study of a Priming Dose of Cyclophosphamide Prior to Pembrolizumab to Treat Metastatic Triple Negative Breast Cancer Mark G. Woodcock, MD; Carey K. Anders, MD; Amanda E. Van Swearingen; Dominic T. Moore; Maria J. Sambade; Luz A. Cuaboy; Amy L. Garrett; Karen McKinnon; Kristen Cowens; Dante S. Bortone; Benjamin C. Calhoun; Lisa Carey; Claire Dees; Trevor Jolly; Hyman Muss; Katherine Reeder-Hayes; Rebecca Kaltman; Rachel Jankowitz; Vinay Gudena; Oludamilola Olajide; Charles M. Perou; Benjamin G. Vincent, MD; Jonathan S. Serody, MD; Completed Clinical Trials B cell; Checkpoint blockade; Clinical trial; Gene expression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment
259 Poster Presentation Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC Gulam A. Manji, MD PhD; Nathan Bahary, MD PhD; Vincent Chung, MD; Florence Dalenc; Michel Ducreux; Carlos A. Gomez-Roca, MD; Seock-Ah Im; Jeremy Kortmansky; Jill Lacy, MD; Neil H. Segal, MD; Olivier Tredan; Olivera Cirovic, MD, PhD; Kelly DuPree; Christelle Lenain; Danny Lu; Lidia Robert; Jeffrey Xu; Xiaosong Zhang, MD PhD; Sung-Bae Kim; Completed Clinical Trials Checkpoint blockade; Chemotherapy; Clinical trial
260 Poster Presentation T Cell Infiltrating Repertoire Diversity is Associated with Enhanced Survival Following Neoadjuvant Therapy in Patients with Resectable Pancreatic Cancer Pranav Murthy, BS; Pragosh Saini; Kira L. Russell, BS; Wenjing Pan, PhD; Daniel Weber, BS; Miranda L. Byrne-Steele, PhD; Jian Han, MD PhD; Viginia Espina, PhD; Lance Liotta, MD, PhD; Herbert J. Zeh III, MD; Nathan Bahary, MD PhD; Aatur D. Singhi, MD PhD; Tullia C. Bruno, PhD; Amer H. Zureikat, MD; Michael T. Lotze, MD; Completed Clinical Trials B cell; Bioinformatics; Biomarkers; Chemotherapy; Immune contexture; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
261 Poster Presentation Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180 Manish A. Shah, MD; Takashi Kojima; Daniel Hochhauser; Peter M. Enzinger, MD; Judith Raimbourg; Antoine Hollebecque, MD; Florian Lordick; Sung-Bae Kim; Masahiro Tajika; Heung Tae Kim; A. Craig Lockhart; Hendrick-Tobias Arkenau; Farid El-Hajbi; Per Pfeiffer; Pooja Bhagia, MBBS, MD; Z. Alexander Cao; Jared Lunceford; Shailaja Suryawanshi; Mark Ayers, PhD; Matt Marton; Ken Kato, MD, PhD; Completed Clinical Trials Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment
262 Poster Presentation Tumoral DKK1 expression correlates with better clinical outcomes in patients with advanced esophagogastric cancer (EGC) treated with DKN-01 Samuel J. Klempner, MD; Michael Kagey, PhD; Cynthia Sirard, MD; Cynthia Sirard, MD; Completed Clinical Trials Antibody; Biomarkers; Clinical trial; RNA; Targeted therapy
263 Poster Presentation Pleiotropic effects of IL-7 in prostate cancer patients receiving Sipuleucel-T vaccination Caroline Duault, PharmD, PhD; Nirasha Ramchurren, PhD; Russell Pachynski, MD; Lawrence Fong, MD; Sean C. Bendall, PhD; Mina Pichavant; Bita Sahaf, PhD; Chihiro Morishima, MD; Leonard D'Amico, PhD; Martin A. Cheever, MD; Steven P. Fling, PhD; Holden T. Maecker, PhD; Completed Clinical Trials Antigen presenting cells; Clinical trial; Costimulation; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; Vaccine
264 Poster Presentation Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma Myles Dillon, PhD; Lianjie Li, MD PhD; Jeongsook Bang, MS; Nicholas Gaspar, PhD; Jessica Kuhnert, BS; Nathalie M. Fiaschi, PhD; Vladimir Jankovic, MD; Israel Lowy, MD, PhD; Gavin Thurston, PhD; Glenn Kroog, MD; Kyoung Soo Ha, MD; Raquel Deering, PhD; Raquel Deering, PhD; Completed Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; T cell; Tumor microenvironment; Vaccine
265 Poster Presentation Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort Jean-Laurent Deville; Alain Ravaud; Marco Maruzzo; Theodore S. Gourdin, MD; Michele Maio, MD; Luc Dirix, MD; XiaoZhe Wang; Yulia Vugmeyster; Frank Beier; Jeorg Seebeck; Sarah Chennoufi, MD, PhD; James L. Gulley, MD, PhD; James L. Gulley, MD, PhD; Completed Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Cytokine; Solid tumors
266 Poster Presentation Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) Sophie Wildsmith; Jill Walker, PhD; Anne L’Hernault; Weimin Li; Hannah Bye; Philip He; Feng Xiao; Qu Zhang; Ross Stewart; Melissa de los Reyes, MS; Rajiv G. Raja, PhD; Wendy Levin; Ashok K. Gupta, MD, PhD; Thomas Powles, MBBS, MD, MRCP; Joaquim Bellmunt; Matthew D. Galsky, MD; Alexandra Drakaki, MD,PHD; Michiel van der Heijden, MD; Completed Clinical Trials Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
267 Poster Presentation Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer David M. O'Malley, MD; Waldo Ortuzar Feliu, MD; Isabelle Ray-Coquard, MDPhD; Michael O'Neal; Jerome Alexandre, MD; Julie Cole, MD; Robert Ludwig, MD; Madhavi Nallewar; Jennifer S. Buell, PhD; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Victoria Borisovskaya; Completed Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors
268 Poster Presentation A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101) Dominique Berton-Rigaud; Ignace Vergote; Patricia Pautier; Anna Kryzhanivska, MD; Antoine Angelergues; Deanna Kornacki, PhD; Monika Dudzisz-Sledz; Chuan Tian, PhD; Nawel Bourayou, MD; Frederic Selle; Completed Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Solid tumors
269 Poster Presentation Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer Tze Heng Tan; Sriram Sridhar; Helen K. Angell, PhD, BSc; Emma Jones; Amelia Raymond; Sophie Willis; Dimitris Polychronopoulos; Alejandro Yovine; Nassim Morsli; Patricia McCoon, PhD; Carl Barrett; Maria L. Ascierto, PhD; Completed Clinical Trials Biomarkers; Cytokine; Gene expression; Immune contexture; Immune monitoring; Tumor microenvironment
270 Poster Presentation A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort Young Kwang Chae, MD, MPH, MBA; Megan Othus; Sandip P. Patel, MD; Sarah E. Fenton, MD PhD; Ding Wang, MD; Cristina Rodriguez; Adedayo Onitilo; Ahmad H. Mattour, MD; Igor Rybkin, MD, PhD; Jourdain Hayward; Christine M. McLeod; Helen Chen, MD; Elad Sharon, MD, MPH; Edward Mayerson; Christopher W. Ryan; Melissa Plets, M.S.; Charles D. Blanke; Razelle Kurzrock, MD; Young Kwang Chae, MD, MPH, MBA; Completed Clinical Trials Checkpoint blockade; Clinical trial; Solid tumors
271 Poster Presentation Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial Frauke Schnorfeil; Christiane Geiger, PhD; Iris Bigalke; Dag Josefsen; Yngvar Floisand; Gunnar Kvalheim, MD, PhD; Dolores J. Schendel, PhD; Anna Tafuri; Kai Pinkernell; Completed Clinical Trials Antigen presenting cells; Dendritic cell; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Vaccine
272 Poster Presentation Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC) Fu-Sheng Wang, MD, PhD; Fanping Meng, MD, PhD; Jiehua Jin, PhD; Yuanyuan Li, MD, PhD; Regina Wanju Wong, PhD; Anthony Tanoto Tan, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; Completed Clinical Trials Adoptive immunotherapy; Clinical trial; T cell
273 Poster Presentation Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation Wenjie Chen, MD, PhD; Jintao Cheng, MD; Xiaofang Zheng, BSc; Fan Yang, MD, PhD; Royce Fam, BSc; Sarene Koh, PhD; Lu-En Wai, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; Qi Zhang, MD, PhD; Completed Clinical Trials Adoptive immunotherapy; Clinical trial; T cell
274 Oral Presentation Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer Maria L. Ascierto, PhD; Matthew D. Hellmann, MD; Nathan Standifer; Song L. Wu; Han Si; Chris Morehouse; Marlon C. Rebelatto, DVM, PhD, DACVP; Shaad L. Abdullah; Rajiv G. Raja, PhD; Jean-Charles Soria, MD, PhD; Caroline Germa; Carl Barrett; Completed Clinical Trials B cell; Biomarkers; Checkpoint blockade; Tumor microenvironment
275 Poster Presentation Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC Song Wu; Nathan Standifer, PhD; Melissa de los Reyes, MS; Micheal Oberst; Rajv Raja; Carl Barrett; Maria L. Ascierto, PhD; Maria L. Ascierto, PhD; Completed Clinical Trials Biomarkers; Checkpoint blockade; Immune suppression; Tumor microenvironment
276 Poster Presentation Prognostic value of tumor size varies by treatment in a meta-analysis of 15 randomized clinical trials in advanced non-small cell lung cancer across immunotherapy, TKI, and chemotherapy regimens Jacqueline Buros, BA; Krzysztof Sakrejda, PhD; Daniel Lee, MS; Eric Novik, MS; Jacqueline Buros, BA; Philip Jewsbury, PhD; Completed Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial
277 Oral Presentation Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy Boris Sepesi, MD; Erin M. Corsini; Annikka Weissferdt; Apar Pataer; Mehmet Altan, MD; Mara B. Antonoff, MD; George R. Blumenschein, Jr., MD; Yasir Y. Elamin; Frank Fossella; Bonnie S. Glisson, MD; Wayne Hofstetter; Jonathan Kurie; Xiuning Le, MD, PhD; Cheuk Hong Leung, MS; Heather Lin, MS, PhD; Charles Lu; Reza Mehran; Frank Mott; David Rice; Jack Roth; Ferdinandos Skoulidis; Stephen G. Swisher, MD; Anne Tsao, MD; Ara A. Vaporciyan, MD; Garret Walsh; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Tina Cascone, MD, PhD; Completed Clinical Trials Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors; Surgery; Targeted therapy
278 Poster Presentation Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer George R. Blumenschein, Jr., MD; Siddhartha Devarakonda, MD; Melissa L. Johnson, MD; Victor Moreno, PhD, MD; Justin F. Gainor, MD; Martin Edelman, MD; John V. Heymach, MD, PhD; Ramaswamy Govindan, MD; Carlos Bachier, MD; Bernard Doger de Spéville; Matthew J. Frigault, MD, MSc; Anthony J. Olszanski, MD, RPh; Vincent K. Lam; Natalie Hyland; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula M. Fracasso, MD, PhD Completed Clinical Trials Adoptive immunotherapy; Targeted therapy
279 Poster Presentation Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival MD; Lukas Kaesmann, MD; Julian Taugner; Chukwuka Eze; Claus Belka; Farkhad Manapov; Completed Clinical Trials Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors
280 Poster Presentation Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Carmen Anadon; David Noyes; Ana Landin; Xiaoqing Yu; Dongliang Du; Zachary Thompson; Bin Fang, PhD; John M. Koomen, PhD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Dung-Tsa Chen; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; Completed Clinical Trials Adoptive immunotherapy; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens
281 Poster Presentation JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC) Gabriella Galffy, MD; Iwona Lugowska; Elena Poddubskaya; Byoung Chul c. Cho, MD, PhD; Myung-Ju Ahn; Ji-Youn Han, MD, PhD; Wu-Chou Su; Ralph J. Hauke, MD; Stephen Dyar; Dae Ho Lee; Piotr Serwatowski; David Lorente Estelles; Viran Holden; Yu Jung Kim; Vladimir Vladimirov; Zsolt Horvath; Abhimanyu Ghose; Allison Goldman; Alessandra di Pietro; Jing Wang; Danielle Murphy; Mikhail Laskov Completed Clinical Trials Angiogenesis; Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy
282 Poster Presentation Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy Lingkang Huang; Jared Lunceford, PhD; Junshui Ma; Kenneth Emancipator, MD; Completed Clinical Trials Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
283 Poster Presentation Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; Completed Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR
284 Poster Presentation Real World Data of Sequencing Immune Checkpoint Inhibitors (ICI) after Initial ICI Krishna S. Gunturu, MD; Muhammad A. Awidi, MD; Rojer Ranjit, NP; Brendan Connell, MD; Rachel Carrasquillo; Brigitte Gil; Natalie Dalbo, MD; Lewena Maher; Seanna Reilly; Stephanie McDonald, NP; Philip Tsoukas, MD; Linda Voner, RN; Completed Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Immune tolerance; Solid tumors
285 Poster Presentation Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors David S. Hong, MD; Marcus O. Butler, MD; Russell Pachynski, MD; Ryan J. Sullivan, MD; Partow Kebriaei; Sarah Boross-Harmer; Matthew J. Frigault, MD, MSc; Ecaterina I. Dumbrava, MD; Amy Sauer; Francine Brophy; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula G. Fracasso Completed Clinical Trials Adoptive immunotherapy; Targeted therapy
286 Poster Presentation Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4-1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer Maria Jose Garcia Velloso; Ivan Penuelas; Mariano Ponz-Sarvise; Miguel Sanmamed; Maria E. Rodriguez-Ruiz, MD, PhD; Ignacio J. Melero, Dr., MD, PhD; Danielle Vugts; Ronald Boellaard; Marc Huisman; Guus van Dongen; Ernesto Guarin; Florian Heil; Maurizio Ceppi, PhD; Marta Canamero, MD, PhD; Camilla Matheisen; Francois Iglesias; Radoiane Helbaj; Oliver Krieter; Michael Hettich; Completed Clinical Trials Bispecifics; Clinical study; Clinical trial; Solid tumors; T cell; Tumor microenvironment; Tumor stroma
287 Poster Presentation Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors Solmaz Sahebjam, MD; Jameel Muzaffar, MD; Timothy A. Yap, MD, PhD; David S. Hong, MD; Olivier Rixe, MD, PhD; Ursa Brown-Glaberman, MD; Andreea Varga, MD; Christophe Massard, MD; Capucine Baldini, MD; Sergey Efuni, MD, PhD; Barbara Kapelan, BS; Yi Liu, PhD; Eniola Ogunmefun, MD; Tomonori Tayama, MS; Henry Zhao, PhD; Denis J. Healy, MBA; Robert Latek, PhD; Daisuke Nakashima, MS; Emrullah Yilmaz, MD, PhD Completed Clinical Trials Antibody; Biomarkers; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Solid tumors
288 Poster Presentation A Phase 1 Study of IMC-001, a PD-L1 Blocker, in Patients with Metastatic or Locally Advanced Solid Tumors Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; Completed Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell
289 Poster Presentation PGV-001: A Phase 1 Trial of a Personalized Neoantigen Peptide Vaccine for the Treatment of Malignancies in the Adjuvant Setting. Thomas U. Marron, MD, PhD; Julia Kodysh, PhD; Alex Rubinsteyn, PhD; John Finnigan, MD PhD; Ana Blazquez, PhD; Mansi Saxena, PhD; Marcia Meseck; Timothy O’Donnell; Daniela Delbeau, RN; Matthew Galsky, MD; Deborah , Doroshow, MD PhD; Brett Miles, MD; Krysztof Misiukiewicz, MD; Hanna Irie, MD PhD; Amy Tiersten, MD; Samir Parekh, MD; Marshall Posner, MD; Andrea Wolf, MD MPH; John Mandeli, PhD; Jeffrey Hammerbacher, PhD; Michael Donovan, MD PhD; Rachel Brody, MD PhD; Sacha Gnjatic, PhD; Eric Schadt, PhD; Philip Friedlander, MD PhD; Nina Bhardwaj, MD PhD; Completed Clinical Trials Clinical trial; Immune monitoring; Neoantigens; Solid tumors; Vaccine
290 Poster Presentation Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells Dobrin Draganov, PhD; Antonio F. Santidrian; Ivelina Minev, MSc; Duong H. Nguyen, PhD; Dmitriy Zamarin, MD, PhD; Francesco M. Marincola, MD; Boris Minev, MD; Completed Clinical Trials Adoptive immunotherapy; Antigen presenting cells; Clinical study; Immune monitoring; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; Stem cell/cancer-initiating cell; T cell; T cell lineages
291 Poster Presentation Phase Ib Study of Selicrelumab (CD40 agonist) in Combination with Atezolizumab (anti-PD-L1) in Patients with Advanced Solid Tumors Fabrice Barlesi, Prof, MD, PhD; Martijn Lolkema, MD, PhD; Kristoffer Staal Rohrberg, MD, PhD; Cinta Hierro, MD; Aurelien Marabelle, MD, PhD; Albiruni Abdul Razak, MD; Luis Teixeira, MD, PhD; Valentina Boni, MD, PhD; Wilson H. Miller, Jr, MD, PhD; Charu Aggarwal, MD, MPH; Martin Stern, MD; Olivera Cirovic, MD, PhD; Olivera Cirovic, MD, PhD; Barbara Romagnoli, PhD; Randolph Christen, MD; Raksha Dodia, PhD; Kevin Smart, PhD; Bernhard Reis, PhD; Nicolas Staedler, PhD; Carl Watson; Neeltje Steeghs, MD, PhD; Completed Clinical Trials Antigen presenting cells; Checkpoint blockade; Clinical study; Solid tumors
292 Poster Presentation Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management HoWai D. Siu, MBBS, MMed; Robert S. O'Neill, MedSci MBBS; Matthew H. Tong, MD; JunHee Hong, Bmed, MD; Carole A. Harris, MBBS (Hons) MMed BPharm FRACP; Morteza Aghmesheh, MD, GradDipSC, PhD, FRACP; Hussein S. Hussein, Dr; Completed Clinical Trials Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation
293 Poster Presentation Results of the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Kerstin Guenther; Amir Alpert; Borje Andersson, MD, PhD; Zoe Coughlin; Jens Fritsche, PhD; Norbert Hilf; Patrick M. Hwu, MD; Mamta Kalra, PhD; Sabrina Kuttruff-Coqui, PhD; Dominik Maurer, PhD; Regina Mendrzyk; Ali Mohamed; Becky Norris; Anna Nowak; Rita Ort; Carsten Reinhardt, MD, PhD; Fabian Richter; Arun Satelli; Oliver Schoor, PhD; Kerry A. Sieger; Harpreet Singh, PhD; David Vining, MD; Claudia Wagner; Toni Weinschenk, PhD; Cassian Yee, MD; Steffen Walter, PhD; Completed Clinical Trials Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens
294 Oral Presentation CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody Michael D. Farwell, MD; Raymond F. Gamache, PhD; Neeta Pandit-Taskar, MD; Mike Postow, MD; Michael S. Gordon; Ian A. Wilson, PhD; Alessandro Mascioni, PhD; Anna M. Wu, PhD; William Le; Avital Weiss; Ronald Korn, MD PhD; Completed Clinical Trials Biomarkers; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
295 Poster Presentation First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas Nehal Lakhani, MD, PhD; Marlana Orloff, MD; Siqing Fu, MD, PhD; Ying Liu; Yan Wang; Hui Zhou; Kedan Lin, PhD; Fang Liu; Shuling Yan; Amita Patnaik, MD FRCP(C) Completed Clinical Trials Autoimmunity; Clinical trial; Immune toxicity
296 Poster Presentation Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors Yo-Ting Tsai, PhD; Arun Rajan, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD; Completed Clinical Trials Autoimmunity; B cell; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors
297 Poster Presentation Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers Alexandra Gyurdieva; Stefan Zajic; Ya-Fang Chang; E. Andres Houseman; Shan Zhong; Jaegil Kim; David C. Turner; Laura A. Johnson; Ioanna S. Eleftheriadou; Jenna Tress; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Naimish Pandya; John Glod, MD; Dejka Araujo, MD; Warren Chow; Mihaela Druta; George D. Demetri; Brian A. Van Tine, MD, PhD; Sandra P. D’Angelo; Completed Clinical Trials Adoptive immunotherapy; Biomarkers; Chemokine; Cytokine; Gene expression; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy
298 Poster Presentation Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) Sandra P. D'Angelo, MD; George D. Demetri; Brian A. Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Naimish Pandya; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Jenna Tress; Julie Edwards; Tim Young; Mary Woessner; Alexandra Gyuerdieva; Stefan Zajic; Sophia Goodison; Dejka Araujo, MD; Completed Clinical Trials Adoptive immunotherapy; Clinical trial; Solid tumors; T cell; Tumor antigens
299 Poster Presentation Immuno-Metabolic Signatures of Dendritic Cells Associate With T-cell Responses in Melanoma Patients Juraj Adamik, PhD; Deena M. Maurer, MS; Paul Munson, PhD; Alexis J. Combes, PhD; Philippe Pierre, PhD; Matthew F. Krummel, PhD; Rafael J. Argüello, PhD; Lisa H. Butterfield, PhD; Completed Clinical Trials Antigen presenting cells; Dendritic cell; Gene expression; Metabolism; Vaccine
300 Poster Presentation Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Patrick M. McCarthy, MD; Anne E. O'Shea, MD; Phil M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; Completed Clinical Trials Clinical trial; Dendritic cell; Solid tumors; Tumor antigens; Vaccine
301 Poster Presentation Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study Paolo A. Ascierto, MD; Karl D. Lewis, MD; Caroline Robert, MD, PhD; Daniil Stroyakovskiy, MD, PhD; Helen Gogas, MD, PhD; Svetlana Protsenko, MD, DSc; Rodrigo P. Pereira, MD; Thomas Eigentler, MD; Piotr Rutkowski, MD; Lev Demidov, MD, DSc; Georgy Moiseevich Manikhas, MD, PhD; Haocheng Li, PhD; Qian Zhu, PhD; Edward McKenna, PharmD, BCOP; Virginia McNally, PhD; Ralf Gutzmer, MD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; Completed Clinical Trials Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy
302 Poster Presentation A phase I trial of intratumoral PVSRIPO in patients with unresectable treatment refractory melanoma Georgia M. Beasley, MD, MHs; Nellie E. Farrow, MD; Karenia Landa, MD; Maria Angelica Seilm, MD; Sin-Ho Jung, PhD; Darell D. Bigner, MD, PhD; Andrea True Kelly, PhD; Smita Nair, PhD; Matthias Gromeier, MD; April Salama, MD; Completed Clinical Trials Clinical trial; Solid tumors; Vaccine
303 Oral Presentation Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo): Final Results. Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Richelle DeBlasio, B.Sc.; Joe-Marc JM. Chauvin, PhD; Quanquan Ding; Ornella Pagliano; Amy Rose, RN; John M. Kirkwood, MD; Hassane M. Zarour, MD; Completed Clinical Trials Checkpoint blockade; Clinical trial; Immune contexture; TLR
304 Poster Presentation Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; Diwakar Davar, MD; Elizabeth I. Buchbinder, MD; Theresa Medina, MD; Adil Daud, MD; Antoni Ribas, MD, PhD; Jiaxin Niu, MD, PhD; Geoffrey T. Gibney, MD; Kim A. Margolin, MD; Anthony J. Olszanski, MD, RPh; Inderjit Mehmi, MD; Takami Sato, MD; Montaser Shaheen, MD; Aaron J. Morris, PhD; David Mauro, MD, PhD; Katie Campbell, PhD; Heather Kelley, MA; Riyue Bao, PhD; George J. Weiner, MD; Jason J. Luke, MD; Arthur M. Krieg, MD; James E. Wooldridge, MD; John M. Kirkwood, MD; Completed Clinical Trials Checkpoint blockade; Clinical study; Dendritic cell; T cell; TLR; Tumor microenvironment
305 Poster Presentation Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples Tyler D. Hether; Tim Howes, PhD; Christine N. Spencer, PhD; Travis Hollman, PhD, MD; Jason W. Reeves; Danny Wells, BA, PhD; Claire F. Friedman, MD; Theresa LaVallee; Jedd D. Wolchok, MD, PhD; Sarah E. Warren, PhD; Completed Clinical Trials Antibody; Bioinformatics; Biomarkers; Clinical trial; Gene expression; RNA; Solid tumors; Tumor microenvironment; Tumor stroma
306 Poster Presentation Predictors of immunotherapy benefit in Merkel cell carcinoma Alec J. Kacew, BA; Harita Dharaneeswaran; Gabriel J. Starrett; Manisha Thakuria; Nicole R. LeBoeuf, MD, MPH; Ann W. Silk, MD, MS; James A. DeCaprio; Glenn J. Hanna, MD; Completed Clinical Trials Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
307 Poster Presentation Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study Karl D. Lewis, MD; Paolo A. Ascierto, MD; Caroline Robert, MD, PhD; Rodrigo Munhoz, MD; Gabriella Liszkay, MD; Luis De La Cruz Marino, MD; Judit Olah, MD; Paola Queirolo, MD; Jacek Mackiewicz, MD, PhD; Kalpit Shah, PhD; Harper Forbes, MSc; Christian Hertig, PhD; Yibing Yan, PhD; Ralf Gutzmer, MD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; Completed Clinical Trials Checkpoint blockade; Clinical study
308 Poster Presentation Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma Jeffrey S. Weber, MD, PhD; Paolo A. Ascierto, MD; Mark R. Middleton, MD, PhD; Delphine Hennicken; Roberto Zoffoli; Anne Pieters; Adenike Amadi; Katrin Kupas; Srividya Kotapati; Andriy Moshyk, MSc, MD; Dirk Schadendorf, MD; Completed Clinical Trials Checkpoint blockade; Immune adjuvant; Solid tumors
309 Poster Presentation The role of tumor-draining lymph nodes in the tuning of systemic T cell immunity by CTLA-4 blockade is revealed by local delivery of tremelimumab in early-stage melanoma: data from a Phase-I trial Jessica C. Notohardjo, MD; Kim M. van Pul, MD; Anita G. Stam; Dafni Chondronasiou; Sinead Lougheed; Petrousjka M. van den Tol; Karin Jooss, PhD; Ronald J. Vuylsteke, MD, PhD; Alfons J. van den Eertwegh; Tanja D. de Gruijl, PhD; Completed Clinical Trials Checkpoint blockade; Clinical study; Dendritic cell; Immune adjuvant; Immune monitoring; MDSC; T cell; TLR; Tumor microenvironment
310 Poster Presentation The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma Anne E. O'Shea, MD; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Lexy M. Adams, MD, MPH; Patrick M. McCarthy, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, MD; Jessica L. Cindass, MD; Tommy A. Brown, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; Completed Clinical Trials Antigen presenting cells; Clinical trial; Dendritic cell; Solid tumors; Tumor antigens; Vaccine
311 Poster Presentation Phase II Trial of Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Vaccination in Patients with Metastatic Melanoma Chantal Saberian, MD; Rodabe N. Amaria, MD; Cara Haymaker, PhD; Marie Andree Forget, PhD; Roland L. Bassett, BS; Isabella C. Glitza, MD, PhD; Gregory A. Lizee, PhD; Cassian Yee, MD; Jeniffer L. McQuade, MD; Michael K. Wong, MD PhD FRCPC; Hussein A. Tawbi, MD, PhD; Sapna Patel, MD; Adi Diab, MD; Michael A. Davies, MD, PhD; Patrick M. Hwu, MD; Chantale Bernatchez, PhD; Completed Clinical Trials Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine
312 Poster Presentation Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition Ahmad A. Tarhini, MD, PhD, MS; Ni Kang; Sandra Lee; F. Stephen Hodi, Jr., MD; Gary I. Cohen; Omid Hamid, MD; Laura F. Hutchins; Jeffrey A. Sosman, MD; Harriett M. Kluger; Zeynep Eroglu, MD; Henry Koon, MD; Donald P. Lawrence, MD; Kari L. Kendra; David R. Minor, MD; Carrie Lee, RN, MSN, OCN; Mark R. Albertini, MD; Lawrence E. Flaherty, MD; Teresa Petrella; Howard Striecher; Vernon K. Sondak, MD; John M. Kirkwood, MD; Completed Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Immune tolerance; Solid tumors
313 Poster Presentation A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms Manish Patel, MD; Jason J. Luke, MD; Erika P. Hamilton, MD; Bartosz Chmielowski, MD, PhD; George R. Blumenschein, Jr., MD; Hedy L. Kindler, MD; Shakeela Bahadur, MD; Cesar A. Santa-Maria, MD, MSCI; Janine Koucheki; Jichao Sun, PhD; Sanjeev Kaul, PhD; Francine Z. Chen, MD; Xiaoyu Zhang; John J. Muth; Patrick Kaminker, PhD; Paul A. Moore, PhD; Bradley J. Sumrow, MD; Susanna Ulahannan, MD, MMED; In-Progress Clinical Trials Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy
315 Poster Presentation W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody Ignacio J. Melero, Dr., MD, PhD; Carlos A. Gomez-Roca, MD; Pierre Ferre, VetMD, PhD; Pierre Ferre, VetMD, PhD; Eric Chetaille; Aurelie Petain; Celine Thuilliez; Isabelle Vandenberghe; Francisco Cruzalegui, PhD; Asmaa Boudribila; Mariya Pavlyuk; Aurelien Marabelle, MD, PhD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment
316 Poster Presentation EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A Aurelien Marabelle, MD, PhD; Christiane Jungels, MD; Johann S. De Bono, MD; Norbert Vey, MD; Martin Wermke, MD; Elena Garralda, MD; Aude de Gassart, PhD; Patrick Brune; Emmanuel Valentin, PhD; Marina Iché; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Cytokine; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
317 Poster Presentation A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors Leisha A. Emens, MD, PhD; Muralidhar Beeram, MD; Erika P. Hamilton, MD; Sarina A. Piha-Paul, MD; Valerie Odegard, PhD; Sue Hamke; Naomi Hunder, MD; Samuel J. Klempner, MD; In-Progress Clinical Trials Antibody; Clinical study; Clinical trial; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens
318 Poster Presentation Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007 Timothy A. Yap, MD, PhD; Mallika Dhawan; Andrew E. Hendifar; Michele Maio, MD; Taofeek K. Owonikoko; Miguel Quintela-Fandino; Ronnie Shapira-Frommer, MD; Sanatan Saraf, MD; Ping Qiu, PhD; Fan Jin, MD; Alexander Gozman; Douglas A. Levine; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Targeted therapy
319 Poster Presentation Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine Daniela Bota, MD, MD., PhD; David E. Piccioni, MD, PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Robert O’Donnell; Robert Aiken, MD; Frank Hsu; Xiao-Tang Kong; Thomas H. Taylor, PhD; Gabriel I. Nistor, MD; Robert O. Dillman, MD; Daniela Bota, MD, MD., PhD; In-Progress Clinical Trials Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell
320 Poster Presentation Phase IIa Study of Alpha-DC1 Vaccine against HER2/HER3, Chemokine Modulation Regimen and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative or HER2+ Breast Cancer Shipra Gandhi, MD; Peter A. Forsyth, MD; Mateusz Opyrchal, MD, PhD; Kamran A. Ahmed, MD; Hung T. Khong, MD; Kristopher Attwood, PhD; Ellis G. Levine, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Robert A. Fenstermaker, MD; Dheerendra Prasad, MD; Kazuaki Takabe, MD,PhD; Brian J. Czerniecki, MD,PhD; Pawel Kalinski, MD, PhD; In-Progress Clinical Trials Checkpoint blockade; Chemokine; Clinical trial; Vaccine
321 Poster Presentation Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer Shipra Gandhi, MD; Mateusz Opyrchal, MD, PhD; Cayla Ford; Victoria Fitzpatrick; Melissa Grimm, PhD; Per H. Basse, MD, PhD; Marie Quinn, MD; Agnieszka Witkiewicz, MD; Kristopher Attwood, PhD; Marc S. Ernstoff, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Ellis G. Levine, MD; Pawel Kalinski, MD, PhD; In-Progress Clinical Trials Chemokine; Chemotherapy; Clinical trial; Immune adjuvant; TLR; Tumor infiltrating lymphocytes (TILs)
322 Poster Presentation Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study. Joo H. Sohn, PhD; Joo H. Sohn, PhD; Young Hyuk Im; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Cytokine; Immune adjuvant; T cell
323 Poster Presentation Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients Lajos Pusztai, MD; Hailing Lu, MD, PhD; Christopher Hale, PhD; Anne Grosse-Wilde, PhD; Jennifer Specht, MD; Shanu Modi, MD; Hyo Han, MD; Javier Cortes, MD PhD; Mafalda Oliveira, MD, PhD; Phillip Garfin, MD, PhD; Zejing Wang, MD, PhD; Matthew Onsum, PhD; In-Progress Clinical Trials Antibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
324 Poster Presentation BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) Agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors. Manish Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony W. Tolcher, MD; Lixin Li, PhD; Adam Zong, PhD; Alexander Chung, PhD; Robert H. Andtbacka, MD, CM; In-Progress Clinical Trials COVID and Immunotherapy; Adoptive immunotherapy; Clinical study; Clinical trial; Cytokine; Dendritic cell; Monocyte/Macrophage; Solid tumors; TLR
325 Poster Presentation Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells Gerard J. Criner, MD; Mehrdad Mobasher, MD, MPH; Craig M. Hill, PhD; Shenshen Hu, PhD; Suresh Mahabhashyam, MD, MPH; Joshua Brody, MD; Thomas U. Marron, MD, PhD; Stephen Willingham, PhD; Richard A. Miller, MD; In-Progress Clinical Trials COVID and Immunotherapy; Antibody; B cell; Clinical study; Clinical trial; Immune adjuvant; Vaccine
326 Poster Presentation SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer Pedro Noronha; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric D. Sousa; Jéssica O. Kamiki; Patrícia A. António; Carolina Condenço; Inês Silva; Andreia Maia, PhD student; Mireia Castillo-Martin; António Beltran; Carlos Carvalho, MD; Joana R. Lerias, PhD; Alimuddin Zumla; Markus J. Maeurer, MD, PhD, FRCP(London); In-Progress Clinical Trials COVID and Immunotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs)
327 Poster Presentation Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor Jian Shi, MD; Baoen Shan; Junyan Wang; Jiayin Liu; Rongfeng Liu; Yujie Shan; In-Progress Clinical Trials COVID and Immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Gene expression; Immune toxicity; Solid tumors; Targeted therapy
328 Poster Presentation Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003) Carlos A. Mayo, MD; Ellen B. Gurary; Patricia Marinello; In-Progress Clinical Trials Angiogenesis; Chemotherapy; Clinical study; Targeted therapy
329 Poster Presentation Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab Tom R. Lillie, MD; Andrew Stone; Sarah Lockwood; Richard R. Brown; Andrew Fox; Eirini Bournazou; John W. Beadle, MBBCH; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
330 Poster Presentation Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies Cameron J. Herting, PhD; Yuchen Zhang; Deon B. Doxie, PhD; Matthew R. Farren, Ph.D.; Michael B. Ware; Olatunji B. Alese, MD; Christina Wu, MD; Walid L. Shaib, MD; Mehmet Akce; Mohammad Y. Zaidi, MD, MS; Amanda N. Ruggieri; Madhav Dhodapkar, MD; Kavita M. Dhodapkar, MD; Juan Sarmiento; Rafi Ahmed, PhD; Shishir K. Maithel; Bassel El-rayes, MD; Gregory B. Lesinski, PhD; In-Progress Clinical Trials Checkpoint blockade; Chemokine; Clinical trial; Cytokine; Immune monitoring; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
331 Poster Presentation Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C) Pashtoon M. Kasi, MD, MS; Beau M. Toskich, MD; Sandeep T. Laroia, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Inflammation; Neoantigens; Radiotherapy; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma
332 Oral Presentation Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. Keun-Wook Lee, MD, PhD; Young Suk Park, MD, PhD; Joong Bae Ahn, MD; Jin Kyung Lee, PhD; Jiyeon Ryu, Ph.D; Bitna Oh, MD; Chan-Young Ock, MD, PhD; Sunjin Hwang, MD; Ki Baik Hahm, MD, PhD; Seong-Jin Kim, PhD; Tae Won Kim, MD; Keun-Wook Lee, MD, PhD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment
333 Poster Presentation Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program Douglas C. Palmer, PhD; Beau R. Webber; Yogin Patel, PhD; Matthew J. Johnson, PhD; Christine M. Kariya; Walker S. Lahr; Maria r. Parkhurst; Jared Gartner, MS; Todd D. Prickett; Frank J. Lowery; Rigel J. Kishton; Devikala Gurusamy; Zulmarie Franco; Suman Vodnala; Miechaleen D. Diers; Natalie K. Wolf; Nicholas J. Slipek; David H. McKenna, Jr., MD; Darin Sumstad; Lydia Viney; Tom Henley; Tilmann Bürckstümmer; Oliver Baker; Ying Hu; Chunhua Yan; Daoud Meerzaman; Kartik Padhan; Winnie Lo; Parisa Malekzadeh; Li Jia; Drew C. Deniger; Shashank J. Patel; Paul F. Robbins; R. Scott McIvor, PhD; Modassir Choudhry; Steven A. Rosenberg; Branden S. Moriarity, PhD; Nicholas P. Restifo; In-Progress Clinical Trials Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; Neoantigens; Tumor antigens; Tumor infiltrating lymphocytes (TILs)
334 Poster Presentation Phase II Study Evaluating a Chemokine-Modulatory (CKM) Regimen in Patients with Colorectal Cancer (CRC) Metastatic to the Liver Sarbajit Mukherjee, MD, MS; Patrick Boland; Medhavi Gupta; Melissa Grimm, PhD; Kristopher Attwood, PhD; Pawel Kalinski, MD, PhD; In-Progress Clinical Trials Chemokine; Clinical trial
335 Poster Presentation Novel CoupledCARTM Technology for Treating Colorectal Cancer Song Li; Chengfei Pu; Zhiyuan Cao; Ning Li; Xinyi Yang; Youli Luo; Haiyan Zhao; Hang Yang; Xi Huang; Xiaogang Shen; Xiuwen Wang; Yongping Song; Junjie Mao; Pengfei Pang; Qun Hu; Zhao Wu; Lei Xiao, Ph.D.; In-Progress Clinical Trials Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens
337 Poster Presentation Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI David Tougeron, MD, PhD; Jean Francois Emile; Stephano Kim; Carole Monterymard; marine gilabert; Jérémie BEZ; Astrid Lievre; Laetitia Dahan; Pierre Laurent-puig; Laurent Mineur; ROmain Coriat; Jean Louis Legoux; Vincent Hautefeuille; Jean marc Phelip; Thierry Lecomte; Harry Sokol; Claude Capron; Claire Gallois; Violaine Randrian; Come Lepage; Julien Taieb; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs)
338 Poster Presentation Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + Modified FOLFOX-6 (mFOLFOX-6) Akshata R. Udyavar, Ph.D; Michael Cecchini; Daniel DiRenzo, PhD; Sean Cho, PhD; Lisa Seitz, MS; Kristen Zhang, BS; Stephen W. Young, PhD; Amy E. Anderson, PhD; Kimberline Y. Gerrick; Matthew J. Walters, PhD; Houston N. Gilbert, PhD; Olivia S. Gardner; Cheng Quah, MD; Juan C. Jaen, PhD; William Grossman, MD; In-Progress Clinical Trials Bioinformatics; Biomarkers; Chemotherapy; Clinical trial; Gene expression; Immune suppression; Metabolism; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
339 Poster Presentation Preliminary Safety, Tolerability and Efficacy Results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in Patients (pts) with HER2 aberrated solid tumors Jifang Gong, MD; Zhi Dong; Dan Liu; June Xu; Jing Yang; Yue Yang; Yakun Qi; Jie Men; Paul Kong; Ting Xu; Lin Shen, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Targeted therapy
340 Poster Presentation Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer Lisa Horvath; Tanya Dorff, MD; Matthew Rettig, MD; Jean-Pascal Machiels, MD, PhD; Martijn Lolkema, MD, PhD; Karen Autio, MS, MD; Richard Greil; Sylvie Rottey, MD; Nabil Adra, MD, MSc; Mark E. Salvati, PhD; Shirley Poon, MS, MBA; Daniel Tan, MBBS, MRCP; Gabor Jurida; Hosein Kouros-Mehr; Karim Fizazi; Ben Tran, MD; Lisa Horvath; In-Progress Clinical Trials Bispecifics; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor antigens
341 Poster Presentation Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC) Rahul Aggarwal, MD; Dan Costin, MD; Jingsong Zhang, MD, PhD; Paul Monk, MD; Mark Linch, MD; Lawrence I. Karsh, MD; Diane Healey, MS; Stefani Corsi-Travali; Sreenivas Adurthi, PhD; Adedayo Adedoyin; Vincent O'Neill, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor microenvironment
342 Poster Presentation A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk Toni K. Choueiri; Laurence Albiges, MD; Thomas Powles, MBBS, MD, MRCP; Nehal Mohamed; Fong Wang; Robert J. Motzer, MD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Solid tumors; Targeted therapy
343 Poster Presentation Phase 3 Study of Pembrolizumab + Docetaxel and Prednisone/Prednisolone for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Next-Generation Hormonal Agents (NHAs) (KEYNOTE-921) Daniel P. Petrylak, MD; Neal Shore, MD; Mostefa Bennamoun; Raffaele Ratta; Josep M. Piulats; Ben Li; Charles Schloss; Karim Fizazi; In-Progress Clinical Trials Checkpoint blockade; Clinical trial
344 Poster Presentation Phase 3 Trial of Pembrolizumab and Enzalutamide Versus Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) Julie Nicole Graff; Joseph Burgents; Li Wen Liang; Arnulf Stenzl; In-Progress Clinical Trials Checkpoint blockade; Clinical trial
345 Poster Presentation Phase 3 Study of Combination Pembrolizumab + Olaparib Therapy Versus Enzalutamide/Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Progression on Chemotherapy (KEYLYNK-010) Evan Y. Yu, MD; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim, MD; Emmanuel S. Antonarakis, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial
346 Poster Presentation KEYNOTE-991: Phase 3 Study of Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy (ADT) for Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Christian Gratzke; Cuizhen Niu; Christian H. Poehlein, MD; Joseph Burgents; In-Progress Clinical Trials Checkpoint blockade; Clinical trial
347 Poster Presentation Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial Ira Winer, MD, PhD; Lucy Gilbert, MD; Ulka N. Vaishampayan, MD; Seth Rosen, MD; Christopher J. Hoimes, DO; Jameel Muzaffar, MD; Anna Spreafico, MD PhD; David F. McDermott, MD; Quincy Chu, MD; Olivier Dumas, MD; Aman Chauhan, MD; Arvind Chaudhry, MD; Piotr Tomczak, MD; Valentina Boni, MD, PhD; Debora S. Bruno, MD; Kelly K. Curtis, MD; Yan Wang, PhD; Elizabeth Dorn, PhD; Jessicca Rege, PhD; Yangchun Du, PhD; Ilda Bidollari; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Marc S. Ernstoff, MD; Vamsidhar Velcheti, MD; James Strauss, MD; In-Progress Clinical Trials Clinical study; Clinical trial; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
348 Poster Presentation A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO) Brian M. Slomovitz, MD; Bradley J. Monk; Katherine Moxley; Nadeem Ghali; Justyna Fronczek Sokol; Chuan Tian, PhD; Nawel Bourayou, MD; Jalid Sehouli; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy
349 Poster Presentation Early Safety and Efficacy of a Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Alain P. Algazi, MD; William Smith; Timothy Panella; Dong M. Shin, MD; Marie-Louise H. Fjaellskog; John Celebi; Alice Drumheller; Jean Campbell, PhD; Robert H. Pierce, Jr., MD; Michael Guarino; In-Progress Clinical Trials Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Tumor antigens; Tumor microenvironment; Vaccine
351 Poster Presentation Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 Kevin Harrington, PhD, FRCP, FRCR; Ezra EW. Cohen, MD; Lilian L. Siu, MD; Danny Rischin, MBBS, MD; Lisa Licitra, MD; Jan Vermorken; Quynh-Thu Le, MD, FACR, FASTRO; Makoto Tahara; Jean-Pascal Machiels, MD, PhD; Natalyn Hawk; Joy Ge; Behzad Bidadi, MD, MS; Ramona F. Swaby, MD; Barbara A. Burtness, MD; In-Progress Clinical Trials Angiogenesis; Checkpoint blockade; Clinical trial; Targeted therapy
352 Oral Presentation Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab Ezra EW. Cohen, MD; Michael Postow, MD; Ryan J. Sullivan, MD; David S. Hong, MD; Heather Yeckes-Rodin, MD; Jerry McCarter, RN, BSN; Nora Zizlsperger; Jeffery Kutok, MD, PhD; Brenda O'Connell, PhD; Kara Page; Jennifer Roberts; Halle Zhang, PhD; Bartosz Chmielowski, MD, PhD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment
353 Poster Presentation Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC Antonio Jimeno, MD, PhD; Sophie Papa, PhD, MBBS, MRCP; Missak Haigentz, MD; Juan F. Rodríguez-Moreno,, MD; Julian Schardt; Maria Fardis, PhD; Friedrich Graf Finckenstein, MD; Rana Fiaz; Guang Chen; Alex Cacovean; Zelanna Goldberg; Ammar Sukari, MD; In-Progress Clinical Trials Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
354 Poster Presentation A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer Sara I. Pai, MD PhD; Douglas R. Adkins, MD; Lori J. Wirth, MD; Christine H. Chung, MD; Michael K. Gibson, MD PhD; Ammar Sukari, MD; Francis P. Worden, MD; Dimitrios Colevas, MD; Nabil F. Saba, MD; Barbara A. Burtness, MD; Cristina P. Rodriguez, MD; Julie E. Bauman, MD, MPH; Bonnie S. Glisson, MD; Lara A. Dunn, MD; Anish Suri, PhD; Mark Haydock, B.S.; Steven N. Quayle, PhD; Saso Cemerski, PhD; Megan Leader; Jason Brown; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; In-Progress Clinical Trials Biomarkers; Clinical trial; Costimulation; Cytokine; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens
355 Poster Presentation First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies Nina Shah, MD; Alan Tan, MD; Lihua E. Budde, MD, PhD; Craig C. Hofmeister, MD; Andrew J. Cowan, MD; Hayder Saeed, MD; Jing C. Ye, MD; Mitchell S. Cairo, MD; David A. Rizzieri, MD; Gregory J. Orloff, MD; Xue Snow Ge, PhD; Zachary Lee, PharmD; Neha Dixit, PhD; Wildaliz Nieves, PhD; Mona Vimal, MSc; Haijun Ma, PhD; Takahiro Miyazaki, PhD; Loui Madakamutil, PhD; Mario Q. Marcondes, MD, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Krina K. Patel, MD; In-Progress Clinical Trials Biomarkers; Clinical trial; Cytokine; Leukemia/Lymphoma; NK/NK T cell; T cell
356 Poster Presentation Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab Neil L. Berinstein, MD; Isabelle A. Bence-Bruckler; Nick Forward; Pierre Laneuville; Joy Mangel; Douglas Stewart; Irina Amitai; Gail Klein; Nancy Pennell; Iran Rashedi; Kim Roos; Yogesh Bramhecha, PhD; Rebekah Conlon; In-Progress Clinical Trials B cell; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune monitoring; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor microenvironment; Vaccine
357 Poster Presentation TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma Sabrina C. Collins, BS; Adarsh Joshi; Lei Shen; Subhasree Das; Kaveri Suryanarayan; Dean C. Bottino; Cheryl Li; Michael Curley; Dannie Wang; Michael Abadier; Ryan Larson; Xavier Parot; In-Progress Clinical Trials Biomarkers; Chemokine; Cytokine; Immune contexture; Immune monitoring; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
358 Poster Presentation Trial In Progress: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC) Hailey K. Carroll, MD; Umair Aleem, MD; Pooja Varghese; Marie Galligan, PhD; Michèle Bourke; Katherine Hoey; Ronan Ryan, MD; Peter Doran, PhD; Stephen Stewart, MD PhD; Cliona O'Farrelly, PhD; Tim F. Greten, MD; Diarmaid Houlihan, MD; Raymond McDermott, MD; Austin G. Duffy, MD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Coinhibition; Immune monitoring; Microbiome; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment
359 Oral Presentation AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results Hossein Borghaei, MS, DO; Michael Boyer; Melissa L. Johnson, MD; Ramaswamy Govindan, MD; Luis Paz-Ares Rodrigues; Fiona Blackhall; Rene Boosman; Stéphane Champiat; Horst-Dieter Hummel; W. Victoria Lai; Hibiki Udagawa; Anne Chiang; Afshin Dowlati, MD; Christine L. Hann, MD, PhD; Ravi Salgia, MD; Everett E. Vokes, MD; Mukul Minocha; Nooshin Hashemi-Sadraei; Aditya Shetty; Marie-Anne Damiette Smit, MD, MS; Hui Yang; Taofeek K. Owonikoko, MD, PhD; In-Progress Clinical Trials Bispecifics; Clinical trial
360 Poster Presentation A Phase 1 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC) Jonathan W. Goldman, MD; Thomas Stinchcombe, MD; Gregory J. Gerstner, MD; Missak Haigentz Jr., MD; Surya Vangala; Megan Parsi; Victor Kabala; Dinesh Simkhada; Andres A. Gutierrez, MD PhD; Suresh S. Ramalingam, MD; In-Progress Clinical Trials Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; T cell; Tumor antigens
361 Poster Presentation A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12 month analysis of biomarkers and clinical outcomes Magnus Jaderberg, MD; Luis Paz-ares; Susana Cedres; Luis Paz-Ares; Xavier Serres; Charles Ricordel; Nicolas Isambert; Santiago Ponce Aix; Victor Levitsky; Lukasz Kuryk, PhD; Anne-Sophie Moller; Sylvia Vetrhus; In-Progress Clinical Trials Clinical study; Gene expression; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
362 Oral Presentation A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis James Spicer, PhD, FRCP; Åslaug Helland, MD, PhD; Enric Carcereny, MD; Edurne Arriola, MD, PhD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez, MD, PhD; Jonathan R. Thompson, MD; James Strauss, MD; Ana Laura Ortega Granados, MD; Enriqueta Felip, MD PhD; Emmett V. Schmidt, MD PhD; Michael J. Chisamore, PhD; Noelly Madeleine, PhD; Austin Rayford, MS; Katherine Lorens; Abdul Siddiqui, MD; Hani Gabra, MD, PhD, FRCP; Jaya Nautiyal, PhD; David Micklem, PhD; James B. Lorens, PhD; Matthew G. Krebs, MD, PhD; In-Progress Clinical Trials Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
363 Poster Presentation Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result Byoung Chul c. Cho, MD, PhD; Ki Hyeong Lee, MD, PhD; Ji-Youn Han, MD, PhD; Byoung yong Shim, MD, PhD; Hye Ryun Kim, MD, PhD; Kyoung-Ho Pyo, PhD; Jae-Hwan Kim, PhD; Chung-Feng Xin; Jin Kyung Lee, PhD; Jiyeon Ryu, PhD; Bitna Oh, MD; Sunjin Hwang, MD; Ki Baik Hahm, MD, PhD; Seong-Jin Kim, PhD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Coinhibition; Immune monitoring; Solid tumors; Tumor microenvironment
364 Poster Presentation A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC Mark Awad, MD, PhD; David R. Spigel, MD; Edward B. Garon, MD; Saiama Waqar, MD; Aaron Lisberg, MD; Melissa A. Moles; Jennifer Tepper; April Lamb; Amy Wanamaker; Zakaria Khondker; John Srouji; Jesse Z. Dong; Asaf Poran; Kristen N. Balogh; Meghan Bushway; Mark DeMario, MD; Lakshmi Srinivasan, PhD; Richard B. Gaynor; Ramaswamy Govindan, MD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine
365 Poster Presentation Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study Ticiana A. Leal, MD; Raphael Bueno; Libor Havel; Jeffrey Ward, MD, PhD; Ticiana A. Leal, MD; In-Progress Clinical Trials Checkpoint blockade; Chemotherapy; Clinical trial; Targeted therapy
366 Poster Presentation A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC Wenxiang Wang; Lin Wu, MD; Wei Zhang; Shun Lu; Haohui Fang; Guohua Yu, MD; Ming Zhou; Wenqun Xing; Qixun Chen; Xingya Li; Nong Yang; Minhua Ye; Wentao Fang; Yunchao Huang; Jichun Liu; Lijie Tan; Xiaosheng Hang; Wengang Zhang; Liwei Zhang; Jun Chen; Xun Zhang; Yu Zhang; Jie Jiang; Aihong Zhong; Shanqing Li; Yunpeng Liu; Guowu Wu; Xiaoyan Kang; Ying Tian; Tao Xu; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Immune adjuvant; Solid tumors; Surgery
367 Poster Presentation A Phase 1/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors Jason J. Luke, MD; Filip Janku, MD, PhD; Anthony J. Olszanski, MD, RPh; Kevin Leach; Radhakrishnan Iyer; Atif Abbas, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Cytokine; Immune monitoring; T cell; Tumor microenvironment
368 Oral Presentation REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors Adi Diab, MD; Brendan D. Curti, MD; Mehmet A. Bilen, MD; Andrew S. Brohl, MD; Evidio Domingo-Musibay, MD; Erkut H. Borazanci, MD; Christie Fanton, PhD; Cat Haglund; Mona Vimal, MSc; Mann Muhsin, MD; Mario Q. Marcondes, MD, PhD; Anh Nguyen; Mary A. Tagliaferri, MD; Wei Lin, MD; Jonathan Zalevsky, PhD; Sandra P. D'Angelo, MD; In-Progress Clinical Trials Biomarkers; Clinical trial; Cytokine; Solid tumors; T cell; TLR; Tumor microenvironment
369 Poster Presentation Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies Jeffrey Yachnin, MD, PhD; Gustav J. Ullenhag, PhD, MD; Ana Carneiro, MD PhD; Dorte Nielsen, MD, PhD; Kristoffer Staal Rohrberg, MD, PhD; Anne Månsson Kvarnhammar, PhD; Lena Schultz; Erika Bågeman, PhD; Erika Bågeman; Camilla Wennersten, PhD; Charlotte A. Russell, MD, PhD; In-Progress Clinical Trials Antibody; Bispecifics; Checkpoint blockade; Clinical trial; Solid tumors
370 Poster Presentation Pharmacodynamic assessment of a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors Victor Moreno, PhD, MD; Tatiana Hernandez; Ignacio J. Melero, Dr., MD, PhD; Miguel Sanmamed; Iben Spanggaard; Kristoffer Staal Rohrberg, MD, PhD; Josep Tabernero, MD, PhD, MSc.; Analia Azaro; Maria Martinez Garcia; Alejo Rodriguez-Vida; Christina Claus; Florian Heil; Oliver Krieter; Oliver Grimm; Marta Canamero, MD, PhD; Jose Duarte; Alexandra-Cristina Nica; Iakov Davydov; Michael Hettich; Chia-Huey Ooi; Christian Heichinger; Ernesto Guarin; Radoiane Helbaj; Tamara Tanos; Eveline Nueesch; Maurizio Ceppi, PhD; Irene Moreno; Emiliano Calvo; In-Progress Clinical Trials Biomarkers; Bispecifics; Checkpoint blockade; Clinical trial; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
371 Poster Presentation The association of the gut microbiota and clinical response to immune checkpoint inhibitors in patients with advanced cancer Cheng-Hsun Chiu; Chih-Yu Tsai; Yu-Fen Lin; John W. Chang, MD; Chiao-En Wu; Yuan-Ming Yeh; Yung-Chi Shen; Ming-Mo Hou; Jia-Juan Hsieh; John W. Chang, MD; In-Progress Clinical Trials Biomarkers; Clinical study; Microbiome; Solid tumors
372 Poster Presentation Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the Phase 1 solid tumor trial of AMV564, a novel T-cell engager Sarina A. Piha-Paul, MD; Alexander N. Starodub, MD; Raghad Karim, MD; Michael Shafique, MD; Gabriel R. Tinoco Suarez, MD; Curtis Ruegg, PhD; Victoria Smith, PhD; Patrick Chun, MD; In-Progress Clinical Trials Bispecifics; Clinical study; Clinical trial; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment
373 Poster Presentation Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2 John D. Powderly, II, MD; Bradley C. Carthon, MD Ph.D; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; John M. Wrangle, MD; Anthony F. Shields, MD PhD; Sarina A. Piha-Paul, MD; Kelly K. Curtis, MD; Ilda Bidollari; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Bruce Dezube, MD; Ulka N. Vaishampayan, MD; In-Progress Clinical Trials Clinical study; Clinical trial; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell
374 Poster Presentation A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors Devalingam Mahalingam, MBBChBAO; Devalingam Mahalingam, MBBChBAO; Wael A. Harb, MD; Amita Patnaik, MD FRCP(C); Susanna Ulahannan, MD, MMED; Haider Mahdi, MD; Manmeet S. Ahluwalia, MD; Manish Patel, MD; Afshin Dowlati, MD; Andrea Bullock, MD; Patrick Wen, MD; Shubham Pant, MD; Mary Mulcahy, MD; Robert Guttendorf, Rph, PhD; Lou Vaickus, MD; Suming Wang, PhD; Marsha Crochiere, PhD; Melanie Vincent, PhD; Michael Cieslewicz, PhD; Jing Watnick, PhD; In-Progress Clinical Trials Angiogenesis; Clinical study; Clinical trial; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment
375 Poster Presentation Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa Nicole J. Toney, Ph.D; Yo-Ting Tsai, PhD; Claire S. Rumfield, PhD; Samuel T. Pellom, PhD; Caroline Jochems, MD, PhD; Julius Strauss, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Tumor antigens; Vaccine
376 Poster Presentation A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR
377 Poster Presentation AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects Claire H. Galand, PhD; Vignesh Venkatraman; Marilyn D. Marques; James Strauss, MD; Richard D. Carvajal, MD; Min Lim; Benjamin Morin, PhD; Olga Ignatovich, PhD; Mark A. Findeis, PhD; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Irina Shapiro, PhD; Lernik Ohanjanian, MD, MPH; Anna Wijatyk, MD; Nicholas Wilson, PhD; Jennifer S. Buell, PhD; Dhan Chand, PhD; David Savitsky, PhD; Anthony W. Tolcher, MD; In-Progress Clinical Trials Antibody; Clinical trial; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
378 Poster Presentation A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies Filip Janku, MD, PhD; Sae-Won Han; Toshihiko Doi, MD, PhD; Jaffer A. Ajani, MD; Yasutoshi Kuboki; Ping Mahling; Kulandayan Subramanian; Marc Pelletier; Vasileios Askoxylakis, PhD; Salvatore Siena; In-Progress Clinical Trials Antibody; Clinical study; Clinical trial; Cytokine; T cell; TLR; Tumor infiltrating lymphocytes (TILs)
379 Poster Presentation Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor David S. Hong, MD; David S. Hong, MD; David S. Hong, MD; Jeffrey M. Clarke, MD; Tanner Johanns; Partow Kebriaei; John V. Heymach, MD, PhD; Ahmed Galal; Samuel Saibil; Adrian Sacher, MD, MSc; Francine Brophy; Gareth Betts, PhD; Natalie Bath, MSc; Spinner William; Alex J. Tipping, PhD; Jessica Tucci; Raymond Luke; Trupti Trivedi, MS; Quan Lin; Jean-Marc Navenot, PhD; Paula M. Fracasso, MD, PhD; Karen Miller, PhD; Elliot Norry, MD; Mark Dudley; Marcus O. Butler, MD; In-Progress Clinical Trials Adoptive immunotherapy; Targeted therapy
380 Poster Presentation Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors David Hong, MD; Sandip P. Patel, MD; Manish R. Patel, D.O.; Kimberly Musni, BSHA; Marlisa Anderson, MPH; Sarah Cooley, PhD, MS; Bahram Valamehr, PhD; Wayne Chu, MD; In-Progress Clinical Trials Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; NK/NK T cell; Solid tumors
381 Poster Presentation Role of CT Scans of Abdomen and Pelvis in Management of Patients with Immunotherapy-induced Colitis Juan J. Ibarra Rovira, MD; Raghunandan Vikram, MD; Selvi Thirumurthi, MD; Bulent Yilmaz, MD; Heather Lin, MS, PhD; Fechukwu O. Akhmedzhanov, MD, MPH; David S. Hong, MD; Abdulrazzak Zarifa; Melissa Tagart, MD; Funda Meric-Bernstam, MD; Aung Naing, MD, FACP; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Immune toxicity; Inflammation; Targeted therapy
382 Poster Presentation Targeting Innate Immunity with BXCL701 in Combination with Pembrolizumab in Patients with Advanced Solid Cancers: Phase 2 Basket Study Filip Janku, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Veronica R. Holley; Abha Adat, MD; Ozgur Karakuzu, PhD; Greg Call, PhD; Gabriele Urschel; Diane Healey, MS; Vincent O’Neill; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Inflammation; Solid tumors
383 Poster Presentation First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors Filip Janku, MD, PhD; Siqing Fu, MD, PhD; Ravi Murthy, MD; Daniel D. Karp, MD; David S. Hong, MD; Apostolia M. Tsimberidou, MD, PhD; Maura L. Gillison, MD PhD; Abha Adat, MD; Anjali Raina; Greg Call, PhD; Brent L. Kreider; David Tung; Mary Varterasian, MD; Khashayarsha Khazaie, PhD, DSc; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Inflammation; Vaccine
384 Poster Presentation A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas Amy AP. Prawira, MD; Jermaine Coward; Anna Mislang, MD; Adnan Nagrial, MD; Hui K. Gan, MBBS PhD; Xiaoping Jin, PhD; Baiyong Li, PhD; Zhongmin Maxwell Wang, PhD; Kon Yew Kwek; Dennis Xia; Yu Xia, PhD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Monocyte/Macrophage; Solid tumors; Tumor antigens; Tumor evasion
385 Poster Presentation A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results Jordan Berlin, MD; Wael A. Harb, MD; Alex A. Adjei, MD PhD; Yan Xing, MD, PhD; Paul Swiecicki, MD; Mahesh Seetharam, MD; Lakshminarayanan Nandagopal, MD; Ajay Gopal, MD; Cong Xu, MD, PhD; Cong Xu, MD, PhD; Yuan Meng, MD; Linda Lee, PharmD; Yonggang Zhao, PhD; Zhengyi Wang, PhD; Joan Huaqiong Shen, MD, PhD; In-Progress Clinical Trials Antibody; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors
386 Oral Presentation Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors Rom S. Leidner, MD; Andrea Wang-Gillam, MD, PhD; Sumati Gupta, MD; Robert Wesolowski, MD; Douglas G. McNeel, MD, PhD; Kevin C. Conlon, MD; Nehal S. Parikh, MD; Jessica A. O’Keeffe, PhD; Niladri Roy Chowdhury, PhD; Xiaoli Wang, PhD; Ryan Sullivan, PhD; John A. Thompson, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors
387 Poster Presentation A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies Chia-Chi Lin, MD, PhD; Elena Garralda, MD; Patrick Schöffski; David S. Hong, MD; Lillian Siu, MD; Miguel Martin, MD; Michela Maur, MD; Rina Hui, MD; Ross Soo, MD; Joanne Chiu, MD; Tian Zhang, MD; Brigette Ma, MD; Chrisann Kyi, MD; Daniel Tan, MBBS, MRCP; Philippe Cassier, MD; John Sarantopoulos, MD; Andrew Weickhardt, MBBS, FRACP, DMedSc; Rich Carvajal, MD; Jennifer Spratlin, MD; Taito Esaki, MD; Fréderic Rolland; Wallace Akerley, MD; Barbara Deschler-Baier; Catherine A. Sabatos-Peyton, PhD; Niladri Roy Chowdhury, PhD; Daniel Gusenleitner, PhD; Eunice Kwak, PhD; Vasileios Askoxylakis, PhD; Filippo De Braud; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors
388 Poster Presentation Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors Johanna C. Bendell, MD; Wells Messersmith, MD; Drew Rasco, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; Lei Zhou, MD, MS; Laura L. Carter, PhD; Jean-Marie Bruey, PhD; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johann S. De Bono, MD; In-Progress Clinical Trials Clinical trial; Gene expression; Immune contexture; Immune monitoring; Inflammation; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
389 Poster Presentation Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors Wells Messersmith, MD; Drew Rasco, MD; Johann S. De Bono, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; David Nickle, PhD; Anna Galkin, PhD; Beatrice Ferguson, MS; Laura L. Carter, PhD; Lei Zhou, MD, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johanna C. Bendell, MD; Jean-Marie Bruey, PhD; In-Progress Clinical Trials Biomarkers; Clinical trial; Gene expression; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
390 Poster Presentation Emerging safety and activity data from GEN-009-101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors Maura L. Gillison, MD PhD; Roger B. Cohen, MD; Przemyslaw Twardowski, MD; Ammar Sukari, MD; Melissa L. Johnson, MD; Rudy Lackner, MD; Thomas A. Davis, MD; Thomas A. Davis, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Kevin J. Mancini, MS; Mara G. Shainheit, PhD; Jessica B. Flechtner, PhD; Mark Awad, MD, PhD; Mark Awad, MD, PhD; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine
391 Poster Presentation A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors Oliver Bechter, MD; Jochen Utikal, MD; Jean-Francois Baurain, MD; Christophe Massard, MD; Ugur Sahin, MD; Evelyna Derhovanessian; Marie-Laure Ozoux, Phd; Rahul Marpadga, MD; Esteban-Rodrigo Imedio, MD; Nicolas P. Acquavella, MD; Carmen Loquai, MD; In-Progress Clinical Trials B cell; Checkpoint blockade; Clinical trial; Costimulation; Cytokine; Immune toxicity; RNA; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
392 Poster Presentation Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies Elizabeth Martinez, PhD/DHA, MSN, HCC,; Jason Faris, MD; Reinhard Von Roemeling, MD; Steven Angelides; Melissa L. Johnson, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma
393 Poster Presentation First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results Claire F. Friedman, MD; Paolo A. Ascierto, MD; Diwakar Davar, MD; Mark O'Hara, MD; Ronnie Shapira-Frommer, MD; Matthew Dallos, MD; Vivek Khemka, MD, MBA; Lee James, MD, PhD; Bruce S. Fischer, MD; Shilpa Demes, PhD; Li Li, PhD; Martin Kozicki, MBC; Palanikumar Ravindran, PhD; Ke Xu, PhD; Georgia Kollia, PhD; Jacqueline Shoukry, MBS; Mona Yunan, BA; Ashish Massey, MD, PhD; Martin Gutierrez, MD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
394 Poster Presentation Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results Diwakar Davar, MD; Matteo Simonelli, MD; Martin Gutierrez, MD; Emiliano Calvo, MD PhD; Jason Melear, MD; Sarina A. Piha-Paul, MD; Donald Richards, MD, PhD; Matthew Dallos, MD; Janaki Parameswaran, MD; Vinit Kumar, PhD; Xiaochen Zhao, PhD; Santanu Dutta, PhD; Ignacio J. Melero, MD, PhD; In-Progress Clinical Trials Antibody; Biomarkers; Checkpoint blockade; Chemokine; Clinical trial; Cytokine; MDSC; Myeloid cells; Solid tumors; Tumor microenvironment
395 Poster Presentation A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy Timothy A. Yap, MD, PhD; Deborah J. Wong, M.D., Ph.D.; Siwen Hu-Lieskovan, PhD, MD; Kyriakos P. Papadopoulos, MD; Michelle Morrow, PhD; Michelle Morrow, PhD; Urszula Grabowska, PhD; Daniel Gliddon, PhD; Josefin-Beate Holz, MD, PhD; Patricia LoRusso, DO; In-Progress Clinical Trials Antibody; Bispecifics; Checkpoint blockade; Clinical trial; Coinhibition; T cell
396 Poster Presentation Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side James W. Welsh, MD; Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD, PhD; Jared Weiss, MD; Jimmy Caudell, MD; Hu Yun, PhD; Hampartsoum Barsoumian, PhD; Juliette Thariat, MD, PhD; Sylvie Bonvalot, MD; Zsusanna Papaï; Maria Angelica Cortez, PhD; Ping Zhang, PhD; Katherine L. Jameson, PhD; Patricia Said; Sébastien Paris; Tanguy Seiwert, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
397 Poster Presentation Intra-Tumor Immunotherapy Injections utilizing Image guidance in Interventional Radiology: Clinical Trial Experience at a Tertiary care Cancer Center Ravi Murthy; Rahul A. Sheth, MD; Alda Tam; Sanjay Gupta; Vivek Subbiah, MD; Filip Janku, MD, PhD; Timothy A. Yap, MD, PhD; Adi Diab, MD; Aung Naing, MD, FACP; Sapna Patel, MD; Funda Meric-Bernstam, MD; In-Progress Clinical Trials Clinical trial; Solid tumors; Vaccine
398 Poster Presentation AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy Steven J. O'Day, MD; Anthony El khoueiry, MD; Chethan Ramamurthy, MD; Andrea Bullock, MD; Irina Shapiro, PhD; Serina Ng, BS; Haiyong Han, PhD; Lernik Ohanjanian Namagerdi, MD, MPH; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Olivia J. Wijatyk; waldo Ortuzar, MD; Marek Ancukiewicz, PhD; Jennifer S. Buell, PhD; Dhan Chand, PhD; Michael S. Gordon; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Solid tumors
399 Poster Presentation Cosibelimab, an anti-PD-L1 antibody: Preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial Dean L. Harris, MD FRACP; Daniel Brungs; Rahul Ladwah; Andrew Mant, MD; Margaret McGrath; Andrea Tazbirkova; Andrey Akopov; Natalia Fadeeva; Boris Kasparov; Nadezhda V. Kovalenko; Vadim Kozlov; Fedor Moiseenko; Vasiliy Oschepkov; Piotr Koralewski; Dariusz Kowalski; Iwona Lugowska; Chaiyut Charoentumn; Arunee Dechaphunkul; Virote Sriuranpong; James Oliviero; Philip R. Clingan; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors
400 Poster Presentation CoupledCARTM Technology for Treating Thyroid Cancer Xingchen Liu; Keshu Zhou; Yong Huang; Chengfei Pu; Zhiyuan Cao; Ruihong Zhu; Haiyang Tang; Zhipeng Huang; Hang Yang; Xi Huang; Yongping Song; Renbin Liu; Zhao Wu; Lei Xiao, Ph.D.; In-Progress Clinical Trials Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens
401 Poster Presentation Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Manish R. Sharma, MD; Ecaterina Ileana Dumbrava, MD; Richard D. Carvajal, MD; Daniel V. Catenacci, MD; Leisha A. Emens, MD, PhD; Glenn J. Hanna, MD; Dejan Juric; Yoon-Koo Kang; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Bob T. Li; Kathleen N. Moore; Mark D. Pegram; Paula R. Pohlmann; Drew Rasco; Alexander I. Spira, MD, PhD, FACP; Antoinette Tan; Ding Wang, MD; Shelley E. Ackerman, PhD; Heidi N. LeBlanc; David Dornan, PhD; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Edith A. Perez, MD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Immune adjuvant; Myeloid cells; Solid tumors; T cell; Targeted therapy; TLR; Tumor microenvironment
402 Poster Presentation DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone Johanna C. Bendell, MD; Lu Gan; Johanna C. Bendell, MD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Solid tumors
403 Poster Presentation Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors Timothy J. Price, MBBS, DHlthSc (Medicine), FRACP; Sant P. Chawla, MD; Gerald S. Falchook, MD, MS; Hans Prenen, MD; Iwona Lugowska; Vivek Subbiah, MD; Jose Monzon; Yuichi Ozawa; Tobias Arkenau, MD, PhD; Caio S. Rocha Lima, MD; Yasutoshi Kuboki; Tomohiro Nishina; Mun Hui; Erik Rasmussen, PhD; Hansen Wong; Saltanat Najmi; Nooshin H. Sadraei; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors
404 Poster Presentation ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC) Keun-Wook Lee, MD, PhD; Hyun C. Chung, MD, PhD; Won Seog Kim, MD; Laura Q. Chow, MD; Nehal Lakhani, MD, PhD; Wells Messersmith, MD; Yung-Jue Bang, MD PhD; Patricia LoRusso, DO; Philip S. Fanning, PhD; Pierre Squifflet, MSc; Feng Jin, PhD; Alison Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin F. Gainor, MD; In-Progress Clinical Trials Antibody; Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical trial; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment
405 Poster Presentation CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3) Rachel E. Sanborn, MD; Ralph J. Hauke, MD; Nashat Y. Gabrail, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Rodolfo E. Bordoni, MD; Michael S. Gordon; Danny Khalil, MD, PhD; Maen Abdelrahim; Thomas U. Marron, MD, PhD; Thomas Hawthorne; Lawrence J. Thomas, PhD; Tracey Rawls, MA; Mark Rogalski; Diego Alvarado; Laura Vitale, BS; Tibor Keler, PhD; Michael Yellin, MD; In-Progress Clinical Trials Antibody; Biomarkers; Clinical trial; Dendritic cell; Leukemia/Lymphoma; Solid tumors; Tumor microenvironment
406 Poster Presentation CDX527-01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies Michael Yellin, MD; Tracey Rawls, MA; Diane C. Young, MD; Philip Golden; Laura Vitale, BS; Li-Zhen He, MD; Lawrence J. Thomas, PhD; Tibor Keler, PhD; In-Progress Clinical Trials Antibody; Biomarkers; Bispecifics; Checkpoint blockade; Clinical trial; Costimulation; Solid tumors
407 Poster Presentation Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors Elaine Shum, MD; Adil Daud, MD; Matthew J. Reilley, MD; Yana G. Najjar, MD; John A. Thompson, MD; Joaquina C. Baranda, MD; R. Donald Harvey, PharmD; Rom S. Leidner, MD; Anthony F. Shields, MD PhD; Ezra EW. Cohen, MD; Roger B. Cohen, MD; Alain Mita, MD; Shubham Pant, MD; Mark N. Stein, MD; Bartosz Chmielowski, MD, PhD; Siwen Hu-Lieskovan, MD, PhD; Catherine A. Fleener, MS; Ying Ding, PhD; Sowmya Chollate, MS; Hector Avina; Jolene S. Shorr; Raphael Clynes, MD, PhD; Barbara Hickingbottom, MD; In-Progress Clinical Trials Antibody; Biomarkers; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell
408 Poster Presentation Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors Kevin Harrington, PhD, FRCP, FRCR; Eileen Parkes; Jared Weiss, MD; Mathew Ingham; Andrés Cervantes; Emiliano Calvo, MD PhD; Matthew Riese; Ute Klinkhardt; Patricia Sikken; Michael Schmohl; Elena Garralda, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors
409 Poster Presentation A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) John H. Stewart, IV, MD, MBA; John H. Strickler, MD; Niharika B. Mettu, MD, PhD; Shannon MacLaughlan, MD; Donna Niedzwiecki, PhD; Edward Levine, MD; Daniel Blazer, MD; In-Progress Clinical Trials Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
410 Poster Presentation Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD; Jared Weiss, MD; Jimmy Caudell, MD; Katherine L. Jameson, PhD; Patricia Said; Tanguy Seiwert, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs)
411 Poster Presentation Novel intratumoral agent, INT230-6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients Anthony El-Khoueiry, MD; Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Ian B. Walters, MD, MBA; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Lilian L. Siu, MD; In-Progress Clinical Trials Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Neoantigens; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs)
412 Poster Presentation First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors Elena Garralda, MD; Ravit Geva, MD; Eytan Ben-Ami; Corinne Maurice-Dror; Emiliano Calvo, MD PhD; Patricia LoRusso, DO; Özlem Türeci; Michelle Niewood; Ugur Sahin; Maria Jure-Kunkel; Ulf Forssmann; Tahamtan Ahmadi; Ignacio J. Melero, MD, PhD; In-Progress Clinical Trials Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Costimulation; Solid tumors; Targeted therapy
413 Poster Presentation GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors Mara G. Shainheit, PhD; Devin P. Champagne; Gabriella Santone; Syukri Shukor; Ece Bicak; Samuel Tipps; Li Xue; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; Mara G. Shainheit, PhD; In-Progress Clinical Trials Biomarkers; Clinical study; Neoantigens; Solid tumors; T cell; Vaccine
414 Poster Presentation Enhancing T cell therapy for patients with relapsed/refractory Wilms Tumor Amy Hont, MD; Conrad R. Cruz; Maja Stanojevic; Robert Ulrey; Madeline Terpilowski; Emily Reynolds; Fahmida Hoq; Maria F. Fortiz; Haili Lang; Jeffrey S. Dome; Patrick J. Hanley; Catherine Bollard, MD; Holly J. Meany; In-Progress Clinical Trials Adoptive immunotherapy; Clinical trial; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy; Tumor antigens
415 Poster Presentation Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study Kunkun Li, MD; Xiao Yang; Wei Luo; Qiang Ma; Yingjian Wang; Yanli Xiong; Xiaolong Zhao; Xianfeng Lu; Tao Bao; Wei Guo; Mengxia Li; In-Progress Clinical Trials Checkpoint blockade; Chemotherapy; Clinical study; Surgery
416 Poster Presentation SQ3370-001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors Vivek Bhadri, MD; Nam Bui, MD; Alexander Guminski, MD; Jose M. Mejia Oneto, MD, PhD; Ravi Murthy, MD; Kamalesh Sankhala, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; Sangeetha Srinivasan, PhD; Robert Steffner, MD; Vivek Subbiah, MD; Ding Wang, MD; Nathan A. Yee, PhD; In-Progress Clinical Trials Chemotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
417 Poster Presentation Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors Gregory A. Durm, MD; Sophia Frentzas; Erik Rasmussen; Saltanat Najmi; Nooshin H. Sadraei; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Cytokine; Solid tumors
418 Poster Presentation A Phase 1, Dose Escalation and Dose Expansion Study of SQZ PBMC HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, or Metastatic Solid Tumors. Cathy Eng, MD; Joaquina C. Baranda, MD; Matthew H. Taylor; Michael S. Gordon; Ursula A. Matulonis, MD; Filip Janku, MD, PhD; Martin Kornacker, MD; Asha Kamat, PhD; Oliver Rosen; Antonio Jimeno, MD, PhD; Cathy Eng, MD; In-Progress Clinical Trials Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Clinical study; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine
419 Poster Presentation Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial Sarina A. Piha-Paul, MD; Tara C. Mitchell, MD; Solmaz Sahebjam, MD; Janice M. Mehnert, M.D.; Thomas Karasic; Kevin O’Hayer; Ryan Geschwindt, BS; Susan Spitz, PhD; Hao Liu, PhD; Johanna C. Bendell, MD; Sarina A. Piha-Paul, MD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Inflammation; Solid tumors; T cell
420 Oral Presentation Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study Adi Diab, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Michele Maio, MD; Brendan D. Curti, MD; Karl D. Lewis, MD; Sekwon Jang, MD; Ewa Kalinka, PhD, MD; Igor Puzanov, MD, MSCI; Alexander I. Spira, MD, PhD, FACP; Daniel C. Cho, MD; Shanhong Guan, PhD; Erika Puente, MD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell
421 Poster Presentation Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors Francesca Aroldi, MD; Joseph Sacco, MSc, MBChB, MRCP, Ph; Kevin Harrington, PhD, FRCP, FRCR; Anna C. Olsson-Brown, MD; Pablo Nanclares, MD; Lavita Menezes; Praveen K. Bommareddy, MS, PhD; Suzanne Thomas, PhD; Howard L. Kaufman, MD; Selda Samakoglu, MD, PhD; Mark R. Middleton, MD, PhD; Robert S. Coffin, PhD; In-Progress Clinical Trials Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
422 Poster Presentation An Open-label, multicenter, Phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: Updated results from the skin cancer cohorts Mark R. Middleton, MD, PhD; Francesca Aroldi, MD; Joseph Sacco, MSc, MBChB, MRCP, Ph; Mohammed M. Milhem, MBBS; Brendan D. Curti, MD; Ari M. VanderWalde, MD, MPH, MBioeth; Scott Baum, MD; Adel Samson, MBChB, PhD; Anna C. Pavlick, MD, MBA; Jason A. Chesney, MD; Jiaxin Niu, MD; Terence Rhodes, MD, PhD; Tawnya L. Bowles, MD; Robert M. Conry, MD; Anna C. Olsson-Brown, MD; Douglas Earl Laux, MD; Howard L. Kaufman, MD; Praveen K. Bommareddy, MS, PhD; Alex Deterding; Selda Samakoglu, MD, PhD; Robert S. Coffin, PhD; Kevin Harrington, PhD, FRCP, FRCR; In-Progress Clinical Trials Clinical trial; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine
423 Poster Presentation Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors Steven J. O'Day, MD; Cesar A. Perez, MD; Trisha M. Wise-Draper, MD, PhD; Glenn J. Hanna, MD; Shailender Bhatia, MD; Ciara Kelly, MD; Theresa Medina, MD; Douglas E. Laux, MD; Adil Daud, MD; Sunandana Chandra, MD; Montaser F. Shaheen, MD; Ling Gao, MD; Melissa Burgess, MD; Leonel Hernandez-Aya, MD; Cecilia CS. Yeung, MD; Kimberly Smythe, PhD; Emil M. DeGoma, MD; Weston L. Daniel, PhD; Douglas E. Feltner, MD; Laurel Sindelar; Robert E. Michel, PhD; Alice S. Bexon, MD; Martin Bexon, MD; Mohammed M. Milhem, MBBS; In-Progress Clinical Trials Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR; Tumor microenvironment
425 Poster Presentation Investigation of Wnt Ligand Signaling Regulators as a Predictor of Anti-PD-1 Response in Metastatic Melanoma Nicholas DeVito, MD; Michael Sturdivant, B.S.; Luke P. Wachsmuth, B.S.; John H. Strickler, MD; Georgia M. Beasley, MD, MHs; Rami Al-Rohil; April Salama, MD; Brent A. Hanks, MD, PhD; In-Progress Clinical Trials Biomarkers; Checkpoint blockade; Clinical trial; Dendritic cell; Gene expression; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; RNA
426 Poster Presentation MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma Reinhard Dummer, MD; Georgina V. Long, BSc, PhD, MB, BS, FRACP; Anna Pavlick, DO; Michael Postow, MD; Antoni Ribas, MD, PhD; Caroline Robert, MD, PhD; Richard A. Scolyer, BMedSci, MBBS, MD, FRCPA, FRCPath; Janis M. Taube, MD; Michael Tetzlaff, MD, PhD; Jason Liao, PhD; Sama Ahsan, MD; Scott J. Diede, MD, PhD; Hussein A. Tawbi, MD, PhD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy
427 Poster Presentation A Phase 1b/2 Study of Cabozantinib in Combination with Pembrolizumab in Advanced Melanoma Jayanshu Jain, MD; Melanie Frees; Hesham Yasin; Jaime Bonner; Michele Freesmeier; Rohan Garje; Vyshak Alva Venur, MD; Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Targeted therapy
428 Poster Presentation Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) Karl D. Lewis, MD; Ketty Peris, MD; Alexander J. Stratigos, MD, PhD; Lara A. Dunn, MD; Zeynep Eroglu, MD; Anne Lynn S. Chang, MD; Michael R. Migden, MD; Siyu Li, PhD; Kosalai Mohan, PhD; Ebony Coates, MHA; Emmanuel Okoye, MBBS, MPH; Jean-François Baurain, MD, PhD; Oliver Bechter, MD; Axel Hauschild, MD; Marcus O. Butler, MD; Leonel Hernandez-Aya, MD; Lisa Licitra, MD; Rogerio I. Neves, MD PhD FACS; Emily S. Ruiz, MD; Frank Seebach, MD; David M. Weinreich, MD; George D. Yancopoulos, MD, PhD; Israel Lowy, MD, PhD; Timothy Bowler, MD, PhD; Matthew G. Fury, MD, PhD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical trial
429 Poster Presentation Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma Georgina V. Long, MBBS, PhD, BSc, FRAC; Reinhard Dummer, MD; Douglas B. Johnson, M.D.; Olivier Michielin, MD PhD; Salvador Martin-Algarra; Sheryl A. Treichel; Edward L. Chan; Scott J. Diede, MD, PhD; Antoni Ribas, MD, PhD; In-Progress Clinical Trials Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy
430 Poster Presentation A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma(UM) (CA224-094) Jose Lutzky, MD, FACP; Lynn Feun, MD; William J. Harbour, MD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors; T cell
431 Poster Presentation Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma Patrick M. McCarthy, MD; Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Anne E. O'Shea, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; Jessica L. Campf, MD; John W. Myers, MD; Tommy A. Brown, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; In-Progress Clinical Trials Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; Surgery; Targeted therapy; Vaccine; Extracellular vesicles/exosomes
432 Poster Presentation 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov, MD, DSc; Edward L. Chan; Hoi-Shen Radcliffe; Mark B. Faries, MD; Merrick Ross, MD; In-Progress Clinical Trials Clinical trial; Solid tumors; Surgery
433 Poster Presentation Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial Igor Puzanov, MD, MSCI; Jason A. Chesney, MD; Frances A. Collichio, MD; Parminder Singh, MD; Mohammed M. Milhem, MBBS; John Glaspy, MD; Omid Hamid, MD; Merrick Ross, MD; Philip Friedlander, MD PhD; Claus Garbe, MD, PhD; Theodore F. Logan, MD; Axel Hauschild, MD; Celeste Lebbe; Min Yi; Wendy Snyder; Janice M. Mehnert, M.D.; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Solid tumors
434 Poster Presentation Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab Michael Postow, MD; Ryan J. Sullivan, MD; Ezra EW. Cohen, MD; Martin Gutierrez, MD; David S. Hong, MD; Conor Steuer, MD; Jerry McCarter, RN, BSN; Nora Zizlsperger; Jeff Kutok, MD, PhD; Brenda O'Connell, PhD; Jennifer Roberts; Kara Page; Halle Zhang, PhD; Bartosz Chmielowski, MD, PhD; In-Progress Clinical Trials Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment
435 Poster Presentation A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma Saba S. Shaikh, MD; Yan Zang, MS; Hong Wang, PhD; Xi Yang, BS; Cindy Sander; Amy Rose; Diwakar Davar, MD; Jason J. Luke, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; In-Progress Clinical Trials Angiogenesis; Checkpoint blockade; Clinical trial; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
436 Poster Presentation Rational Sequencing of Immune-Oncology Therapies Achieves Durable Response and Immunologic Memory Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell; Andrew Sharabi, MD, PhD, FACS; Joseph Califano; J. Silvio Gutkind; Combination Immunotherapies Checkpoint blockade; Immune adjuvant; Radiotherapy; Solid tumors; Surgery; T cell; Targeted therapy
437 Poster Presentation Adenovirus IL-12 and Docetaxel in Combination with Anti-PD1 as an Effective Treatment Strategy for TNBC Ann C. Anselme, BS; Wei Qian, BS; Roberto R. Rosato, PhD; Jianying Zhou; Jenny C. Chang, MD; Ann C. Anselme, BS; Combination Immunotherapies Checkpoint blockade; Chemotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
438 Poster Presentation Synergy Between SEA-CD40 and Chemotherapeutics Drives Curative Antitumor Activity in Preclinical Models Weiping Zeng; Haley Neff-LaFord; Sahar Ansari; Celine Jacquemont, PhD; Michael Schmitt, MD, PhD; Shyra J. Gardai, PhD; Combination Immunotherapies Antibody; Antigen presenting cells; Chemotherapy; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment
439 Poster Presentation Dual modes of action for anti-TIM-3 antibody MBG453 in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity Catherine A. Sabatos-Peyton, PhD; Tyler A. Longmire; Lisa Baker; Nidhi Patel; Anne-Sophie Wavreille; Melanie Verneret; Pushpa Jayaraman, PhD; Xiaomo Jiang; Stephanie Schwartz; Viviana Cremasco; Hongbo Lu; Shumei Qiu; Fiona A. Sharp, PhD; Mikael Rinne; Glenn Dranoff, MD; Combination Immunotherapies Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment
440 Poster Presentation Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer Guo Gui Sun; Jing Hao Jia; Peng Gao; Xue Min Yao; Ming Da Chen; Wei Nan Yao; Lu Sun; Wei Wang; Combination Immunotherapies COVID and Immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor evasion; Tumor microenvironment
441 Poster Presentation Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized Omar Alhalabi, MD; Elshad Hasanov; John Araujo; Jianbo Wang; Matthew T. Campbell, MD; Sangeeta Goswami, MD, PhD; Amishi Shah; Jianjun Gao, MD PhD; Pavlos Msaouel, MD, PhD; Nizar M. Tannir, MD, FACP; Combination Immunotherapies Checkpoint blockade; Clinical study; Solid tumors
442 Poster Presentation ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugué; Emmanuel Valentin, PhD; Jennifer Sims; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; Rene HOET; Combination Immunotherapies Antibody; T cell; T cell lineages
443 Poster Presentation An Immunotherapy Trio in advanced HNSCC for coordinated B and T cell antigen response Bernard A. Fox, PhD; Tarsem L. Moudgil, MS; Traci L. Hilton, PhD; Noriko NI. Iwamoto, PhD; Christopher C. Paustian, PhD; Adi Mehta, PhD; Fridtjof Lund-Johansen, MD, PhD; Rachel E. Sanborn, MD; Bryan R. Bell, MD, DDS, FACS; Madeleine Laws, BS; Glenna McDonnell, MS; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Brian D. Piening, PhD; Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Takashi Shimada, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Marcus A. Couey, MD, DDS; Combination Immunotherapies Antibody; Clinical study; Clinical trial; Costimulation; Neoantigens; Solid tumors; Surfaceome; T cell; Tumor antigens; Vaccine
444 Poster Presentation MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination Mathieu Gigoux, PhD; Roberta Zappasodi, PhD; Joseph J. Park; Stephane Pourpe; Arnab Ghosh, MD, PhD; Cansu Cimen Bozkus, PhD; Levi M. Mangarin, BS; David Redmond; Svena Verma, BS; Sara Schad, BS; William Duke; Max Jan; Matthew J. Leventhal; Vincent Ho; Gabriela S. Hobbs; Trine Alma Knudsen; Vibe Skov; Lasse Kjær; Thomas Stauffer Larsen; Dennis Lund Hansen; R. Coleman Lindsley; Hans Hasselbalch; Jacob H. Grauslund; Mads H. Andersen, PhD; Morten O. Holmström; Timothy A. Chan, MD, PhD; Raajit Rampal; Omar Abdel-Wahab, M.D.; Nina Bhardwaj, MD, PhD; Jedd D. Wolchok, MD, PhD; Ann Mullally, M.D.; Taha Merghoub, PhD; Mathieu Gigoux, PhD; Combination Immunotherapies Checkpoint blockade; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor evasion; Vaccine
445 Poster Presentation Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa Lucas A. Horn, PhD; Linjie Tian, PhD; Dallas B. Flies, PhD; Linda N. Liu, PhD; Solomon Langermann, PhD; Jeffrey Schlom, PhD; Claudia M. Palena, PhD; Combination Immunotherapies Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
446 Oral Presentation Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. Peter I. Joyce, PhD; Lesley Young, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong; Kristopher Clark, PhD; Edd James, PhD; Emma Reeves, PhD; Alihussein Remtulla, PhD; Henry Leonard; Camila de Almeida; Elisa Lori; Nicola Ternette, PhD; Fergus Poynton, PhD; Andrew Leishman; Combination Immunotherapies Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
447 Poster Presentation VISTA targeting remodels the tumor microenvironment to overcome adaptive resistance Janet L. Lines, Ph.D.; Evelien Schaafsma; Walburga Croteau; Mohamed ElTanbouly; Elizabeth Nowak; Nicole Smits; Cecilia A. Webber; Dina Rabadi; Jie Deng; Chao Cheng; Randolph Noelle; Combination Immunotherapies Gene expression; MDSC; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
448 Poster Presentation Discovery of clinical candidate IK-175, a selective orally active AHR antagonist KAREN MCGOVERN, PhD; KAREN MCGOVERN, PhD; Alfredo C. Castro; Jill Cavanaugh; Marta Sanchez-Martin; Jeremy H. Tchaicha, PhD; Sakeena Syed; Hyejin Frosch; Prabitha Natarajan; Katie O'Callaghan; Ben Amidon, PhD; X. Michelle Zhang; Jeff Ecsedy; Mark Manfredi, PhD; Combination Immunotherapies Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
449 Oral Presentation Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation Lauren Milling, BS; Darrell J. Irvine, PhD; Combination Immunotherapies Checkpoint blockade; Cytokine; NK/NK T cell; Surgery
450 Poster Presentation Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice Sujeong Park, graduate student; Ji-Hae Kim; Yeon-Woo Kang; Kun-Joo Lee; Dain Moon; Nara Tae; Yunji Park; Dae Hee Kim; Byung Ha Lee, PhD; Donghoon Choi, PhD; Se Hwan Yang, PhD; Seung-Woo Lee; Combination Immunotherapies Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs)
451 Poster Presentation Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D.; Combination Immunotherapies Cytokine; NK/NK T cell; Radiotherapy; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
452 Poster Presentation Combination treatment using KISIMATM protein-based cancer vaccine and systemic STING agonist results in profound modulation of tumor microenvironment and improved tumor control Matteo Rossi, PhD; Elodie Belnoue; Susanna Carboni; Wilma Besson-Di Berardino; Erika Riva; Marie-Laure Santiago-Raber; Madiha Derouazi; Combination Immunotherapies Immune adjuvant; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine
453 Poster Presentation Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment Jonas RM. Van Audenaerde, MSc; Elly Marcq; Bianca von Scheidt; Ashleigh S. Davey, PhD; Amanda J. Oliver; Jorrit De Waele; Delphine Quatannens; Jinthe Van Loenhout; Patrick Pauwels; Geert Roeyen; Filip Lardon; Clare Y. Slaney; Marc Peeters, MD, PhD; Michael H. Kershaw, PhD; Phillip K. Darcy; Evelien LJ. Smits; Combination Immunotherapies Antibody; Antigen presenting cells; Cytokine; Dendritic cell; NK/NKT cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
454 Poster Presentation Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures Namita Varudkar, MS, PhD Candidate; Namita Varudkar, MS, PhD Candidate; Jeremiah L. Oyer; Alicja Copik, PhD; Griffith Parks, PhD; Combination Immunotherapies Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy
455 Oral Presentation Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer Sarmad Sadeghi, MD; Tyler D. Hether; Jason Yeon; Richard Mangio; Jason W. Reeves; Yan Liang, MD PhD; Sarah E. Warren, PhD; Troy McEachron, MD; Parkash S. Gill, MD; Combination Immunotherapies Biomarkers; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
456 Poster Presentation Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy Julius Strauss, MD; Ravi A. Madan, MD; Marijo Bilusic, MD, PhD; Fatima Karzai; Scot Niglio; Jason M. Redman, MD; Houssein Abdul Sater, MD; Charalampos Floudas; Jung-Min Lee; Andrea B. Apolo, MD; Seth M. Steinberg; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; Combination Immunotherapies Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy
457 Poster Presentation Intratumoral interleukin-12 administered after cryoablation does not improve survival in multiple bilateral murine models Maura R. Vrabel; Jake A. Schulman; David A. Zaharoff, PhD; Combination Immunotherapies Checkpoint blockade; Immune adjuvant; Solid tumors; Targeted therapy; Tumor antigens; Vaccine
458 Poster Presentation Antitumor mechanisms of local radiation and combination immunotherapy in an immunologically cold model of neuroblastoma Taylor Aiken, MD; Julie S. Voeller, MD; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Combination Immunotherapies NK/NK T cell; Pediatric tumors; Radiotherapy; Regulatory T cell (Treg cell); Tumor microenvironment; Vaccine
459 Poster Presentation NK cells activation and recruitment to irradiated tumors is increased in the presence of IL-15. Maud Charpentier, PhD; Karsten A. Pilones, MD, PhD; Elena Garcia-Martinez, MD, PhD; Sandra Demaria, MD; Combination Immunotherapies NK/NKT cell; Radiotherapy
460 Poster Presentation The immuno-metabolic enzyme FASN prevents anti-tumor immune responses in irradiated glioblastoma Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD; Combination Immunotherapies Dendritic cell; Immune suppression; Metabolism; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
461 Poster Presentation Improving Specific Targeting of Tumors Through Bispecific SNIPER Antibodies Amy K. Erbe, PhD; Daniel Gerhardt; Reinier Hernandez, PhD; Bonnie Hammer; Mildred A. Felder, BS; Mark Bercher; Jennifer Dennin; Christopher Massey; Sabrina VandenHeuvel; Arika S. Feils, BS; Mackenzie Heck; Jonathan Engle; Todd E. Barnhart; Jacquelyn A. Hank, PhD; Bryan Glaser, PhD; Roland Green, PhD; Paul M. Sondel, MD, PhD; Combination Immunotherapies Bispecifics; Cytokine; NK/NK T cell; Pediatric tumors; Radiotherapy
462 Poster Presentation Single agent immunotherapy response in patients with head and neck squamous cell carcinoma with prior history of radiation therapy Moises Harari-Turquie, MD; Shashank Cingam, MD; David Lee; Gregory Gan; Emrullah Yilmaz, MD, PhD; Combination Immunotherapies Chemotherapy; Epidemiology; Immune adjuvant; Metabolism; Radiotherapy; Solid tumors; Tumor microenvironment
463 Poster Presentation Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno-modulatory markers Maysaloun Merhi, PhD; Afsheen Raza; Varghese Inchakalody; Siveen Kodappully; Deepak Choubey; Fairooz Sahir; Sarra Mestiri; Shereena Hydrose; Niloofar Allahverdi; Munir D. Jalis; Allan Relecom; Lobna Al-Zaidan; Mohamed Sir Elkhatim Hamid; Mai Mostafa; Abdul Rehman Zar Gul; Shahab Uddin; Mohammed Ussama Al Homsi; Said Dermine; Combination Immunotherapies Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens
464 Poster Presentation Clonal replacement of tumor-infiltrating CD8+ T cells by induction and activation of tumor-residing Batf3-dependent dendritic cells Takaaki Oba, MD,PhD; Mark Long; Tibor Keler, PhD; Henry Marsh, BS PhD; Hans Minderman; Scott I. Abrams, PhD; Song Liu; Fumito Ito; Combination Immunotherapies Costimulation; Dendritic cell; Radiotherapy
465 Oral Presentation Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection Nils-Petter Rudqvist; Claire Lhuillier, PhD; Maud Charpentier, PhD; Erik Wennerberg, PhD; Sheila Spada, PhD; Caroline Sheridan; Xi Kathy Zhou; Tuo Zhang, PhD; Jennifer S. Sims, PhD; Alicia Alonso; Sandra Demaria, MD; Combination Immunotherapies Bioinformatics; Checkpoint blockade; Costimulation; Gene expression; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs)
467 Poster Presentation Anti-EGFR antibody added to ongoing anti-PD-1 antibody treatment for metastatic cutaneous squamous cell carcinoma of the face: two case reports Omar Eton, MD, FACP; Emily Hsu, MD; Akshay V. Patel, DO; Omar Eton, MD, FACP; Richard Cartun, PhD; Jonathan S. Earle, MD; Laila O. Mnayer, PhD; Peter P. Yu, MD, FACP, FASCO; Jennifer Kotowitz, RN BSN; Combination Immunotherapies Biomarkers; Checkpoint blockade; Clinical study; Coinhibition; Solid tumors; Surgery; Targeted therapy; Tumor microenvironment
468 Poster Presentation Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma Sean E. Lawler, PhD; Marilin S. Koch, MD; Mikolay S. Zdioruk, phD; Estuardo Aguilar-Cordova; Laura K. Aguilar, MD, PhD; Brian W. Guzik; Ghazaleh Tabatabai; Michal Nowicki; E Antonio A. Chiocca; Combination Immunotherapies Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
469 Poster Presentation Cooperation between checkpoint inhibitors targeting the PD-1 / PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies Amy Manning-Bog, PhD; Jeff DeFalco, PhD; Alexander Scholz, PhD; Iraz T. Aydin, PhD; Nikhil Vad, PhD; Cathrin Czupalla, Ph.D.; Felix Chu, MS; Mauricio Velasco-Delgado; Michael Harbell, M.S.; Judevin Lugar-Supagay; Yvonne Leung, Ph.D.; Shaun M. Lippow, Ph.D.; Anne Ye, PhD; Ish Dhawan, PhD; Gilson Baia, PhD; Dai-Chen Wu, PhD; Carl Millward, MD; Mark Whidden, PhD; Jonathan Benjamin, MD, PhD; John Vivian, PhD; Ngan Nguyen, BS PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Combination Immunotherapies Antibody; Checkpoint blockade; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
470 Oral Presentation Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors Jeff S. Miller, MD; Nicholas A. Zorko, MD, PhD; Behiye Kodal; Zachary B. Davis, PhD; Alexander J. Lenvik; Todd R. Lenvik; Joshua S. Walker; Daniel A. Vallera; Svetlana Gaidarova, MS; Alejandro Garcia; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Frank S. Cichocki, PhD; Martin S. Felices; Combination Immunotherapies Adoptive immunotherapy; Bispecifics; NK/NK T cell
471 Poster Presentation Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition Francesco Novelli, PhD; Claudia Curcio, PhD; Cecilia Roux; Laura Conti; Roberta Curto; Gianluca Mucciolo; Sara Bulfamante, MS; Silvia Brugiapaglia; Alessandro Scagliotti; Alessandra Ghigo; Paola Cappello, PhD MS; Emilio Hirsch; Francesco Novelli, PhD; Combination Immunotherapies Myeloid cells; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine
472 Oral Presentation ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma Natasha D. Sheybani, PhD; Soumen Paul, PhD; Katelyenn S. McCauley; Victoria R. Breza; Stuart S. Berr, PhD; G. Wilson Miller, PhD; Kiel D. Neumann, PhD; Richard J. Price, PhD; Combination Immunotherapies Antibody; Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Solid tumors; Targeted therapy
473 Poster Presentation Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro. Luis A. Carvajal, PhD.; Luciana Gneo, PhD.; Carmela De Santo, PhD; Matt Perez, B.S; Tracy Garron, B.S; Francis Mussai, M.D; Annalisa D’Andrea, PhD.; Combination Immunotherapies Checkpoint blockade; Immune adjuvant; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
474 Poster Presentation Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: one institutional experience in Taiwan since 2016 Jo-Pai Chen, MD; Wei-Chen Lu, M. D.; Ruey-Long Hong, M.D. PhD; Combination Immunotherapies Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy
475 Oral Presentation Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment Chun Chau Lawrence Cheung, BA, MMedSc; Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Denise Goh, BBiomedSc (Hons); Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Thuan Tong Tan; Shirin Kalimuddin; Jia Lin Ng; Jenny Guek-Hong Low; Joe P. Yeong, MD, PhD; Kiat Hon T. Lim; COVID and Immunotherapy COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
476 Poster Presentation AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19 Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Konyew Kwek, PhD; Chris Wynne, MB, ChB; Adam Konpa, MS; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; COVID and Immunotherapy COVID and Immunotherapy; Antibody; B cell
477 Poster Presentation Deep Learning to Drive COVID-19 Rapid Drug Repurposing Sarah Kolitz, PhD; Jason Kim, PhD; Jenny Zhang, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Rajaraman Krishnan, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; COVID and Immunotherapy COVID and Immunotherapy; Bioinformatics; Systems biology
478 Poster Presentation Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development Christof C. Smith, PhD; Christof C. Smith, PhD; Sarah Entwistle; Caryn Willis; Steven P. Vensko; Wolfgang Beck, AB; Jason Garness; Maria J. Sambade; Eric Routh; Kelly Olsen; Brandon Carpenter; Kaylee Gentry; Maria Fadri; Misha Fini; Amber Washington; Julia Kodysh, MSc; Timothy O'Donnell; Carsten Haber; Kirsten Heiss; Volker Stadler; Erik Garrison; Oliver C. Grant; Robert J. Woods; Mark Heise; Benjamin G. Vincent, MD; Alexander Rubinsteyn, PhD; COVID and Immunotherapy COVID and Immunotherapy; Antibody; B cell; Neoantigens; T cell; Vaccine
479 Poster Presentation A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; Christopher M. Haqq, MD, PhD; Aniela Jakubowski; Lisa K. McNeil, PhD; COVID and Immunotherapy COVID and Immunotherapy; Immune adjuvant; T cell; Vaccine
480 Oral Presentation Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12 Shawn M. Jensen, PhD; Christopher G. Twitty, PhD; Christopher C. Paustian, PhD; Madelein Laws; Glenna McDonnell, MS; Keith Wegmann; Tarsem L. Moudgil, MS; Michael E. Afentoulis, MSc; Mia Han; Kellie Malloy Foerter; David A. Canton, PhD; Jack Y. Lee; Bianca A. Nguyen; John Rodriguez; Kim Jaffe, PhD; Brian D. Piening, PhD; Carlo B. Bifulco, MD; Daniel J. O'Connor; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Traci L. Hilton, PhD; Hong-Ming Hu, PhD; Bernard A. Fox, PhD; COVID and Immunotherapy COVID and Immunotherapy; Antibody; B cell; Cytokine; Immune adjuvant; Immune monitoring; T cell; Vaccine
481 Poster Presentation Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors Kevin Tyan, BA; Ai-Tram N. Bui, BA; Anita Giobbie-Hurder, MS; Isaac A. Klein, MD, PhD; Michael P. Manos, BA; Leyre Zubiri, MD, PhD; Kerry L. Reynolds, MD; Shilpa Grover, MD, MPH; Gerald L. Weinhouse, MD; Patrick A. Ott, MD, PhD; Nicole R. LeBoeuf, MD, MPH; Osama E. Rahma, MD; COVID and Immunotherapy COVID and Immunotherapy; Checkpoint blockade; Immune toxicity
482 Poster Presentation COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center. David Viñal; Laura Gutierrez; Julia Villamayor; Oliver Higuera; Dario Sanchez Cabrero; Javier De Castro; COVID and Immunotherapy COVID and Immunotherapy; Clinical study; Solid tumors
483 Poster Presentation Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis Olivier OD. Demaria, PhD; Julien Carvelli, MD; Nassima Chouaki Benmansour, MD; Joanna Fares, PhD; Luciana Batista, PhD; Marie-Laure Thibult, PhD; Ariane Morel, PhD; Sabrina Carpentier, PhD; Romain Remark, PhD; Agnes Represa; Frederic Vely, PhD; Mikael Ebbo, MD; Nicolas Schleinitz, MD; Robert Zerbib, MSc; Yannis Morel, PhD; Eric Vivier, PhD; Olivier OD. Demaria, PhD; COVID and Immunotherapy COVID and Immunotherapy; Antibody; Biomarkers; Cytokine; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells
484 Poster Presentation BioTuring Browser: Interactively explore public single cell sequencing data Son K. Pham; Tri Le, BSc; Tan Phan; Minh Pham; Huy Nguyen; Loc Lam; Nam Phung; Tuan Tran; Duy Phung; Thang Tran; Hoa Pham; Khoa Nguyen; Ha-An Nguyen; Trang Nguyen; Tam Luu; Hao Tran; Data Sharing, Handling and Access Checkpoint blockade; Gene expression; RNA; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
485 Poster Presentation RAFT: A framework to support rapid and reproducible immuno-oncology analyses Steven P. Vensko, II, Ph.D.; Benjamin G. Vincent, MD; Dante S. Bortone; Steven P. Vensko; Data Sharing, Handling and Access Bioinformatics
486 Poster Presentation iReceptor Plus: a data integration platform to share, compare and analyze Adaptive Immune Receptor Repertoire (AIRR-seq) data from antibody/B- and T-cell repertoires Felix Breden, PhD; Data Sharing, Handling and Access Antibody; B cell; Bioinformatics; Biomarkers; Genetic polymorphism; Immune monitoring; Leukemia/Lymphoma; Systems biology; T cell; T cell lineages
487 Poster Presentation Reasons for not testing for biomarkers in non-small cell lung cancer: A regional comparison of patients in the US and Europe Nikita Sharma; Mahaletchumy Krishnam; Ayse Levent, MSc; Ayse Levent, MSc; Ayse Levent, MSc; Education and Treatment Management Biomarkers; Solid tumors
488 Poster Presentation The impact of education on novel concepts in metastatic melanoma: triplet therapy Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Sara Fagerlie, PhD; Patrick Kugel, MBA; Richard Caracio, MBA; Ryan J. Sullivan, MD; Education and Treatment Management Checkpoint blockade; Targeted therapy
489 Poster Presentation The impact of education on novel concepts in adjuvant melanoma: a closer look at high risk stage II disease Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Kinjal Parikh, PharmD, BCOP; Charlotte Warren; Emily Van Laar, MS; Jason J. Luke, MD; Education and Treatment Management Checkpoint blockade
490 Poster Presentation An immuno-oncology census: assessment of clinician knowledge and educational needs in 2020 Janelle Schrag, MPH; Fitzgerald Draper, MS; Monique Dawkins, EdD, MPA; Lorna Lucas, MSM; Leigh Boehmer, Pharm.D, BCOP; Janelle Schrag, MPH; Education and Treatment Management Bispecifics; CAR T cells; Checkpoint blockade
491 Poster Presentation Developing Educational Materials about Immunotherapy for Patients and Their Caregivers Maria B. Gonzalo; Claire Saxton, MBA; Kirstin Fearnley, MALS; Jenny Karubian, MA; Nick Power, BS; Alyssa Jaisle, PhD; Education and Treatment Management Immune adjuvant; Targeted therapy
492 Poster Presentation Integration of high dimensional datasets in an immunocompetent mammary mouse model reveals pathways of tolerance and resistance to immune checkpoint blockade Jade Moore, PhD; Lin Ma, PhD; Jian-Hua Mao, PhD; Mary Helen Barcellos-Hoff, PhD; Immune Cell Biology Checkpoint blockade; Gene expression; Immune monitoring; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
493 Poster Presentation Tired and Hungry: A potential role for CD47 in T cell exhaustion Levi M. Mangarin, BS; Cailian Liu, MD; Roberta Zappasodi, PhD; Pamela M. Holland, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; Chien-Huan Weng, PhD; Chien-Huan Weng, PhD; David Schroder, MD; Immune Cell Biology Adoptive immunotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
494 Poster Presentation Bias in Cross-Presentation by Dendritic Cells Impacts anti-tumor T cell Responses Timothy B. Fessenden, PhD; Lauren Stopfer; Therese Cordero-Dumit; Forest White; Stefani Spranger, PhD; Immune Cell Biology Dendritic cell; Neoantigens; Tumor antigens; Vaccine
495 Poster Presentation Basal Cell Carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies Geoffrey T. Gibney, MD; Joanne Xiu; Gino K. In, MD, MPH; Steven J. O'Day, MD; Jose Lutzky, MD, FACP; Joseph J. Drabick, MD, FACP, FIDSA; Ari M. VanderWalde, MD, MPH, MBioeth; Kelsey Poorman; W. M. Korn; Michael B. Atkins, MD; Immune Cell Biology Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
496 Poster Presentation Immune cell profiling across solid tumor types by mass cytometry reveals tumor enrichment of PD-1+/LAG-3+ CD8 memory T cells that exhibit tumor-reactive yet dysfunctional features Bradley Garman, MSc; Laurence Menard, PhD; Can Jiang, MSc; Sherif Daouti, MSc; Priyanka Mehta, MSc; Miye Jacques, MSc; Mohan Bolisetty, PhD; Christos Hatzis, PhD; Nataly Manjarrez Orduno, PhD; Michaela Bowden, PhD; Justin M. David, PhD; Justin M. David, PhD; Justin M. David, PhD; Immune Cell Biology Immune contexture; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
497 Poster Presentation Longitudinal immune profiling reveals unique myeloid and T cell phenotypes associated with spontaneous immunoediting in a novel prostate tumor model Casey R. Ager, PhD; Aleksander Obradovic; Juan M. Arriaga, PhD; Matthew G. Chaimowitz; Cory Abate-Shen, PhD; Andrea Califano, PhD; Charles G. Drake, MD, PhD; Immune Cell Biology Dendritic cell; Granulocyte; Immune contexture; Immune monitoring; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment
498 Poster Presentation Downregulation of CD5 in CD8+ T tumour-infiltrating lymphocytes associates with increased level of activation and exhaustion Faizah Alotaibi; Mark D. Vincent, MD, FRCPC, MRCPUK; Weiping Min; James Koropatnick; Immune Cell Biology Checkpoint blockade; Immune suppression; Immune tolerance; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
499 Poster Presentation AT1636, a colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin. Tim Beaumont, PhD; Martijn Kedde, PhD; Sabrina J. Merat, MSc; Mark J. Kwakkenbos, PhD; Lina Bartels; Dorien van der Berg; Koen Wagner, PhD; Arjen Q. bakker; Kelly Maijoor; Martino Bohne; Camille Bru; Veronika Kattler; Yvonne Claassen; Gemma Moiset, PhD; Hans Van Eenennaam, PhD; Victorine Roos; Frank Kallenberg; Jan P. Medema; Paul J. Hensbergen; Pauline M. van Helden, PhD; Evelien Dekker; Hergen Spits, PhD; Immune Cell Biology Antibody; B cell; Bispecifics; Post-translational modifications; Solid tumors; Targeted therapy; Tumor antigens
500 Poster Presentation P2RX7 agonist treatment boosts the ability of IL-12-activated CD8+ T cells to infiltrate and control murine melanoma Kelsey M. Wanhainen; Stephen C. Jameson; Henrique Borges Da Silva, PhD; Immune Cell Biology Adoptive immunotherapy; Immune adjuvant; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs)
501 Poster Presentation VISTA regulates the differentiation and suppressive function of myeloid-derived suppressor cells Juan Dong, MD; Cassandra Gilmore; Hieu M. Ta, PhD; Keman Zhang; Sarah Stone; Li Wang, PhD; Immune Cell Biology Antibody; Immune suppression; MDSC; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
502 Poster Presentation The co-expression of two immune complex molecules, VISTA and TIGIT, define a dysfunctional cytotoxic T cell subset Cassandra K. Gilmour, BS; Li Wang, PhD; Juan Dong, MD; Hieu M. Ta, PhD; Immune Cell Biology Biomarkers; Checkpoint blockade; Costimulation; Immune suppression; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
503 Poster Presentation Tumor infiltrating lymphocytes in soft tissue sarcomas upregulate the exhaustion marker TIGIT and are reinvigorated by IL-15 stimulation and TIGIT blockade Sean J. Judge, MD, MS; Morgan A. Darrow, MD; Steven W. Thorpe, MD; Alicia A. Gingrich, MD; Edmond F. O'Donnell, MD; Alyssa R. Bellini, MD; Ian R. Sturgill; Logan V. Vick; Cordelia M. Dunai, MS; Kevin M. Stoffel, MS; Yue M. Lyu; Shuai M. Chen, PhD; May M. Cho, MD; Robert M. Rebhun, DVM PhD; Arta M. Monjazeb, MD, PhD; William J. Murphy, PhD; Robert J. Canter, MD, MAS, FACS; Immune Cell Biology NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
504 Poster Presentation Using multiplexed immunofluorescence to quantitatively analyze myeloid derived suppressor cells (MDSCs) in relation to tertiary lymphoid structures (TLS) in bladder cancer Anna Juncker-Jensen, PhD; Gang Huang; Mate L. Nagy; Xin Lu; Anna Juncker-Jensen, PhD; Anna Juncker-Jensen, PhD; Immune Cell Biology Adoptive immunotherapy; B cell; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
505 Poster Presentation Activation of NK T cells promote the inflammatory tumor microenvironment and control the growth of solid tumor Sourav Paul, PhD; Amrita Mishra, MSc; Sushanta Chhatar; Girdhari Lal, PhD; Girdhari Lal, PhD; Immune Cell Biology Chemotherapy; Costimulation; Cytokine; Immune adjuvant; Inflammation; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
506 Poster Presentation The tumor immune microenvironment of metastatic osteosarcoma is marked by lymphocyte exclusion and impacts patient progression-free survival John A. Ligon, MD; Woonyoung Choi; Gady Cojocaru; Wei Fu; Emily H. Hsiue, MD; Teniola F. Oke; Carol D. Morris; Adam Levin; Daniel S. Rhee; David J. McConkey; Robert A. Anders, MD, PhD; Drew M. Pardoll, MD, PhD; Nicolas J. Llosa, MD; Immune Cell Biology Checkpoint blockade; Chemokine; Cytokine; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment
507 Poster Presentation High dimensional flow cytometry analysis in newly diagnosed acute myeloid leukemia predicts patients outcomes Francesco Mazziotta, MD; Rupkatha Mukhopadhyay; Hanna A. Knaus; Anish Chowdhury; Amanda Blackford; Ivana Gojo, MD; Leo Luznik, MD; Immune Cell Biology Bioinformatics; Chemotherapy; Immune contexture; Immune monitoring; Leukemia/Lymphoma; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
508 Poster Presentation Different neoantigen expression patterns impact the strength of anti-tumor immune responses Kim B. Nguyen, B.A.; Stefani Spranger, PhD; Christopher J. Copeland, B.S.; Immune Cell Biology Immune suppression; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs)
509 Poster Presentation Potent And Selective Inhibition Of AXL Receptor Tyrosine Kinase For The Treatment of Cancer Susan L. Paprcka, PhD; Akshata R. Udyavar, Ph.D; Subhasree Sridhar; Dillon H. Miles, PhD; Yu Chen, PhD; Sean Cho, PhD; Corinne N. Foley, PhD; Rebecca Grange, PhD; Manmohan R. Leleti, PhD; Sharon Zhao, PhD; Lixia Jin, PhD; Stephen W. Young, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD; Immune Cell Biology Dendritic cell; Gene expression; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment
510 Poster Presentation Helping the killers: innovative cancer immunotherapy harnessing quasi-universal tumor antigen-specific CD4 T cells Margaux Saillard; Amelie Cachot; Georg Alexander Rockinger; Philippe Guillaume; Julien Schmidt, PhD; Alexandre Harari, PhD; Camilla Jandus, MD, PhD; Pedro J. Romero, MD; Immune Cell Biology Antigen presenting cells; T cell; Tumor antigens; Vaccine
511 Poster Presentation Tumor immune microenvironment in adult mice asynchronously cross-fostered as pups Vianca Vianzon, BS; Ishita Garg; Kara G. Greenfield; Kathryn A. Knoop, PhD; Laura M. Rogers, PhD; Immune Cell Biology Immune tolerance; Microbiome; Tumor infiltrating lymphocytes (TILs)
512 Oral Presentation Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors Paolo DA. Vignali, BA; Kristin DePeaux, BS; McLane Watson, BS; Ashley Menk, MS; Nicole E. Scharping, PhD; Greg M. Delgoffe, PhD; Immune Cell Biology Immune suppression; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
513 Poster Presentation CD26 enzymatic activity modulates efficient migration of adoptively transferred T cells to solid tumors Megan M. Wyatt, MS; Michelle H. Nelson, PhD; Stefanie R. Bailey, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; Immune Cell Biology Adoptive immunotherapy; Chemokine; Costimulation; Solid tumors; T cell
514 Poster Presentation Disturbed Mitochondrial Dynamics Rewire the Epigenetic Program for CD8+ TIL Exhaustion Yi-Ru Yu, PhD; Haiping Wang; Fabien Franco; Ping-Chih Ho, PhD; Immune Cell Biology Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
515 Oral Presentation Metabolic reprogramming of antitumor CD8+ T cell immunity Alison Jaccard, MS; Mathias Wenes, PhD; Gábor Gyülvészi; Ping-Chih Ho, PhD; Pedro J. Romero, MD; Immune Cell Biology Adoptive immunotherapy; Epigenetics; Immune monitoring; Metabolism; Post-translational modifications; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
516 Poster Presentation Caspase-8 regulated senescence as an immune checkpoint in T lymphocytes for adoptive cell therapy Valérie Janelle, PhD; Mathieu Neault, PhD; Marie-Eve Lebel, PhD; Dave De Sousa, MSc; Salix Boulet, PhD; Ludovic Durrieu, PhD; Cedric Carli, PhD; Sebastien Lemieux, PhD; Nathalie Labrecque, PhD; Heather J. Melichar, PhD; Frederick A. Mallette, PhD; Jean-Sebastien Delisle, PhD, MD; Immune Cell Biology Adoptive immunotherapy; Bioinformatics; CAR T cells; Gene expression; Leukemia/Lymphoma; Metabolism; T cell; Targeted therapy
517 Oral Presentation Regulatory T cell functional identity is sustained by a glucose:lactate axis that is exploited in the tumor microenvironment McLane Watson, BS; Paolo DA. Vignali, BA; Steven Mullet; Abigail E. Overacre-Delgoffe, PhD; Ronal M. Peralta; Stephanie Grebinoski; Ashley Menk, MS; Natalie Rittenhouse; Kristin DePeaux, BS; Ryan D. Whetstone, MS, PhD; Dario A. Vignali, PhD; Timothy W. Hand, PhD; Amanda Poholek; Brett Morrison, MD, PhD; Jeffrey Rothstein; Stacy Wendell, PhD; Greg M. Delgoffe, PhD; Immune Cell Biology Metabolism; Regulatory T cell (Treg cell); Tumor evasion; Tumor microenvironment
518 Poster Presentation Epigenetic dysfunction of terminally exhausted tumor infiltrating T cells Rhodes Ford, BSc; Paolo DA. Vignali, BA; Natalie Rittenhouse; Nicole Scharping; Andrew Frisch; Greg M. Delgoffe, PhD; Amanda Poholek; Immune Cell Biology Bioinformatics; Epigenetics; Gene expression; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
519 Poster Presentation Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes Javier Arranz-Nicolas, PhD; Cristina Rodríguez-Rodríguez; Rosa Liébana; Judith Leitner; Antonia Ávila-Flores; Peter Steinberger; Isabel Mérida; Immune Cell Biology Antibody; Biomarkers; Checkpoint blockade; Costimulation; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs)
520 Poster Presentation The immune landscape of pediatric tumors Shimaa M. Sherif, MSc.; Jessica Roelands, Master; William Mifsud; Blessing Dason; Darawan Rinchai, PhD; Adrian Charles; Ayman Saleh; Chiara Cugno, MD; Khalid Fakhro; Borbala Mifsud; Davide Bedognetti, MD, PhD; Wouter RL. Hendrickx, PhD; Immune Cell Biology Bioinformatics; Biomarkers; Gene expression; Immunoscore; Pediatric tumors; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; RNA
521 Poster Presentation Immune Regulatory Metabolites in Human Ovarian Cancer Julian J. Lum, PhD; Marisa Kilgour, BSc; Sarah MacPherson; Lauren Zacharias; Sarah Keyes; Bertrand Allard, PhD; Julian Smazynski; Peter Watson; John Stagg, PhD; Bradley Nelson, PhD; Ralph Deberardinis; Phineas Hamilton; Julian J. Lum, PhD; Immune Cell Biology Immune suppression; Metabolism; Tumor infiltrating lymphocytes (TILs)
522 Poster Presentation Metabolic requisites for T cell protein translation in tumors Katie E. Hurst; Megan Tennant; Megan Tennant; Alex M. Andrews, PhD; Lee Leddy, MD, MsCR; David M. Neskey, MD; Lauren Ball, PhD; Jessica E. Thaxton, PhD, MS; Immune Cell Biology Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
523 Poster Presentation A subset of mature neutrophils contains the strongest PMN-MDSC activity in blood and tissue of patients with head and neck cancer Yu Si; Kirsten Bruderek; Simon Merz; Philip Jansen; Stephan Lang; Matthias Gunzer; Joachim Klode; Anthony Squire; Sven Brandau, PhD; Immune Cell Biology Biomarkers; Granulocyte; Immune monitoring; Inflammation; MDSC; Myeloid cells; Solid tumors; Tumor microenvironment; Tumor stroma
524 Poster Presentation Tim-4+ Resident Macrophages Impair Anti-Tumor Immunity In the Serous Body Cavities By Sequestering Viable and Cytotoxic CD8+ T cells Expressing High Levels of Phosphatidylserine Andrew Chow, MD, PhD; Sara Schad, BS; Michael D. Green, MD, PhD; Matthew D. Hellmann, MD; Nicholas Ceglia, PhD; Viola Allaj; Giulia Zago, PhD; Nisarg Shah; Sai K. Sharma, PhD; Marissa Mattar; Joseph Chan, MD, PhD; Hira Rizvi; Hong Zhong, BS; Cailian Liu, MD; Yonina Bykov; Dmitriy Zamarin, MD, PhD; Hongyu Shi; Sadna Budhu, PhD; Corrin Wohlhieter; Fathema Uddin; Aditi Gupta, MD; Inna Khodos; Jessica J. Waninger, BS; Angel Qin; Vinod Balachandran, MD; Weiping Zou, MD, PhD; Sohrab Shah, PhD; Andrew McPherson, PhD; Katherine S. Panageas, PhD; Jason S. Lewis, PhD; Justin Perry, PhD; Elisa de Stanchina, PhD; Triparna Sen, PhD; John T. Poirier, PhD; Jedd D. Wolchok, MD, PhD; Charles M. Rudin, MD, PhD; Taha Merghoub, PhD; Immune Cell Biology Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor evasion; Tumor microenvironment
525 Poster Presentation KIT mutation with a low MS4A1/CD20 expression is associated with poor prognosis in melanoma Shashank Cingam, MD; Moises Harari-Turquie, MD; Dulcinea Quintana, MD; Leslie Andritsos, MD; Emrullah Yilmaz, MD, PhD; Immune Cell Biology B cell; Checkpoint blockade; Targeted therapy; Tumor microenvironment
526 Poster Presentation InhibigenTM-specific responses suppress anti-tumor immunity and promote tumor growth Victoria L. DeVault, PhD; Tulin Dadali, PhD; Hanna Starobinets, PhD; Kevin Lema; Stephanie Rinaldi; Osaruese Odeh; Julie N. Arnold; Dylan Sheehan; Cindy K. Nguyen; Louisa Dowal, PhD; Jessica B. Flechtner, PhD; Alberto Visintin, PhD; Hubert Lam, PhD; Immune Cell Biology Antigen presenting cells; Checkpoint blockade; Immune suppression; Neoantigens; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment
527 Poster Presentation Tumor organoid and immune cell co-culture system potentiates Immuno-Oncology drug development Hongjuan Zhang, PhD; Jun Zhou; Shuang Zhu; Jia Zheng; Limei Shang; Chunmei Li; Xuefei Yan, PhD; Rui Zhang; Mingfa Zang; Annie Xiaoyu An; Xiaoxi Xu; Shuzong Wang; Henry Q. Li; Yujun Huang; Immune Cell Biology Bispecifics; CAR T cells; Checkpoint blockade; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
528 Oral Presentation Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b Defne Bayik, PhD; Yadi Zhou; Chihyun Park; Chngjin Hong; Danielle Silver, PhD; Dionysios C. Watson, MD; Alice Lo; Tae Hyun Hwang; Feixiong Cheng; Peter A. Sims; Antonio Iavarone; Justin D. Lathia, PhD; Immune Cell Biology Cytokine; Granulocyte; Immune suppression; Myeloid cells; MDSC; Tumor microenvironment
529 Poster Presentation Cancer cells educate natural killer cells to a metastasis promoting cell state Isaac S. Chan, MD, PhD; Hildur Knu´tsdo´ttir, PhD; Gayathri Ramakrishnan; Veena Padmanaban; Manisha Warrier; Juan Carlos Ramirez; Joel S. Bader; Elizabeth M. Jaffee, MD; Isaac S. Chan, MD, PhD; Andrew Ewald; Immune Cell Biology NK/NKT cell; Tumor evasion; Tumor microenvironment
530 Poster Presentation T-cell immunoglobulin– and mucin domain–containing (TIM)–3 downregulation in response to ex vivo activation and cancer targets correlates to NK cell functionality. Tram N. Dao, BS; Sandro Matosevic, PhD; Sagar Utturkar, PhD; Nadia A. Lanman, PhD; Sandro Matosevic, PhD; Immune Cell Biology Cytokine; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs)
531 Oral Presentation AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies Lucila Kerbauy; Nancy D. Marin, PhD; Mecit Kaplan; Pinaki Banerjee; Melissa Berrien-Elliott; Michelle Becker-Hapak; Rafet Basar; Mark Foster; Luciana Garcia Melo; Carly Neal; Ethan McClain; May Daher, MD; Ana Karen Nunez Cortes; Sweta Desai; Francesca Wei Inng Lim; Mayela Carolina Mendt; Timothy Schappe; Li Li; Hila Shaim; Mayra Hernandez Sanabria; Pamela Wong; Enli Liu; Sonny Ang; Rong Cai; Vandana Nandivada; Vakul Mohanty; Yifei Shen; Natalia Baran; Natalie Fowlkes; Ken Chen; Luis Muniz-Feliciano; Joachim Koch, PhD; Martin Treder; Wolfgang Fischer; Oswaldo Keith Okamoto; Yago Nieto, MD PhD; Richard E. Champlin, MD; Elizabeth J. Shpall, MD; Todd A. Fehniger; Katy Rezvani, MD, PhD; Immune Cell Biology Antibody; Bispecifics; NK/NK T cell; Targeted therapy
532 Poster Presentation SOCS3 deficiency blocked autophagy-dependent myeloid differentiation of early-stage myeloid-derived suppressor cells via the miR-155/C/EBPß/Wnt axis Jinpu Yu, Ph.D.; Wenwen Zhang; Immune Cell Biology Carcinogenesis; Immune suppression; MDSC; Tumor evasion; Tumor microenvironment
533 Poster Presentation Cross-species immunogenomic analysis identifies pathways of canine natural killer cell response to cytokine therapy, and reveals convergence of activated dog and human natural killer transcriptomes Alicia A. Gingrich, MD; Taylor Reiter; Sean J. Judge, MD, MS; Daniel York; Mio Yanagisawa, MD; Ian R. Sturgill; Rachel Brady; Kevin M. Stoffel, MS; Arta M. Monjazeb, MD, PhD; Robert M. Rebhun, DVM PhD; C. Titus Brown, PhD; Robert J. Canter, MD, MAS, FACS; Immune Cell Types Bioinformatics; Cytokine; Gene expression; NK/NK T cell
534 Poster Presentation Better Immune Profiles on Elderly Colorectal Cancer Patients Correlated With 1 Year Diseases Free Survival (DFS) Budhi Ida Bagus, MD; Metria Ida Bagus; Mastini Ida Ayu Kade; Immune Cell Types Chemotherapy; Immune monitoring; Solid tumors; Surgery
535 Poster Presentation Electroporation of B cells is correlated with cell size change during B cell expansion Jian Chen, PhD; George Sun; Jian Chen, PhD; Immune Cell Types B cell; Gene expression
536 Poster Presentation Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer Ayana Ruffin, MS; Anthony R. Cillo, PhD; Tracy Tabib; Angen Liu; Sayali Onkar; Sheryl R. Kunning; Caleb Lampenfeld, B.S.; Irina Abecassis; Zengbiao Qi; Ryan Soose, MD; Umamaheswar Duvvuri; Seungwon Kim, MD; Steffi Oesterrich; Robert Lafyatis; Robert L. Ferris, MD, PhD; Dario A. Vignali, PhD; Tullia C. Bruno, PhD; Immune Cell Types B cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
537 Poster Presentation Conventional type 1 dendritic cells and natural killer cells demonstrate strong correlation to T lymphocyte infiltration in cervical cancer tumors Anushka Dikshit, PhD; Xiao-jun Ma, PhD; Bingqing Zhang, PhD; Anushka Dikshit, PhD; Immune Cell Types Dendritic cell; NK/NK T cell; RNA; Tumor infiltrating lymphocytes (TILs)
538 Poster Presentation Harnessing cross-dressing dendritic cells to strengthen anti-tumor immunity Ellen Duong, Sc.B.; Timothy B. Fessenden, PhD; Arjun Bhutkar; Stefani Spranger, PhD; Immune Cell Types Antigen presenting cells; Dendritic cell; Myeloid cells; Tumor microenvironment
539 Oral Presentation High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content Anastasia Prokopi, PhD; Marta Lopez-Gonzalez; Jan Verhoeff; Rieneke R. Van de Ven, PhD; Juan J. Garcia-Vallejo, PhD; Patrizia Stoitzner, PhD; Tanja D. de Gruijl, PhD; Immune Cell Types Dendritic cell; Immune suppression; Myeloid cells; Regulatory T cell (Treg cell); T cell
540 Poster Presentation Transcriptionally defined immune landscape in human gliomas Pravesh Gupta, PhD; Minghao Dang, PhD; Krishna Bojja; Huma Shehwana, PhD; Tuan M. Tran; Linghua Wang, PhD; Krishna P. Bhat, PhD; Pravesh Gupta, PhD; Immune Cell Types Antigen presenting cells; Dendritic cell; Immune contexture; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment
541 Poster Presentation Investigating myeloid derived suppressor cells (MDSCs) and Oligonucleotide based targeting of STAT3 in Renal Cell Carcinoma Marice Alcantara; Dayson F. Moreira, PhD; Chia-Yang Hung, PhD; Chunsong Yu; Dongfang Wang, PhD; JoAnn Hsu, BS; Sumanta K. Pal, MD; Marcin Kortylewski, PhD; Marice Alcantara; Immune Cell Types Checkpoint blockade; Immune monitoring; Immune suppression; MDSC; Myeloid cells; T cell; Tumor microenvironment
542 Poster Presentation Expansion of cytotoxic NK Cells from PBMCs using individualized cytokine combination Andreia Maia, PhD student; Joana R. Lerias, PhD; Markus J. Maeurer, MD, PhD, FRCP(London); Mireia Castillo-Martin, MD, PhD; Andreia Maia, PhD student; Immune Cell Types Adoptive immunotherapy; Cytokine; NK/NK T cell; Tumor evasion
543 Poster Presentation Natural killer cells restrict the growth of liver metastases in nude hosts Alexandra Quackenbush, BS; Pepper Schedin; Immune Cell Types NK/NK T cell; Solid tumors
544 Poster Presentation Multiomic characterization of T-cell populations at the single-cell level utilizing sensitive dextramers and BD® AbSeq on the BD RhapsodyTM Single-Cell Analysis system Kivin Jacobsen, PhD; Cynthia Sakofsky, PhD; Vadir Lopez-Salmeron, PhD; Margaret Nakamoto, PhD; Liselotte Brix, PhD; Stefanie Mortimer; Cynthia Sakofsky, PhD; Immune Cell Types Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; T cell
545 Oral Presentation TUMOR-SPECIFIC CYTOLYTIC CD4 T CELLS MEDIATE PROTECTIVE IMMUNITY AGAINST HUMAN CANCER Amélie Cachot; Mariia Bilous; Yen-Cheng Liu; Xiaokang Li; Alexander Rockinger; Margaux Saillard; Tania Wyss; Philippe Guillaume; Julien Schmidt, PhD; Raphael Genolet; Maria Pia Protti; Walter Reith; Laurence De Leval; Kalliopi Ioannidou; George Coukos, MD, PhD; Alexandre Harari, PhD; Daniel E. Speiser, MD; Alexander Mathis; David Gfeller; Hatice Altug; Pedro J. Romero, MD; Camilla Jandus, MD, PhD; Immune Cell Types Adoptive immunotherapy; Solid tumors; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
546 Poster Presentation The Differentiation status of Systemic PD1+ CD8 T Cells is Associated with Favorable Outcome to PD1 Blockade Therapy in Non Small Cell Lung Cancer Asma Khanniche, PhD; Ying Wang; Immune Cell Types Biomarkers; Checkpoint blockade; T cell
547 Oral Presentation Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis Rossana N. Lazcano Segura, MD; Santhoshi N. Krishnan; Morgan D. Oneka; Federico Netto; Xin Lu; Priya Rao, MD; Renganayaki K. Pandurengan; Curtis R. Pickering; Curtis A. Pettaway, MD; Jad Chahoud; Edwin R. Parra, MD, PhD; Edwin R. Parra, MD, PhD; Immune Cell Types Immune contexture; Immune suppression; Solid tumors; T cell; Tumor microenvironment
548 Poster Presentation CD8+ Tissue-resident memory T cells are tumour reactive and increase after immunotherapy in a case of metastatic mucosal melanoma Angela Pizzolla, PhD; Simon P. Keam, PhD; Ismael Vergara; Franco Caramia; Minyu Wang; Nikolce Kocovski; ThuNgoc Nguyen; Sean Macdonald; Daniela Tantalo; Pasquale Petrone; Han Xian Aw Yeang; David E. Gyorki; Alison Weppler, MD; George Au-Yeung; Shahneen Sandhu, MBBS FRACP; Maurizio Perdicchio, PhD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; Tony Papenfuss; Paul J. Neeson, PhD; Immune Cell Types Checkpoint blockade; Neoantigens; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
549 Oral Presentation Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates Sara Schad, BS; Sara Schad, BS; Andrew Chow, MD, PhD; Heng Pan; Levi M. Mangarin, BS; Roberta Zappasodi, PhD; Mathieu Gigoux, PhD; David Redmond; Daniel Hirschhorn-Cymerman, PhD; Sadna Budhu, PhD; Hong Zhong, BS; Xia Yang; Olivier Elemento, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; Immune Cell Types Adoptive immunotherapy; CAR T cells; Gene expression; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
550 Poster Presentation An Axl-targeting monoclonal antibody that inhibits Axl activity and potently stimulates the innate immune response Diego Alvarado; Laura Vitale, BS; Mike Murphy; Thomas O'Neill, BA; Edward J. Natoli; Jay Lillquist; Linda Crew; Anna Wasiuk; Jeffrey Weidlick, BS; Crystal Sisson; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; James M. Boyer; Eric Forsberg; April R. Baronas; Taylor M. Mathieu; Amelia C. Fields; Russell Hammond; Li-Zhen He, MD; Joel Goldstein, PhD; Lawrence J. Thomas, PhD; Henry C. March; Tibor Keler, PhD; Immune-stimulants and immune modulators Antibody; Bispecifics; Checkpoint blockade; Coinhibition; Dendritic cell; Immune suppression; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor microenvironment
552 Poster Presentation SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models Akito Nakamura, PharmD; Keli Song, PhD; Stephen Grossman, PhD; Kristina Xega; Yuhong Zhang; Allison J. Berger, PhD; Allison J. Berger, PhD; Gary S. Shapiro, PhD; Dennis Huszar, PhD; Immune-stimulants and immune modulators Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Post-translational modifications
553 Poster Presentation CUE-100 series Immuno-STATs from concept to the clinic: Leveraging protein engineering to stimulate and selectively deliver affinity-attenuated IL-2 to antigen-specific T cells Alex Histed, MSc; Natasha Girgis, PhD; Miguel Moreta; Jonathan Soriano, MSc; Luke Witt, B.S.; Zohra Merazga, MSc; Fulvio Diaz; Fan Zhao, PhD; Melissa Kemp, PhD; Paige Ruthardt, MSc; Dharma Thapa, PhD; Anish Suri, PhD; Ronald D. Seidel, PhD; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; Steven N. Quayle, PhD; John F. Ross, Ph.D.; Saso Cemerski, PhD; Saso Cemerski, PhD; Saso Cemerski, PhD; Immune-stimulants and immune modulators Antigen presenting cells; Clinical trial; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine
555 Poster Presentation Inhibition of FOXP3 by stapled alpha-helical peptides alters Regulatory T Cell function Katrina M. Hawley, AB; Rachel J. Eclov, PhD; Marie Fefferman, MD; Gregory H. Bird, PhD; Mathew R. Schnorenberg; Ravand Samaeekia, MD; Loren D. Walensky, MD, PhD; Matthew V. Tirrell, PhD; James L. LaBelle, MD, PhD; Immune-stimulants and immune modulators Regulatory T cell (Treg cell); Targeted therapy
557 Poster Presentation Determining the efficacy of ADCC by the 3D-EX ex vivo platform utilizing tumoroids of fresh patient tumor samples with intact tumor microenvironment Jenny Kreahling, PhD; Jared C. Ehrhart, PhD; Stephen Iwanowycz, PhD; Mibel Pabon, PhD; Tina Pastoor; Soner Altiok, MD, PhD; Immune-stimulants and immune modulators Antibody; Checkpoint blockade; Cytokine; Gene expression; Immune monitoring; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
558 Poster Presentation Programmed death (PD)-1 and PD-ligand-1 inhibitors in the treatment of non-small cell lung cancer: a systematic review of their efficacy and safety Melissa Lingohr-Smith; Chelsea Deitelzweig; Grace Lin; Jay Lin; Immune-stimulants and immune modulators Checkpoint blockade; Clinical trial; Targeted therapy
559 Poster Presentation Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer Remya Raja, PhD; Christopher Wu; Kristina A. Butler, M.D., MS; Marion Curtis, Ph.D.; Immune-stimulants and immune modulators Chemotherapy; Cytokine; Inflammation; Solid tumors; T cell
560 Poster Presentation Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo Fernanda Szewc, MSc; Longzhen Song, Ph.D.; Sean P. Rinella, MPH, CCRP; Christopher Dubay, Ph.D.; Emmanuel T. Akporiaye, Ph.D.; William L. Redmond, Ph.D.; Christian M. Capitini, MD; Immune-stimulants and immune modulators Gene expression; Immune suppression; Myeloid cells; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Epigenetics; RNA
561 Poster Presentation DuoBody®-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Rachelle Kosoff, PhD; Kristina Schödel; Theodora Salcedo; Saskia Burm, PhD; Aras Toker; Lena M. Kranz, PhD; Mathias Vormehr; David Eisel; Mark Fereshteh, PhD; Özlem Türeci; Esther Breij, PhD; Tahamtan Ahmadi; Ugur Sahin, MD; Maria Jure-Kunkel; Immune-stimulants and immune modulators Antibody; Bispecifics; Checkpoint blockade; Coinhibition; Costimulation; Targeted therapy
562 Poster Presentation SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity Zuzana Antosova, PhD; Nada Podzimkova, MSc; Marketa Jiratova, MSc; Eva Nedvedova, PhD; Guy de Martynoff, PhD, CMO; David Bechard, PhD, CEO; Ulrich Moebius, PhD,CSO; Radek Spisek, MD,PhD,CEO; Irena Adkins, PhD; Immune-stimulants and immune modulators Antibody; Cytokine; Immune adjuvant; Leukemia/Lymphoma; Solid tumors; T cell
563 Poster Presentation Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys Nada Podzimkova, MSc; Irena Adkins, PhD; Irena Adkins, PhD; Guy de Martynoff, PhD, CMO; David Bechard, PhD, CEO; Radek Spisek, MD,PhD,CEO; Ulrich Moebius, PhD,CSO; Immune-stimulants and immune modulators Cytokine; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); T cell
564 Poster Presentation Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents Matthew J. Bernett, PhD; Rajat Varma, PhD; Ke Liu, PhD; Christine Bonzon, PhD; Rumana Rashid, PhD; Nicole Rodriguez, PhD; Nargess Hassanzadeh-Kiabi, PhD; Connie Ardila; Seung Chu, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; Immune-stimulants and immune modulators Bispecifics; Cytokine; Solid tumors; Tumor microenvironment
565 Poster Presentation A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models Subhajit Ghosh, PhD; Ran Yan, PhD; Sukrutha Thotala; Arijita Jash, PhD; Anita Mahadevan, BS; Tong Hu, BS; Byung H. Lee, PhD; Se Hwan Yang, PhD; Dennis Hallahan, MD, PhD; Milan Chheda, MD; Dinesh Thotala, PhD; Jian L. Campian, MD, PhD; Jian L. Campian, MD, PhD; Immune-stimulants and immune modulators Cytokine; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
566 Poster Presentation MDK-202: An empirically-designed peptidyl agonist of the IL-2/15βγc receptor, devoid of Rα interaction, unrelated to IL-2 or IL-15, and fused to an Fc-domain for PK enhancement William J. Dower, PhD; Steven E. Cwirla; Blake M. Williams, MS; Praechompoo Pongtornpipat, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Alice V. Bakker, BA; Michael C. Needels, PhD; Ronald W. Barrett, PhD; Immune-stimulants and immune modulators Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
567 Poster Presentation MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; Immune-stimulants and immune modulators COVID and Immunotherapy; CAR T cells; Cytokine; Immune adjuvant; T cell; T cell lineages; Vaccine
568 Poster Presentation XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates Minjie Zhang; Wilson Guzman; Parker Johnson; Megan McLaughlin; Kurt Jenkins, PhD; Hsin-Jung Wu; Hanumantha Rao Madala; Caitlin O'Toole; Magali Pederzoli-Ribeil; Raphael Rozenfeld; Huawei Qiu; Margaret L. Karow, PhD; Tim Clackson; Ronan O'Hagan; Jennifer O'Neil; Ugur Eskiocak, PhD; Immune-stimulants and immune modulators Cytokine
569 Poster Presentation Targeting IL-15 delivery to PD-L1 Expressing Tumors with an Anti-PD-L1-IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity Angus M. Sinclair, PhD; Thierry D. Giffon; Dean Ng, Ph.D.; Poonam Yakkundi, Ph.D.; Hope Lancero, Ph.D.; Marigold Manlusoc; Rodnie Rosete; Avneesh Saini, Ph.D.; Madeline Tran; Kevin Carlin, Ph.D.; Chitra Saraiya; Ramesh Baliga, Ph.D.; Bruce Keyt, Ph.D.; Immune-stimulants and immune modulators Antibody; Bispecifics; Checkpoint blockade; Cytokine; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs)
570 Poster Presentation IL-15/IL-15Rα heterodimeric complex as cancer immunotherapy in murine breast cancer models Siqi Guo; Ronald Smeltz B. Smeltz, PhD; Anthony Nanajian; Richard Heller; Siqi Guo; Immune-stimulants and immune modulators Cytokine; Solid tumors; T cell
571 Poster Presentation ANV419 is a novel CD122-selective IL-2/anti-IL-2 antibody fusion protein with potent CD8 T cell and NK cell stimulatory function in vitro and in vivo Christoph Huber, PhD; Andreas Katopodis, PhD; Barbara Branetti; Jean-Michel Rondeau; Simone Popp; Catherine Regnier; Daniel Kaiser; Immune-stimulants and immune modulators Antibody; Cytokine; Immune adjuvant; Immune toxicity; NK/NK T cell; Regulatory T cell (Treg cell); T cell
572 Poster Presentation Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkine™ potentiates anti-cancer effects in preclinical cancer models Donggeon Kim, DVM,PhD; Donggeon Kim, DVM,PhD; Dahea Lee; Soomin Ryu; Yeongseon Byeon, PhD; Kyoung-Ho Pyo, PhD; Jae-Hwan Kim, PhD; Seul Lee; Dong Kwon Kim; Eun Ji Lee; Seung Yeon Oh; Byoung Chul c. Cho, MD, PhD; Immune-stimulants and immune modulators Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
573 Poster Presentation A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity Dan Lu, MS; Zhanna Polonskaya; Tzu-Pei Chang, PhD; Stella Martomo, PhD; Xenia Luna; zhikai zhang; Stanley Ng; Faical Miyara, PhD; Jeegar Patel; Immune-stimulants and immune modulators Antibody; Bispecifics; Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
574 Poster Presentation ONM-400, a Novel Approach for Interleukin-2 Therapy Using a pH-Activated Nanoparticle Targeting Metabolic Acidosis in Solid Cancers Xinliang Ding, PhD; Jason B. Miller, PhD; Qingtai Su, PhD; Qingtai Su, PhD; Stephen Gutowski; Ashley Campbell; Drew Robinson; Tian Zhao, PhD; Immune-stimulants and immune modulators Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment
575 Poster Presentation Regression by hetIL-15 monotherapy in different mouse breast cancer models correlates with intratumoral infiltration of a novel population of dendritic cells Sevasti Karaliota; Dimitris Stellas; Vasiliki Stravokefalou, MSc.; Bethany Nagy, BS; Cristina Bergamaschi, PhD; Barbara K. Felber, PhD; George N. Pavlakis, M.D., Ph.D.; Immune-stimulants and immune modulators Antigen presenting cells; Cytokine; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
576 Poster Presentation NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies Carl Walkey, PhD; Ryan Swanson, BS; Umut Ulge, MD, PhD; Daniel Adriano Silva Manzano, PhD; Jonathan G. Drachman, MD; Immune-stimulants and immune modulators Antibody; Bispecifics; Checkpoint blockade; Costimulation; Cytokine; Inflammation; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
577 Poster Presentation Engineered non-pathogenic synthetic biotic producing L-arginine synergize with PD-1-based cancer immunotherapy Fernando P. Canale; Camilla Basso; Ning W. Li, PhD; Anna Sokolovska, PhD; Michela Perotti; Michael J. James, BS; Wenjie Jin; Jean-Philippe Theurillat; Daniel Leventhal; Kip A. West, PhD; Jose Lora; Federica Sallusto; Roger Geiger, PhD; Immune-stimulants and immune modulators Checkpoint blockade; Immune adjuvant; Immune suppression; Metabolism; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
578 Poster Presentation Tumor selective immune responses of STA551, a novel anti-CD137 agonist antibody activated by extracellular ATP Yoshinori Narita, Ph.D.; Mika Kamata-Sakurai, PhD; Immune-stimulants and immune modulators Antibody; Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
579 Poster Presentation Lactate Dehydrogenase C-associated molecular networks predict enhanced tumor growth and impaired immune response in breast cancer. Julie Decock, PhD; Adviti N. Jana; Julie Decock, PhD; Immune-stimulants and immune modulators Carcinogenesis; Immune contexture; Immune suppression; Tumor antigens; Tumor evasion; Tumor microenvironment
580 Poster Presentation High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot Simon P. Keam, PhD; Heloise Halse; ThuNgoc Nguyen; Minyu Wang; Nicolas Van Kooten Losio; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; Immune-stimulants and immune modulators Bioinformatics; Clinical study; Gene expression; Immune contexture; Immune suppression; Inflammation; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
581 Poster Presentation Effects of Acoustic Immune Priming with Low-Intensity Focused Ultrasound (LOFU) and Trabectedin on a Murine Model of Osteosarcoma Shannon Keisling; Immune-stimulants and immune modulators Immune tolerance; Radiotherapy; Solid tumors; Tumor antigens
582 Poster Presentation Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles Audrey Darmon, BS; Ping Zhang, PhD; Sebastien Paris, PhD; Immune-stimulants and immune modulators Radiotherapy; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs)
583 Poster Presentation Novel, potent, and selective inhibitors of Hypoxia-Inducible Factor (HIF)-2α reverse pro-tumorigenic transcriptional programming in cancer, stromal, and immune cells Kelsey E. Sivick Gauthier, PhD; Dana Piovesan, MSc; Kenneth V. Lawson; Soonweng Cho; Akshata R. Udyavar, Ph.D; Jean Chan; Ada Chen, BS; Jennie Au; Cesar Meleza; Xiaoning Zhao; Anh T. Tran; Samuel L. Drew; Balint Gal; Brandon R. Rosen, PhD; Manmohan R. Leleti, PhD; Elaine Ginn; Lixia Jin, PhD; Stephen W. Young; Jay P. Powers, PhD; Matthew J. Walters, PhD; Immune-stimulants and immune modulators Angiogenesis; Chemokine; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment
584 Poster Presentation Therapeutic vascular normalization to promote tumor-associated tertiary lymphoid structures Jessica Filderman, BS; Manoj Chelvanambi; Walter J. Storkus, PhD; Immune-stimulants and immune modulators Angiogenesis; Chemokine; Dendritic cell; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
585 Poster Presentation Intralesional injection of rose bengal improves the efficacy of gemcitabine chemotherapy against pancreatic cancer. Patrick Innamarato, B.S.; Shari A. Pilon-Thomas, PhD; Jennifer Morse, MS; Sarah Asby; Amy Mackay; Matthew Beatty, PhD; Jaime Blauvelt; Scott Kidd; John E. Mullinax, MD; Immune-stimulants and immune modulators Chemotherapy; Inflammation; Solid tumors; T cell
586 Poster Presentation Intratumoral DNA-based gene transfer as an efficient delivery approach to combine checkpoint-inhibiting antibodies with interleukin 12 Liesl Jacobs, MPharm; Elien De Smidt; Nick Geukens, PhD; Kevin Hollevoet, PhD; Paul Declerck, PhD; Immune-stimulants and immune modulators Antibody; Checkpoint blockade; Costimulation; Cytokine; Gene expression
587 Oral Presentation Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models Kurt Jenkins, PhD; Kurt Jenkins, PhD; Kurt Jenkins, PhD; Parker Johnson; Minjie Zhang; Wilson Guzman; Ugur Eskiocak, PhD; Megan McLaughlin; Caitlin O'Toole; Magali Pederzoli-Ribeil; Miso Park, PhD; John Williams, PhD; Margaret L. Karow, PhD; Jennifer O'Neil; Timothy Clackson; Ronan O'Hagan; Immune-stimulants and immune modulators Antibody; Checkpoint blockade; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
588 Oral Presentation Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases Yannick S. Rakké, MD, MSc; Yannick S. Rakké, MD, MSc; Lucia Campos Carrascosa, PhD; Adriaan A. van Beek, PhD; Valeska de Ruiter, MSc; Michael Doukas, MD, PhD; Susan ter Borg, MD; Pascal G. Doornebosch, MD, PhD; Maarten Vermaas, MD, PhD; Erwin van der Harst, MD, PhD; Peter Paul LO. Coene, MD, PhD; Dirk J. Grünhagen, MD, PhD; Cornelis Verhoef, MD, PhD; Jan NM. IJzermans, MD, PhD; Dave Sprengers, MD, PhD; Jaap Kwekkeboom, PhD; Immune-stimulants and immune modulators Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
589 Poster Presentation Efficacy of oncolytic vaccinia virus requires infection of suppressive immune cells in the tumor microenvironment leading to their reprogramming and deletion Kristin DePeaux, BS; Paolo DA. Vignali, BA; Saumendra Sarkar, PhD; Greg M. Delgoffe, PhD; Immune-stimulants and immune modulators Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
590 Poster Presentation Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy Christianne Groeneveldt, MSc; Priscilla Kinderman; Diana J.M. van den Wollenberg; Ruben L. van den Oever; Jim Middelburg; Dana A.M. Mustafa; Rob C. Hoeben; Sjoerd H. van der Burg, PhD; Thorbald van Hall, PhD; Nadine Van Montfoort; Immune-stimulants and immune modulators Antibody; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Bispecifics
591 Oral Presentation Comparison of Two oHSV Vectors for the Treatment of Glioblastoma Joseph Jackson, PhD; Joseph Jackson, PhD; Bonnie Hall, PhD; Lisa Bailey; E Chiocca, MD; Justus Cohen, PhD; Joseph C. Glorioso, III, PhD; Immune-stimulants and immune modulators Immune adjuvant; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment; Vaccine
592 Poster Presentation Enhancing the therapeutic potential of oncolytic adenoviruses with vSENSᵀᴹ technology Goo-Young Kim, Ph.D.; Ji Yeon Son; So Jin Lee; Sang Woo Jo; Changhoon In; Sang Hoon Kim; Joon Young Park; So-Young Kim; Gyu-Young Moon; Ji-Hye Choi; Suk-Hwan Kim; Minhyuk Yun; Hye Yeong Nam; Helen Cho; Immune-stimulants and immune modulators Immune contexture; Immune monitoring; Immune tolerance; Solid tumors; Systems biology; Targeted therapy; Tumor microenvironment
593 Poster Presentation Tumoral Melanosis Mimicking Residual Melanoma After T-VEC Treatment Song Y. Park, MD; Ata S. Moshiri, MD, MPH; Rouba Hadi, MD; Austin R. Green, MD; Jennifer Gardner, MD; Coley Doolittle-Amieva, PA-C; Song Y. Park, MD; Immune-stimulants and immune modulators Clinical study; Inflammation; Solid tumors; Tumor microenvironment; Vaccine
594 Poster Presentation BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment Monika Semmrich, PhD; Jean-Baptiste j. Marchand, PhD; Laetitia Fend, PhD; Matilda Rehn, PhD; Nathalie Silvestre, PhD; Linda Mårtensson, PhD; Johann Foloppe, PhD; Ingrid Teige, PhD; Eric Quéméneur, PhD; Björn Frendeus, PhD; Immune-stimulants and immune modulators Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine
595 Poster Presentation Armed Myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors Lina S. Franco, PhD; Lino E. Torres-Dominguez, PhD; Joseph Mamola; Ana L. de Matos, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Grant McFadden, PhD; Leslie L. Sharp, PhD; Immune-stimulants and immune modulators Checkpoint blockade; Cytokine; Immune adjuvant; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine
596 Poster Presentation Armed Myxoma virus demonstrates therapeutic activity in xenograft models Lino E. Torres-Dominguez, PhD; Lina S. Franco, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Anna K. Waters; Grant McFadden, PhD; Steven J. Potts, PhD; Leslie L. Sharp, PhD; Immune-stimulants and immune modulators Checkpoint blockade; Costimulation; Gene expression; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
597 Poster Presentation In situ vaccination with oncolytic vesicular stomatitis virus improves anti-tumor immune response and outcome in bladder cancer Coby Rangsitratkul, BSc; Christine Lawson, PhD; Lee-Hwa Tai, PhD; Lee-Hwa Tai, PhD; Immune-stimulants and immune modulators Immune suppression; MDSC; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine
598 Oral Presentation Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez- Villarroel; Ryan Putney, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; Immune-stimulants and immune modulators Adoptive immunotherapy; Bioinformatics; Chemokine; Epigenetics; Immune adjuvant; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs)
599 Poster Presentation New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma Anna S. Herbstritt, MS; Elfriede Noessner, Prof. Dr.; Petra U. Prinz, Dr.; Mani D. Kadiyala, BS; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; Immune-stimulants and immune modulators Adoptive immunotherapy; NK/NK T cell; RNA; Solid tumors; T cell; Tumor evasion
600 Poster Presentation In Vitro Anticancer and Immunomodulatory Activities of NBT-167, a Dimer of Resveratrol Jeffrey Zhang; Everett Henry; L. Harris Zhang; Wanying Zhang; Immune-stimulants and immune modulators Costimulation; Cytokine; NK/NK T cell; T cell
601 Poster Presentation Development of improved small molecule STING agonists suitable for systemic administration Maciej K. Rogacki; Stefan Chmielewski, PhD; Magdalena Zawadzka; Jolanta Mazurek; Katarzyna Wnuk-Lipinska; Kamil Kus; Karolina Gluza; Katarzyna Wójcik-Jaszczynska; Aleksandra Poczkaj; Lukasz Dudek; Wojciech Schonemann; Urszula Glowniak-Kwitek; Marcin Les; Marek Wronowski; Tushar Mahajan; Urszula Kulesza; David Synak; Karol Zuchowicz; Katarzyna Banaszak; Karolina Wiatrowska; Izabela Strojny; Miroslawa Gladysz; Justyna Jablonska; Ewelina Gabor-Worwa; Raghuram Tangirala; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Monika Dobrzanska; Immune-stimulants and immune modulators Antigen presenting cells; Costimulation; Cytokine; Inflammation
602 Poster Presentation STING Agonist-Based Treatment Promotes Vascular Normalization and Tertiary Lymphoid Structure Formation in the Therapeutic Melanoma Microenvironment Manoj Chelvanambi, BS; Ronald Fecek, PhD; Jennifer L. Taylor, Ph.D.; Walter J. Storkus, PhD; Immune-stimulants and immune modulators Angiogenesis; Antigen presenting cells; Chemokine; Dendritic cell; Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
603 Poster Presentation Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration Shelley E. Ackerman, PhD; Felix J. Hartmann, PhD; Cecelia I. Pearson, PhD; Joseph C. Gonzalez; Po Yi Ho; Samuel C. Kimmey; Andrew Luo; Benjamin Ackerman, PhD; Arthur Lee; Richard P. Laura, PhD; Jason C. Paik, MD, PhD; Karla A. Henning, PhD; David Y. Jackson, PhD; Steven J. Chapin, PhD; Bruce H. Devens, PhD; David Dornan, PhD; Sean C. Bendall, PhD; Edgar G. Engleman, MD; Michael N. Alonso, PhD; Immune-stimulants and immune modulators Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; TLR; Tumor microenvironment
604 Poster Presentation Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1-6 mouse models of hepatocellular carcinoma Aaron J. Morris, PhD; Evan D. Walters; Bassel Akache; Michael J. McCluskie; Arthur M. Krieg, MD; Immune-stimulants and immune modulators Dendritic cell; TLR
605 Poster Presentation Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models Heidi N. LeBlanc; Cecelia I. Pearson, PhD; Justin A. Kenkel; LIsa Blum; Po Y. Ho; Angela Luo; Richard P. Laura, PhD; Matthew Zhou; Joshua Gregorio; Andrew Luo; Shelley E. Ackerman, PhD; Brian S. Safina; David Dornan, PhD; Michael N. Alonso, PhD; Marcin Kowanetz, Ph.D.; Immune-stimulants and immune modulators Antibody; Antigen presenting cells; Biomarkers; Cytokine; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR
606 Poster Presentation Epidermal growth factor modulation of CXCL10 in keratinocytes and cutaneous cancers Myles R. McCrary, PhD; David Gibbs, PhD; Carlos S. Moreno, PhD; Brian P. Pollack, MD/PhD; Myles R. McCrary, PhD; Immune-stimulants and immune modulators Carcinogenesis; Chemokine; Cytokine; Gene expression; Immune toxicity; Inflammation
607 Oral Presentation TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy Jane Meng, PhD; Jane Meng, PhD; Zhengyi Wang, PhD; Wei Cao; Chan Chen; Joan Huaqiong Shen, MD, PhD; Christian Augsberger; Julia Neugebauer; Stefan Haertle; Immune-stimulants and immune modulators Antibody; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
608 Poster Presentation Immunodominant Listeria Epitopes Compete with Vaccine-Directed CD8+ T-cell Responses Rescued By Peptide-MHC Stabilizing Modifications John C. Flickinger, Jr., BS; Jagmohan Singh, PhD; Yanki Yarman; Robert Carlson, BS; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; Immune-stimulants and immune modulators Immune adjuvant; Solid tumors; Tumor antigens; Vaccine
610 Poster Presentation Technical challenges in monocyte-derived dendritic cell vaccine manufacturing; a QI project Opal Reddy, MD; Sandhya Panch, MD; Chauha Pham; Mame Thioye Sall; Minh T. Tran, RN; Steven L. Highfill, PhD; Kamille A. West, MD; Ping Jin, PhD; Haksong Jin, PharmD, MSc; Malcolm K. Brenner, MD, PhD,FRCP,FRCPath; Jay A. Berzofsky, MD, PhD; David F. Stroncek, MD; Hoyoung M. Maeng, MD; Immune-stimulants and immune modulators Antigen presenting cells; Dendritic cell; Solid tumors; Targeted therapy; Tumor antigens; Vaccine
611 Poster Presentation RNA-sequencing reveals a unique immune transcriptional landscape in the vaccine sites of patients with circulating T-cell responses to cancer immunization Max O. Meneveau, MD; Pankaj Kumar, PhD; Kevin Lynch, MD; Karlyn E. Pollack, MD; Craig L. Slingluff, Jr., MD; Max O. Meneveau, MD; Immune-stimulants and immune modulators Antigen presenting cells; Dendritic cell; Immune adjuvant; Inflammation; T cell; TLR; Vaccine
612 Oral Presentation Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells Kelly-Anne Masterman; Oscar Haigh; Kirsteen Tullett; Ingrid Leal-Rojas; Carina Walpole; Frances Pearson; Jonathon Cebon; Christopher Schmidt; Liam O’Brien; Nikita Rosendahl; Ghazal Daraj; Irina Caminschi; Eric Gschweng; Roger Hollis; Donald Kohn; Mireille Lahoud; Kristen J. Radford, PhD; Immune-stimulants and immune modulators Antibody; Antigen presenting cells; Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine
613 Poster Presentation HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), with Potent T-Cell Activation and Efficacy in Solid Tumors and Large Predicted Safety Margins in Non-Human Primate (NHP) Fiore Cattaruzza, PharmD, PhD; Ayesha Nazeer; Zachary Lange; Caitlin Koski, PhD; Mikhail Hammond; Trang Dao-Pick; Angela Henkensiefken; Mika K. Derynck, MD; Volker Schellenberger, PhD; Bryan A. Irving, PhD; Immuno-conjugates and chimeric molecules Bispecifics; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor stroma
614 Poster Presentation Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation Melanie Salvermoser; Maria Gerget; Franziska Hasselmann; Elfriede Noessner, Prof. Dr.; Christian Ellinger, Dr. Rer. Nat.; Monika Braun; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Nadja Sailer, Dr. rer. nat.; Immuno-conjugates and chimeric molecules Adoptive immunotherapy; Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor microenvironment
615 Poster Presentation Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity Ons Harrabi, BA; Amy Chen; Emma Sangalang; Laura Doyle; Danielle Fontaine; Bora Han, PhD; Curt W. Bradshaw, PhD; Jaume Pons, PhD; Janet Sim, PhD; Tracy C. Kuo, PhD; Hong I. Wan, PhD; Immuno-conjugates and chimeric molecules Antibody; Antigen presenting cells; B cell; Dendritic cell; Myeloid cells; TLR
616 Poster Presentation A novel non-covalent linker peptide with nanomolar affinity for clinical IgG1 antibodies preserves antibody-antigen affinity and drug potency against PDL1+ melanoma when conjugated with DM1 John T. Butterfield, BS; Shari L. Sutor, BS; Wendy K. Nevala, MS; Svetomir N. Markovic, MD, PhD; Immuno-conjugates and chimeric molecules Antibody; Chemotherapy; Targeted therapy
617 Poster Presentation Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death Elizabeth Gray, PhD; Kelly Hensley; Sean Allred; Esther Trueblood; John Gosink; Robert Thurman; Kaleb Smith; Celine Jacquemont, PhD; Mark Bieda; Jason Gow; Jeffrey R. Harris; Lauren K. Brady; Ibrahima Soumaoro; Shweta Jain; Leonardo Nicacio; Shyra J. Gardai, PhD; Immuno-conjugates and chimeric molecules Antibody; Antigen presenting cells; Solid tumors; Tumor microenvironment
618 Poster Presentation Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications Kerry Klussman, B.S.; Elena-Marie Tenn; Shaylin Higgins; Rebecca Mazahreh; Katie Snead; Joseph Z. Hamilton; Bryan M. Grogan, MS; Johann Sigurjonsson; Anthony Cao; Shyra J. Gardai, PhD; Bernard A. Liu; Immuno-conjugates and chimeric molecules Antibody; Antigen presenting cells; Targeted therapy
619 Poster Presentation Evaluating the effectiveness of targeted ADC therapy in a patient-derived ex vivo tumoroid model, 3D-EX, for quantitative tumor cell killing Jenny Kreahling, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Stephen Iwanowycz, PhD; Tina Pastoor; Soner Altiok, MD, PhD; Immuno-conjugates and chimeric molecules Antibody; Checkpoint blockade; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
620 Poster Presentation Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates Naniye Malli Cetinbas, PhD; Travis Monnell; Winnie Lee; Kalli C. Catcott, PhD; Chen-Ni Chin, PhD; Pamela Shaw; Kelly Slocum; LiuLiang Qin; Kenneth Avocetien; Keith Bentley, PhD; Susan Clardy, PhD; Brian Jones, PhD; Eugene Kelleher; Joshua D. Thomas; Rebecca Mosher, MD; Dorin Toader, PhD; Jeremy Duvall, PhD; Raghida A. Bukhalid, PhD; Marc Damelin, PhD; Timothy B. Lowinger, PhD; Immuno-conjugates and chimeric molecules Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor microenvironment
621 Poster Presentation A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; Francesca Zammarchi, PhD; Immuno-conjugates and chimeric molecules Antibody; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
622 Poster Presentation PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients C. Daniel De Magalhaes Filho; Chung-Wein Lee; Nikolai Suslov; Jerry Fong, PhD; Miguel Garcia-Guzman; Immuno-conjugates and chimeric molecules Antibody; Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy
623 Poster Presentation Immuno-STATs: Leveraging protein engineering to expand and track antigen-specific T cells in vivo Stad H. Zeigler; Andrew W. Woodham, PhD; Mengyan Li, PhD; Ella L. Zeyang, PhD; Stephen C. Kolifrath; Mohammad Rashidian, PhD; Kaitlyn E. O’Connor; Rodolfo J. Chaparro, PhD; Ronald D. Seidel, PhD; Maia Mesyngier; Ross W. Cheloha, PhD; Jason L. Dearling, PhD; Phaneendra K. Duddempudi, PhD; Alev Celikgil, MD; Scott J. Garforth, PhD; Alan Packard, PhD; Harris Goldstein, MD; Hidde L. Ploegh, PhD; Steven C. Almo, PhD; Immuno-conjugates and chimeric molecules Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
624 Poster Presentation IFNγ secreted by tebentafusp (IMCgp100)-redirected T cells inhibits expression of melanin synthesis pathway genes in healthy melanocytes Mariantonella Vardeu, PhD; David Depoil, PhD; Camille Britton-Rivet, PhD; Jane Houghton; Jane Harper, PhD; Gabrielle Le Provost, PhD; Laura Collins, PhD; Koustubh Ranade, PhD; Adel Benlahrech, PhD; Immuno-conjugates and chimeric molecules Bispecifics; T cell; Targeted therapy
625 Poster Presentation Bispecific Personalized Aptamer for the Treatment of Solid Tumors Erez Lavi; Nir Skalka; Neta Zilony Hanin; Zohar Pode; Anastasia Paz; Yeela Scharff; Neria Reiss; Omer Levy; Elinor Debby; Liron Levy- Efrati; Vitaliy Buravenkov; Itay Liron; Yaniv Amir; Raanan Berger, MD; Ido Bachelet; Guy Neev; Irit Carmi Levy, PhD; Immuno-conjugates and chimeric molecules Bispecifics; Solid tumors; Targeted therapy
626 Poster Presentation Improving the yeast transformation efficiency for yeast display in antibody development Jian Chen, PhD; George Sun; Jian Chen, PhD; Immuno-conjugates and chimeric molecules Antibody
627 Poster Presentation The DLL3-targeted Half-life Extended Bispecific T Cell Engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer Keegan Cooke, BS; Juan Estrada; Jinghui Zhan; Jonathan Werner; Fei Lee; Aditya Shetty; Marie-Anne Damiette Smit, MD, MS; Mark E. Salvati, PhD; Julie M. Bailis, PhD; Immuno-conjugates and chimeric molecules Bispecifics; Solid tumors; Targeted therapy; Tumor microenvironment
628 Poster Presentation IL-2 augments ImmTAC-dependent T cell activation and tumour cell killing Duncan M. Gascoyne, PhD; Kristina Petrovic, PhD; Koustubh Ranade, PhD; David Depoil, PhD; Immuno-conjugates and chimeric molecules Bispecifics; Cytokine; T cell; Targeted therapy
629 Oral Presentation Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody Emily H. Hsiue, MD; Katharine M. Wright, PhD; Jacqueline Douglass, MS; Michael Hwang; Brian J. Mog; Alexander H. Pearlman, BS; Annika Schaefer; P. Aitana Azurmendi; Qing Wang; Drew M. Pardoll, MD, PhD; Nickolas Papadopoulos; Kenneth W. Kinzler, PhD; Bert Vogelstein, MD; Sandra B. Gabelli; Shibin Zhou; Emily H. Hsiue, MD; Immuno-conjugates and chimeric molecules Antibody; Neoantigens; Bispecifics
630 Poster Presentation PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models Seema Kantak, PhD, MS, M.Sc.; Bryan Glaser, PhD; Justin Wetter; Bee-Cheng Sim; Jeff Higaki; Jacob Beal; Sara Ollerman; Dileep Pulukkunat; Mandar Bawadekar; Charles Kaplan; Peter Lamb; Bonnie Hammer; Immuno-conjugates and chimeric molecules Antibody; Bispecifics; Checkpoint blockade
631 Poster Presentation Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform Dahea Lee; Donggeon Kim, DVM,PhD; Soomin Ryu; Byoung Chul Lee, PhD; Immuno-conjugates and chimeric molecules Antibody; Bispecifics; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
632 Oral Presentation HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors Jack Lin, Ph.D.; Sony S. Rocha; Kathryn Kwant, Ph.D.; Maria R. Dayao; Tessie M. Ng, Ph.D.; Wade Aaron, BS; Evan Callihan; Maria Gamez-Guerrero; Golzar Hemmati; Kevin J. Wright, Ph.D.; Manasi Barath; Yinghua Xiao, Master Degree; Timothy Yu; Patrick Chew; Thomas Evans; Jessica O'Rear; Scott Gatto; Michael Cremin; Stephen Yu; Purbasa Patnaik; Avneel Hundal; Richard Austin, Ph.D.; Bryan Lemon, Ph.D.; Holger Wesche, Ph.D.; Immuno-conjugates and chimeric molecules Antibody; Bispecifics; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Tumor stroma
633 Oral Presentation Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor Michelle Nelson; Robert Miller; Gabriele Blahnik-Fagan; Lauren Loh; Danielle Van Citters; Lynda Misher; Megan Sprague; Maria Dasovich; Irene Barber; Kathy Maggiora; Franz Gruswitz; Brian Woodruff; Kelsey Huntington; Aelish Guinn; Megan Aguilar; Mollie Daugherty; Elizabeth Haglin; Jane Gross; Peter Pavlik; Catherine McMahan; David Bienvenue; Gabriela Hernandez-Hoyos, PhD; Immuno-conjugates and chimeric molecules Antibody; Bispecifics; Costimulation; NK/NK T cell; T cell
634 Poster Presentation Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies Elisa C. Toffoli, MD; Abdolkarim Sheikhi; Roeland Lameris; Lisa A. King; Jurriaan Tuynman; Jan Spanholtz; Henk Verheul; Tanja D. de Gruijl, PhD; Hans J. Van der Vliet, MD, PhD; Elisa C. Toffoli, MD; Immuno-conjugates and chimeric molecules Antibody; Bispecifics; NK/NK T cell
635 Poster Presentation A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders Christian M. Vidal, PhD; Michael Cukan, PhD; Rajat Varma, PhD; Lawrence Iben, MA; Tanya Berbasova, PhD; Ada Vaill, MS; Anna Bunin, PhD; Ann Marie Rossi, MS; David Trinh, BS; Katy McGrath, BS; Enrique Alvarez, DVM; Matthew Welsch, PhD; Luca Rastelli, PhD; Immuno-conjugates and chimeric molecules Antibody; B cell; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Targeted therapy; Tumor antigens
637 Poster Presentation Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) Dylan J. Martini, BA; Sean T. Evans, BS; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors
638 Poster Presentation Plasma Proteome Analysis in Patients with Immune Checkpoint Inhibitors Related Arthritis and Pneumonitis Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; Hiroyuki Katayama, PhD; Sang Kim, MD, PhD; Samir M. Hanash, MD, PhD; Maria Suarez-Almazor, MD, PhD; Immunotherapy Toxicities Checkpoint blockade; Immune toxicity; Proteomics
639 Poster Presentation Immune-Related Thyroid Dysfunction in Patients with Existing Thyroid Dysfunction Francois Kaleta, MD; Heather Brody, MD; Praveen Namireddy, MD; Immunotherapy Toxicities Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors
640 Poster Presentation Characterizing severe acute kidney injury in patients treated with immune checkpoint inhibitors Chung-Jiah Chen, MD; Lisa Kim, M.S.; Ashley Weaver; Sandip P. Patel, MD; Immunotherapy Toxicities Immune toxicity
641 Poster Presentation Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data Prantesh Jain, MD FACP; Jahir Gutierrez, PhD; Avirup Guha, MD; Chhavi Jain, PhD; Nirav Patil; Tingke Shen; Ilya Stanevich; Ankit Mangla, MD; Marcos De Lima, MD; Jill Barnholtz-Sloan, PhD; Afshin Dowlati, MD; Immunotherapy Toxicities Checkpoint blockade; Chemotherapy; Immune monitoring; Immune toxicity; Solid tumors; Targeted therapy
642 Poster Presentation Retrospective Review of Pulmonary Pathology Associated with Chimeric Antigen Receptor T Cell Therapy Jing Du, MD; David W. Woolston; Kimberly E. Costas, MD; Alexandre Hirayama, MD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; Immunotherapy Toxicities CAR T cells; Clinical study; Granulocyte; Immune toxicity; Leukemia/Lymphoma; Monocyte/Macrophage
643 Poster Presentation Autopsy Review of Chimeric-Antigen Receptor T Cell Therapy: A Single Institution Experience KiBeom Kwon; David W. Woolston; Alexandre Hirayama, MD; Damian Green, MD; David G. Maloney, MD, PhD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; Immunotherapy Toxicities B cell; Biomarkers; CAR T cells; Clinical study; Cytokine; Immune toxicity; Leukemia/Lymphoma; T cell
644 Poster Presentation Ocular adverse events associated with Programmed Death-1 and Programmed Death Ligand-1 immunotherapy LeAnne H. Young, BS; Shanda Finnigan, MPH, RN; Howard Streicher, MD; Helen Chen, MD; James Murray, PhD; H. Nida Sen, MD, MHSc; Elad Sharon, MD, MPH; Immunotherapy Toxicities Checkpoint blockade; Immune toxicity; Inflammation
645 Oral Presentation Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis Nazli Dizman, MD; Milton L. Greenberg, PhD; Andrew C. Newman, PhD; Jonathan Skupsky, MD, PhD; JoAnn Hsu, BS; Zeynep B. Zengin, MD; Nicholas Salgia, BS; Luis Meza, MD; Neal Chawla, MD; Sabrina Salgia; Jasnoor Kaur; Sumanta K. Pal, MD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Cytokine; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell
646 Poster Presentation Evaluating a preclinical model of contact hypersensitivity for skin immune checkpoint toxicity Barbara Ma, MD, MS; Abhinav Jaiswal, B.S.; K Sanjana P. Devi, PhD; Qingrong Huang, PhD; Joy Hsu, B.A.; Yong Liu, PhD; Niroshana Anandasabapathy, MD, PhD, MS; Immunotherapy Toxicities Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
647 Poster Presentation Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™ Hongjuan Zhang, PhD; Daniel X. He; Mingkun Zhang; Xinhe Feng; Annie X. An; Cunxiang Ju; Henry Q. Li; Davy X. Ouyang, PhD; Immunotherapy Toxicities Antibody; Immune toxicity; T cell
648 Poster Presentation Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors Kevin Tyan, BA; Joanna Baginska, PhD; Martha Brainard; Anita Giobbie-Hurder, MS; Mariano Severgnini, MSc; Michael P. Manos, BA; Rizwan Haq, MD, PhD; Elizabeth I. Buchbinder, MD; Patrick A. Ott, MD, PhD; F. Stephen Hodi, Jr., MD; Osama E. Rahma, MD; Immunotherapy Toxicities Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation
649 Poster Presentation Incidence of thromboembolism (TE) in patients with melanoma receiving immune checkpoint inhibitor (ICI) therapy and its adverse impact on survival Tamara A. Sussman, MD; Joanna Roopkumar, MBBS, MPH; Hong Li, MS; Keith R. McCrae, MD; Pauline Funchain, MD; Alok A. Khorana, MD; Immunotherapy Toxicities Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors
651 Poster Presentation NEUROLOGICAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: OUR EXPERIENCE IN A TERTIARY CARE CENTER Pablo Alvarez-Ballesteros; Javier Buisan-Catevilla; Alvaro Beltrán-Corbellini; Iñigo Corral-Corral; Javier Pozas-Perez; Victor Albarran-Fernandez; Lucia Sanz-Gomez; Jorge Esteban-Villarrubia; Javier Torres-Jimenez; Jesús Chamorro-Perez; Diana Rosero-Rodriguez; María San Román-Gil; Ainara Soria-Rivas; Immunotherapy Toxicities Clinical study; Immune toxicity
652 Poster Presentation Early Outcomes of an APP Acute Checkpoint Inhibitor (CPI) Care Clinic Lisa Kottschade, NP, MS, RN; Casey Fazer; Anna Schwecke; Immunotherapy Toxicities Checkpoint blockade; Immune toxicity
653 Oral Presentation Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release Gabrielle Leclercq, M. Sc. Eng.; Helene Haegel, PhD; Anneliese Schneider, PhD; Estelle Marrer Berger, PhD; Antje Walz, PhD; Christophe Boetsch, PhD; Vesna Pulko, PhD; Cristiano Ferlini, MD; Christian Klein, Dr rer nat; Immunotherapy Toxicities Antibody; Bispecifics; Cytokine; Immune suppression; Immune toxicity; Inflammation; T cell; Targeted therapy
654 Poster Presentation Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors. Nerea Lopetegui Lia, M.D.; Syed Imran Jafri; Khalid Shalaby; Dimitrios Drekolias; James Vredenburgh, M.D.; Nerea Lopetegui Lia, M.D.; Immunotherapy Toxicities Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy
655 Poster Presentation Concordance Between Healthcare Providers and Expert Consensus Recommendations in the Management, Monitoring, and Mitigation of Adverse Events Associated with CAR T-Cell Therapy: An Updated Analysis Matthew J. Frigault, MD, MSc; Megan Cartwright, PhD; Krista Marcello, BA; Timothy A. Quill, PhD; Daniel J. DeAngelo, MD, PhD; Ilene A. Galinsky, NP; Shilpa Paul, PharmD, BCOP; Jae H. Park, MD; Matthew J. Frigault, MD, MSc; Immunotherapy Toxicities CAR T cells; Cytokine; Immune toxicity; Leukemia/Lymphoma
656 Poster Presentation Time to diagnostic clarity for suspected checkpoint-inhibitor pneumonitis in patients with lung cancer Eric Olson, MD; Andrew Faucheux, MD; JiaHao Liang, MD; Janardhana Ponnatapura, MD; Jeffrey Lantz, DO; Nathan Roberts, MD; Andy Dothard, MD; Thomas W. Lycan, Jr., DO; Eric Olson, MD; Immunotherapy Toxicities Checkpoint blockade; Immune toxicity; Solid tumors
657 Poster Presentation Interleukin-6 Receptor Blockade for Management of Immune Checkpoint Inhibitor Related Adverse Events in Patients with Melanoma Chantal Saberian, MD; Faisal Fa'ak; Jean H. Tayar, MD; Maryam Buni, MD; Sang Kim, MD, PhD; Huifang Lu, MD, PhD; Maria Suarez-Almazor, MD, PhD; Stephen Gruschkus, PhD; May Daher, MD; Kaysia Ludford; Daniel Johnson, MD; Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; Immunotherapy Toxicities Autoimmunity; Cytokine; Immune toxicity; Inflammation
658 Poster Presentation Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. Sabina Sandigursky; Safa Houssein; Xerxes Pundole, MD, PhD; Elizaveta Efuni; Samuel Cytryn; Maryam Buni, MD; Anna C. Pavlick, MD, MBA; Michelle Krogsgaard, PhD; Chantal Saberian, MD; Mehmet Altan, MD; Maria Suarez-Almazor, MD, PhD; Jeffrey S. Weber, MD, PhD; Adi Diab, MD; Noha Abdel-Wahab, MD, PhD; Immunotherapy Toxicities Autoimmunity; Checkpoint blockade; Immune toxicity
659 Poster Presentation Blocking Cytokine IL-1 with Anakinra for the Prevention of Cytokine Release Syndrome in COVID-19 Erik R. Soule; Jason R. Williams, MD; Matthias Piesche; Immunotherapy Toxicities Clinical study; Cytokine; Immune toxicity; Targeted therapy
660 Poster Presentation Developing generalizable deep learning models for tumor segmentation in pathology images to enable the identification of predictive biomarkers for immunotherapies Qinle Ba, PhD; Qinle Ba, PhD; Peng Yang; Jennifer Yearley, PhD; Machine Learning, Artificial Intelligence and Computational Modeling Biomarkers; Tumor microenvironment; Tumor stroma
661 Poster Presentation Five immunotypic signatures identified in human glioblastoma correlate with tumor contact with the lateral ventricle, immune suppression, and patient outcome. Todd Bartkowiak, MS, PhD; Sierra M. Barone, BS; Madeline J. Hayes, BS; Allison R. Greenplate, Ph.D; Justine Sinnaeve, Ph.D.; Nalin Leelatian, M.D., Ph.D.; Akshitkumar M. Mistry, M.D.; Caroline E. Roe, MLS; Bret C. Mobley, M.D.; Lola B. Chambless, MD; Reid C. Thompson, M.D.; Kyle D. Weaver, M.D.; Rebecca A. Ihrie, Ph.D.; Jonathan M. Irish, Ph.D.; Todd Bartkowiak, MS, PhD; Machine Learning, Artificial Intelligence, and Computational Modeling Bioinformatics; Coinhibition; Cytokine; Immune contexture; Immune suppression; Myeloid cells; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
662 Poster Presentation Statistical learning from clinical and immunogenomic variables to predict response and survival with PD-L1 inhibition in advanced urothelial cancer Wolfgang Beck, AB; Tracy L. Rose, MD; Matthew I. Milowsky, MD; William Y. Kim, MD; Jeff Klomp, PhD; Benjamin G. Vincent, MD; Machine Learning, Artificial Intelligence and Computational Modeling Biomarkers; Checkpoint blockade; Immune suppression; Inflammation; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor microenvironment
663 Poster Presentation Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis Shameer Khader; Youyi Zhang; Daniel Jackson; Kirsty Rhodes; Imran Khan Anwer Neelufer; Sreenath Nampally; Andrzej Prokop; Emmette Hutchison; Jiabu Ye; Feng Liu; Antony Sabin; James Weatherall; Cristina Duran; Renee Iacona; Faisal Khan; Pralay Mukhopadhyay, PhD; Machine Learning, Artificial Intelligence and Computational Modeling Bioinformatics
664 Poster Presentation Applying Advanced Data Analysis to Immunotherapy Drug Discovery for Uveal Melanoma Sarah Kolitz, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; Machine Learning, Artificial Intelligence and Computational Modeling Gene expression; Solid tumors; Systems biology; Targeted therapy
665 Poster Presentation Spatial single-cell analysis of colorectal cancer tumour using multiplexed imaging mass cytometry Minh Tran; Andrew Su; HoJoon Lee, Ph.D.; Richard Cruz, Ph.D.; Lance Pflieger, PhD; Ashely Dean; Quan Nguyen, Ph.D; Hanlee P. Ji, MD; Terence Rhodes, MD, PhD; Machine Learning, Artificial Intelligence and Computational Modeling Antibody; Bioinformatics; Biomarkers; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
666 Poster Presentation Analyzing regulatory requirements in the development of immune checkpoint inhibitors using Artificial Intelligence Krish Perumal; Amin Osmani; Amin Osmani; Machine Learning, Artificial Intelligence and Computational Modeling Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; T cell
667 Poster Presentation Integrated molecular characterization and therapeutic vulnerabilities of neurally programmed tumors across 33 human indications Yasin Senbabaoglu, PhD; Aslihan K. Calviello; Guadalupe O. Munoz; Richard Bourgon, BS, PhD; Shannon J. Turley, PhD; Christine Moussion; Machine Learning, Artificial Intelligence and Computational Modeling Bioinformatics; Checkpoint blockade; Epigenetics; Immune contexture; Immune suppression; Metabolism; Stem cell/cancer-initiating cell; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
668 Poster Presentation A toolkit for the quantitative analysis of the spatial distribution of cells of the tumor immune microenvironment Anna S. Trigos, PhD; Tianpei Yang; Yuzhou Feng; Volkan Ozcoban; Maria Doyle; Anu Pasam; Nikolce Kocovski; Angela Pizzolla, PhD; Yu-Kuan Huang; Greg Bass; Simon P. Keam, PhD; Terrence P. Speed; Paul J. Neeson, PhD; Shahneen Sandhu, MBBS FRACP; David Goode; Machine Learning, Artificial Intelligence and Computational Modeling Bioinformatics; Biomarkers; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
669 Poster Presentation Computational analysis of mutual feedback regulations between IDO1 and PD-L1 Jian Zhu, PhD; Rebecca L. Zhu; Machine Learning, Artificial Intelligence and Computational Modeling Checkpoint blockade; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Systems biology
670 Poster Presentation Develop a Multiplex Immunofluorescence Panel to Identification of distinct complex immune landscapes in pleural effusion liquids from patients with metastatic lung adenocarcinoma Caddie Laberiano, MD; Luisa Solis, MD; Sinchita Roy Chowdhuri; Edwin R. Parra, MD, PhD; Caddie Laberiano, MD; Microbiome and other environmental factors Antibody; Biomarkers; Immune contexture; Tumor microenvironment
671 Poster Presentation Update of a systematic review and meta-analysis studying the association between antibiotic use and clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors Pierre-Alain Bandinelli, MSc; Julie Cervesi; Clément Le Bescop; Renaud Buffet; Jean De Gunzburg; Gérard Zalcman; Pierre-Alain Bandinelli; Microbiome and other environmental factors Autoimmunity; Checkpoint blockade; Microbiome; Solid tumors
672 Oral Presentation Identification of microbial-derived HLA-bound peptides in melanoma Adi Nagler, MSc; Shelly Kalaora; Deborah Gitta Rosenberg; Michal Alon; Eilon Barnea; Ronen Levy; Kevin Vervier; Sophie Trabish; Tali Dadosh; Smadar Zaidman; Leore Geller; Polina Greenberg; Neerupma Bhardwaj; Alexandre Reuben; Reetakshi Arora; Michal Lotem; Arie Admon; Yishai Levin; Trevor Lawley; David Adams; Naama Geva-Zatorsky; Jennifer A. Wargo, MD, MMSc; Ravid Straussman; Yardena Samuels; Microbiome and other environmental factors Antigen presenting cells; Bioinformatics; Checkpoint blockade; Microbiome; Neoantigens; Proteomics; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine
673 Poster Presentation Precision microbiome mapping identifies a microbiome signature predictive of Immune Checkpoint Inhibitor response across multiple research study cohorts Matthew J. Robinson, PhD; Kevin Vervier; Simon R. Harris; David Adams; Doreen Milne; Catherine Booth; Emily Barker; Christine Parkinson; David Bruce; Sarah Welesh; Pippa Corrie, PhD, BMBCh, FRCP; Trevor D. Lawley; Microbiome and other environmental factors Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome
674 Poster Presentation Late antibiotic administration during durvalumab treatment may be associated with clinical benefit Siddharth Sheth, DO MPH; Christopher A. Morehouse, MD; Elizabeth A. Dozier; Chen Gao; Paul Warrener; Vancheswaran Gopalakrishnan, PhD, MPH, BDS; Scott Hammond, PhD; Taylor Cohen; Bret Sellman; Microbiome and other environmental factors Checkpoint blockade; Microbiome; Solid tumors
675 Poster Presentation Oxygen concentration alters Natural Killer cell phenotype and function in the solid tumor microenvironment Upasana Sunil Arvindam, MSc; Phillipa Kennedy; Brianna Ettestad; Peter Hinderlie; Gwen Phung; James Lim; Jeff S. Miller, MD; Martin S. Felices; Microbiome and other environmental factors Adoptive immunotherapy; Immune suppression; Metabolism; NK/NK T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
676 Poster Presentation PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat Shirin Arastu-Kapur; Mai Nguyen; Sean Broce; Joseph P. Vacca; Kirk Ehmsen; Florian Ermini; Ursula L. Haditsch; Aurora Martinez-Horta; Debasish Raha; Leonardo Rodriguez; Casey Lynch; Stephen S. Dominy; Leslie J. Holsinger; Microbiome and other environmental factors Checkpoint blockade; Coinhibition; Immune suppression; Inflammation; Microbiome; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment
677 Poster Presentation Evaluation of anti-PD1 efficacy in germ-free and antibiotic-treated SPF mice bearing MC38 tumors Ying Jin; Xue Liang; Frieda Z. Zhang; Guangmao Mu; Wei Zhou; Annie X. An; Marvin Y. Ouyang; Cai Li; Andy Liaw; Henry Q. Li; Davy X. Ouyang, PhD; Microbiome and other environmental factors Checkpoint blockade; Microbiome
678 Poster Presentation Addition of a single bacteria facilitates anti-tumor immunity and long-term survival in colorectal cancer. Abigail E. Overacre-Delgoffe, PhD; Anthony R. Cillo, PhD; Hannah J. Bumgarner, BS; Ansen Burr; Justin Tometich; Amrita Bhattacharjee; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Timothy W. Hand; Microbiome and other environmental factors Dendritic cell; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
679 Poster Presentation High fiber diet modifies gut microbiome, propionate production, intratumor immune response and is associated with outcome in patients with lung cancer treated with immune checkpoint inhibitors Corentin Richard, PhD; Myriam Benlaifaoui; Omar El Ouarzadi; Khoudia Diop; Antoine Desilets; Julie Malo; Wiam Belkaid; Andréanne Leblanc; Julien Lamontagne; Meriem Messaoudene; Arielle Elkrief; Bertrand Routy; Microbiome and other environmental factors Bioinformatics; Checkpoint blockade; Gene expression; Microbiome; Tumor microenvironment
680 Poster Presentation Automated Ion Torrent based solution enables accurate gut microbiome quantification of bacterial species relevant to research in cancer and its response to immunotherapy Shrutii Sarda, PhD; David Merrill, PhD; Heesun Shin; Anna McGeachy, PhD; Birgit Drews; Wing Lee; Rajesh K. Gottimukkala, MS; Janice K. Au-Young, PhD; Fiona Hyland; Shrutii Sarda, PhD; Microbiome and other environmental factors Autoimmunity; Bioinformatics; Microbiome
681 Poster Presentation Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors Fyza Y. Shaikh, MD, PhD; James R. White, PhD; Joell J. Gills, PhD; Taiki Hakozaki; Richard Corentin; Bertrand Routy; Yusuke Okuma; Mykhaylo Usyk; Abhishek Pandey; Jeffrey S. Weber, MD, PhD; Jiyoung Ahn; Jarushka Naidoo, MB BCH MHS; Evan J. Lipson, MD; Drew M. Pardoll, MD, PhD; Cynthia Sears; Microbiome and other environmental factors Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome; Solid tumors
682 Poster Presentation Antibody-mediated Blockade of Interleukin-10 Receptor-alpha Promotes the Activation of Immune Cells from in vitro Dissociated Tumor Samples Alexey Berezhnoy, PhD, DVM; Kalpana Shah, BS; Daorong Liu; Peter Lung, BS, HT (ASCP); Vatana Long; Kurt Stahl, BS; Douglas Smith, PhD; Francine Z. Chen, MD; Hua Li, MS; Jonathan Li, PhD; Ralph F. Alderson, PhD; Valentina Ciccarone, PhD; James K. Tamura, PhD; Ezio Bonvini, MD; Gundo Diedrich, PhD; Paul A. Moore, PhD; Novel Single-Agent Immunotherapies Antigen presenting cells; Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
683 Poster Presentation A novel mechanism of Neuropilin-1 inhibition results in improved tumor growth inhibition in vivo Daniel Blom; Shalini Sethumadhavan; Chengfeng Merriman; Katherine Molloy; alexandria Fink; Shan Lou; andrew rogantino; Ameya Apte; Mandana abbassi; Tiffany Liao; Hongyue Dai; aaron fulgham; Jonathan Hurov; Pearl Huang; Novel Single-Agent Immunotherapies Angiogenesis; Antibody; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
684 Poster Presentation A low affinity bivalent mesothelin-binding MATCH4 multispecific T cell engager increases cytotoxic selectivity for high mesothelin expressing cells Bithi Chatterjee, PhD; Alexandre Simonin, PhD; Daniel Snell, PhD; Tea Gunde, PhD; Christian Hess, PhD; Matthias Brock, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Niels Kirk; Dania Diem; Naomi Flückiger; Robin Heiz; Benjamin Küttner; Dana Mahler; Diego Morenzoni; Sandro Wagen; Julia Zeberer; David Urech, PhD; Novel Single-Agent Immunotherapies Antibody; Bispecifics; Solid tumors; T cell; Targeted therapy; Tumor antigens
685 Poster Presentation A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model David Ciccone, PhD; Vad Lazari; Ian Linney; Michael Briggs; Samantha Carreiro; Joshua McElwee; Ian Waddell; Chris Hill; Christine Loh; Peter Tummino; Alan Collis; Neelu Kaila; Novel Single-Agent Immunotherapies Antigen presenting cells; B cell; Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs)
686 Poster Presentation Preclinical characterization of a novel therapeutic antibody targeting LILRB2 Maria Jose Costa, PhD; Ryan Stafford, PhD; Zhiqiang Ku, PhD; Jing-Tyan Ma; Krista McCutcheon; Xiaoye Liu, PhD; Heyu Chen, PhD; Kyu Hong; Tao Huang, PhD; Ningyan Zhang, PhD; Zhiqiang An, PhD; Cheng Cheng Zhang, PhD; X. Charlene Liao, PhD; An Song, PhD; Novel Single-Agent Immunotherapies Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor evasion; Tumor microenvironment
687 Poster Presentation Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting Butyrophilin-3A (BTN3A) Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugue; Emmanuel Valentin, PhD; Remy Castellano; Jennifer Sims; Alem Truneh; Daniel Olive, M.D., Ph.D.; Rene Hoet; Novel Single-Agent Immunotherapies Antibody; T cell; T cell lineages
688 Poster Presentation In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells Suresh De Silva, Ph.D.; George J. Fromm, Jr., Ph.D.; Louis E. Gonzalez, Ph.D.; Arpita Patel, BSc; Kyung J. Yoon; Zachery Opheim; Robert Farmer; Dean Chamberlain, Ph.D.; Taylor H. Schreiber, MD, PhD; Novel Single-Agent Immunotherapies B cell; Bispecifics; T cell
689 Poster Presentation ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action Yvonne Leung, Ph.D.; Nikhil Vad, PhD; Anne Ye, PhD; Daniel R. Santos, MS; Wei Cao; Cathrin Czupalla, Ph.D.; John Vivian, PhD; Carlene Williams; Judevin Sapugay, BS; Michael Harbell, M.S.; Shaun M. Lippow, Ph.D.; Chantia Carroll, BS; Lance Kates, BS; Benjamin Haugen, BS; Gary Bolton, BS; Mark Armanini, BS; Iraz T. Aydin, PhD; Mark Whidden, PhD; Mauricio Velasco-Delgado, MS; Felix Chu, MS; Erin Wechsler, PhD; Ngan A. Nguyen, PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Amy Manning-Bog, PhD; Alexander Scholz, PhD; Novel Single-Agent Immunotherapies Chemokine; Cytokine; Dendritic cell; Myeloid cells; RNA; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
690 Poster Presentation CD122-selective IL-2 complexes treat ovarian carcinomas, induce Treg fragility and promote T cell stem cells Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes, BS; Jenny A. Mendez; Aravind Kancharla, MS; Myrna G. Garcia, BS; Haiyan Bai; Alvaro S. Padron, PhD; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; Novel Single-Agent Immunotherapies Antibody; Checkpoint blockade; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs)
691 Poster Presentation MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein William J. Dower, PhD; Steven E. Cwirla; Alice V. Bakker, BA; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; Novel Single-Agent Immunotherapies Bispecifics; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
692 Poster Presentation AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response Sterling C. Eckard, PhD; Aurelien Sarde; Li Mei; Curtis Ruegg, PhD; Patrick Chun, MD; Victoria Smith, PhD; Novel Single-Agent Immunotherapies Clinical trial; Immune suppression; MDSC; Myeloid cells; Solid tumors; T cell; Targeted therapy
693 Poster Presentation APX601, a Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy Erin L. Filbert, PhD; Sushma Krishnan, MSc in Biology; Ryan Alvarado; George Huang; Francis R. Bahjat; Xiaodong Yang, MD, PhD; Novel Single-Agent Immunotherapies Antibody; Immune suppression; MDSC; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
694 Poster Presentation NC410 is a Novel Immunomedicine for the Treatment of Solid Tumors Linjie Tian, PhD; M. Ines Pascoal Ramos, PhD; Emma de Ruiter; Ana Paucarmayta; Eline Elshof; Stefan Willems, MD, PhD; Chang Song, PhD; Zachary Cusumano, PhD; Jason Bosiacki; Linda N. Liu, PhD; Solomon Langermann, PhD; Linde Meyaard, PhD; Dallas B. Flies, PhD; Novel Single-Agent Immunotherapies Checkpoint blockade; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
695 Poster Presentation Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice Loise Francisco-Anderson, PhD; Mary Abdou, BS; Michael Goldberg, PhD; Erin Troy, PhD; Alicia Ballok, PhD; Fabian Romano Chernac, PhD; Maria Sizova, PhD; Krutika Invally, PhD; Shubhra Kashyap, MS; Audrey McBride, BS; Jessica Tsang, BS; Shannon Argueta, PhD; Kristie Barth, PhD; Valeria Kravitz, MS; Holly Ponichtera, PhD; Tyler Rommel, MS; Kevin Huynh, MS; Tanmoy Ganguly, PhD; Mark Bodmer, PhD; Novel Single-Agent Immunotherapies Antigen presenting cells; Extracellular vesicles/exosomes; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
696 Poster Presentation Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo Bryan M. Grogan, MS; Reice D. James, BS; Michelle Ulrich, BS; Shyra J. Gardai, PhD; Ryan Heiser, PhD; Reice D. James, BS; Novel Single-Agent Immunotherapies Antibody; Biomarkers; Immune suppression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor microenvironment
697 Poster Presentation Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors Michael Hedvat, PhD; Veronica Zeng, PhD; Juan Diaz, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Irene Leung, PhD; Norm Bartlow, PhD; Charles Bakhit; Matthew Dragovich, PhD; Liz Bogart, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; Gregory L. Moore, PhD; Novel Single-Agent Immunotherapies Antibody; Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
698 Poster Presentation Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody Douglas Hodges; Christina M. Kochel, PhD; Michael Totagrande; Jeffrey Jones; Megan Welch; Bradley N. Spatola, PhD; Shelby Joe; John A. Corbin, PhD; Vanessa B. Soros, PhD; Courtney Beers, PhD; Achim K. Moesta, PhD; Novel Single-Agent Immunotherapies Antibody; Checkpoint blockade; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; Tumor microenvironment
699 Poster Presentation A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models Ye Liu, Ph.D; Beibei Jiang; Tong Zhang; Zuobai Wang; Yingcai Feng; Haiying Li; Wenfeng Gong; Xing Wang; Yajuan Gao; Xiaosui Zhou; Bo Zhang; Yuan Hong; Jing Wang; Zilin Wang; Hongjia Hou; Hanzi Sun; Xiaomin Song, PhD; Kang Li; Xuesong Liu; Novel Single-Agent Immunotherapies Antibody; Costimulation; T cell
700 Poster Presentation EphA2/CD137 Bicycle tumor-targeted immune cell agonists (TICAsTM) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment Kristen E. Hurov, PhD; Johanna lahdenranta, PhD; Gemma Mudd, .; Punit Upadhyaya, PhD; Elizabeth M. Repash, MSc; Jun Ma, MSc; Julia Kristensson, .; Marianna Kleyman; Jessica Kublin; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Nicholas Keen, PhD; Novel Single-Agent Immunotherapies Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
701 Poster Presentation Nanoparticulate monobenzone (MBEH) as a potential drug candidate for melanoma Dinesh Jaishankar, PhD; Steven Henning; Anqi Zhang, PhD; Basar Bilgicer, PhD; SonBinh Nhuyen, PhD; I. Caroline Le Poole, PhD; Novel Single-Agent Immunotherapies Neoantigens; Solid tumors; T cell
702 Poster Presentation Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Zhongmin Maxwell Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; Novel Single-Agent Immunotherapies Antibody; Bispecifics; Checkpoint blockade; Immune monitoring; Immune suppression
703 Poster Presentation Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control in vivo Monique Kauke, PhD; Nikki Ross, PhD; Dalia Burzyn; Shelly Martin; Ke Xu; Nuruddeen Lewis; Charan Leng; Su Chul Jang, PhD; Christine McCoy; Stephanie Yu; Kevin Dooley; Sriram Sathyanarayanan, PhD; Jonathan Finn; Novel Single-Agent Immunotherapies Antibody; Antigen presenting cells; Dendritic cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Myeloid cells; Proteomics; Solid tumors
704 Poster Presentation Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models Kristel Kemper, PhD; Ellis Gielen; Mischa Houtkamp, PhD; Peter Boross; Saskia Burm, PhD; Stefanie A. De Poot; Patrick Engelberts; Bart E. de Goeij; David Satijn, PhD; Kate Sasser, PhD; Esther Breij, PhD; Novel Single-Agent Immunotherapies Antibody; Biomarkers; Bispecifics; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens
705 Poster Presentation Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) Andrew MacKinnon, PhD; Deepthi Bhupathi; Jason Chen; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD; Novel Single-Agent Immunotherapies Immune suppression; Metabolism; Solid tumors; T cell; Tumor microenvironment
706 Poster Presentation BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment Punit Upadhyaya, PhD; Kristen E. Hurov, PhD; Jessica Kublin; Jun Ma, MSc; Elizabeth M. Repash, MSc; Marianna Kleyman; Julia Kristensson, .; Drasti Kanakia; Fanglei You; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Johanna lahdenranta, PhD; Nicholas Keen, PhD; Novel Single-Agent Immunotherapies Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
707 Poster Presentation Discovery of a novel EP2 and EP4 dual antagonist Yeri Lee; Hyun Jin Kim; Donggeon Kim, DVM,PhD; Joo Youn Lee; Chang Soo Yun; Hyuk Lee; Young Sook Shin; Soo Bong Han; Sang Kyun Lim; Novel Single-Agent Immunotherapies Coinhibition; Dendritic cell; Immune suppression; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment
708 Poster Presentation Application of a novel mSENS drug delivery technology for mRNA therapeutics Sojin Lee, Dr.; Joon Young Park; Goo-Young Kim, Ph.D.; Sang Woo Jo; Minhyuk Yun; Hye Yeong Nam; Helen Cho; Novel Single-Agent Immunotherapies RNA; Solid tumors; T cell; Tumor antigens; Vaccine
709 Poster Presentation Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure Nuruddeen Lewis, PhD; Katherine Kirwin; Sonya Haupt; Gauri Mahimkar; Tong Zi; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Andrew Grube; Christine McCoy; Jorge Sanchez-Salazar; Michael Doherty; Scott Estes; Kyriakos Economides; Douglas E. Williams; Sriram Sathyanaryanan, PhD; Novel Single-Agent Immunotherapies Cytokine; Extracellular vesicles/exosomes; Immune adjuvant; NK/NK T cell; T cell
710 Poster Presentation Development of IL-33 as a novel immunotherapy of cancer Joshua Zhong; Runzi Sun; Binfeng Lu, PhD; Novel Single-Agent Immunotherapies Checkpoint blockade; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
711 Poster Presentation HBM1022, a Novel Anti-CCR8 Antibody Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity with Keytruda Shuang Lu, MS; Shaoping Hu; Xin Gan; Yongqiang Wang; Chuchu Zhao; Yi Ding; Jinqiu He; Qing Du; Xiaocheng Lv; Beibei Qin; Yun He; Lei Niu; Yuntao Wu; Fei Chen; Yuandong Wang; Yunxing Yang; Yang Cao; Musheng Bao; Jason Noon; Wenhao Yu; Juan Liu; Joe Zhao, PhD; Yiping Rong; Shuang Lu, MS; Novel Single-Agent Immunotherapies Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
712 Poster Presentation SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors Heather Metz, PhD; Ty Brender; Brenda Stevens; Damion Winship; Jamie Brevik; Michael Comeau; Monica Childs; Jenny R. Chang; Li-Qun Fan; Hengyu Xu; Jonathan Grey; Jeffrey Adamo; Ben Setter; Ray Carrillo; Sean W. Smith; Phil Tan; Robert E. DuBose; Yvette Latchman, PhD; Peter Baum; Valerie Odegard, PhD; Novel Single-Agent Immunotherapies Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
713 Poster Presentation Antibody-based approach of MT1-MMP metalloprotease inhibition results in decreased invasive properties of pancreatic cancer cells Nikita A. Mitkin, PhD; Alisa M. Gorbacheva; Alina S. Ustiugova; Aksinya N. Uvarova; Kirill V. Korneev; Vsevolod V. Pavshintsev, PhD; Nikita A. Mitkin, PhD; Novel Single-Agent Immunotherapies Antibody; B cell; Immune adjuvant; Inflammation; Tumor microenvironment
714 Poster Presentation PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, PhD; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD; Novel Single-Agent Immunotherapies Antibody; Bispecifics; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
715 Poster Presentation FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action Michelle Morrow, PhD; Mustapha Faroudi, PhD; Krishnendu Chakraborty, PhD; Wenjia Liao, BSc; Julia Winnewisser, PhD; Claire Seal, PhD; Daniel Gliddon, PhD; Neil Brewis, PhD, DSc; Novel Single-Agent Immunotherapies Antibody; Bispecifics; Checkpoint blockade; Coinhibition; T cell
716 Poster Presentation CELL-BASED VIROTHERAPY FOR TARGETING CANCERS Duong H. Nguyen; Alberto Gomez; Forrest Neuharth; Ashley Alamillo; Thomas Herrmann; Barbara Härtl; Laura Schneider; Ivelina Minev; Boris Minev, MD; Dobrin Draganov, PhD; Antonio F. Santidrian; Novel Single-Agent Immunotherapies Solid tumors; Stem cell/cancer-initiating cell; Tumor infiltrating lymphocytes (TILs); Vaccine
717 Poster Presentation AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy Katharina Lueckerath, Dr.; Julie M. Bailis, PhD; Kyle Current, BA; Mark E. Salvati, PhD; Caius Radu, MD; Johannes Czernin, MD; Novel Single-Agent Immunotherapies Bispecifics; Clinical trial; Solid tumors; T cell; Tumor antigens
718 Poster Presentation AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells Cong Li, PhD; Madeline Fort, PhD; Lingming Liang, MS; Gregory L. Moore, PhD; Matthew J. Bernett, PhD; Umesh Muchhal, PhD; Tao Osgood, BS; Rodolfo Yabut, BA; Sarav Kaliyaperumal, MPH, PhD; John Harrold, PhD; Jude Canon, PhD; Anna Rogojina, PhD; Raushan Kurmasheva, PhD; John R. Desjarlais, PhD; Peter Houghton, PhD; Olivier Nolan-Stevaux, PhD; Novel Single-Agent Immunotherapies Antibody; Bispecifics; Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens
719 Poster Presentation CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer Ryan M. Reyes, BS; Yilun Deng, MD, PhD; Deyi Zhang, PhD; Niannian Ji, PhD; Neelam Mukherjee, PhD; Karen Wheeler, MD PhD; Harshita B. Gupta, PhD; Aravind Kancharla, MS; Myrna G. Garcia, BS; Anand VR. Kornepati, BS; Robert S. Svatek, MD MSCI; Tyler J. Curiel, MD, MPH; Novel Single-Agent Immunotherapies Checkpoint blockade; Cytokine; NK/NKT cell; T cell; Tumor microenvironment
720 Poster Presentation Targeting MARCO and IL-37R on anti-inflammatory macrophages in lung cancer blocks regulatory T cells and shift balance to support cytotoxic lymphocyte function Linnéa La Fleur; Johan Botling; Fei He; Catarina Pelicano; Giorgia Palano; Artur Mezheyeuski; Patrick Micke; Jeffrey V. Ravetch, MD, PhD; Mikael Karlsson; Dhifaf Sarhan, PhD; Novel Single-Agent Immunotherapies Immune suppression; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment
721 Poster Presentation AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection Remko Schotte, PhD; Julien Villaudy, PhD; Martijn Kedde, PhD; Wouter Pos, PhD; Daniel Go; Christien Fatmawati; Gemma Moiset, PhD; Etsuko Yasuda; Madalina Cercel; Esmay Frankin; Susan van Hal; Pauline M. van Helden, PhD; Els Verdegaal, PhD; Sjoerd H. van der Burg, PhD; Hergen Spits, PhD; Hans van Eenennaam, PhD; Novel Single-Agent Immunotherapies Antibody; B cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
722 Poster Presentation Inhibition of Integrin avß8-Mediated TGF-ß Activation with C6D4 Provides Improved Potency and Selectivity vs General TGF-ß Inhibitors for Cancer Immunotherapy Robert Seed, PhD; Stephen Nishimura, MD; Robert Seed, PhD; Novel Single-Agent Immunotherapies Antibody; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
723 Poster Presentation Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; Novel Single-Agent Immunotherapies Immune adjuvant; T cell; Vaccine
724 Poster Presentation STAT3 inhibition in acute myeloid leukemia cells allows for TLR9-driven differentiation to immunogenic monocytic cells and induction of T-cell mediated immune responses Yu-Lin Su, PhD; Marcin Kortylewski, PhD; Priyanka Duttagupta, PhD; Novel Single-Agent Immunotherapies Antigen presenting cells; Bispecifics; Immune suppression; Leukemia/Lymphoma; MDSC; Monocyte/Macrophage; Myeloid cells; RNA; Targeted therapy; TLR
725 Poster Presentation Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy Linda Mårtensson, PhD; Mathilda Kovacek; Petra Holmkvist, PhD; Monika Semmrich, PhD; Carolin Svensson; Therese Blidberg; Carl Roos, PhD; Andres McAllister, MD, PhD; Mimoza Demiri, PhD; Marie Borggren, PhD; Ingrid Karlsson, PhD; Björn Frendeus, PhD; Ingrid Teige, PhD; Novel Single-Agent Immunotherapies Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
726 Poster Presentation SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC Andrew C. Lake, PhD; Michael C. Warren, MS; Sonia G. Das, PhD; Christopher C. Wells, BS; Maria Scrivens, BA; Ernest S. Smith, PhD; Vito J. Palombella, PhD; Bijan Etemad-Gilbertson, PhD; Pamela M. Holland, PhD; Austin Dulak, PhD; Novel Single-Agent Immunotherapies Antibody; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs)
727 Poster Presentation Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors Matthew P. Rausch, PhD; Devapregasan Moodley, PhD; Marisa O. Peluso, MS; Secil Koseoglu, PhD; Jing Hua, MD, MS; Gege Tan, MA; Ricard Masia, MD PhD; Benjamin H. Lee, MD PhD; Isabelle Cousineau, PhD; Simon Turcotte, MD MSc; John Stagg, PhD; Vito J. Palombella, PhD; Pamela M. Holland, PhD; Jonathan A. Hill, PhD; Novel Single-Agent Immunotherapies Antibody; Cytokine; Immune suppression; Myeloid cells; Tumor evasion
728 Poster Presentation Antibiotics and response to immunotherapy: Real-world experience Yasar Ahmed, MD, FRCP; Paula Calvert; Yasar Ahmed, MD, FRCP; Other Microbiome; Solid tumors
729 Poster Presentation The impact of immune and targeted therapies for Melanoma in Asian populations: A National Cancer Database analysis 2004-2016 Lifen Cao, MD PhD; Lifen Cao, MD PhD; Kavin Sugumar, MD; Ankit Mangla, MD; Megan E. Miller, MD; Luke D. Rothermel, MD MPH; Other Epidemiology
730 Poster Presentation Histotripsy focused ultrasound ablation induces immunological cell death in treated and distant untreated tumors Anutosh Ganguly, Ph.D; Ashley A. Pepple, MS; Reliza McGinnis; Ryan Hubbard; Amy E. Felsted, MD; Tejaswi Worlikar; Hannah Garavaglia; Joe Dib; Joe Guy; Michal Olszewski; Zhen Xu; Clifford S. Cho, MD, FACS; Other Inflammation; Solid tumors; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
731 Poster Presentation Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis Jonathan Kish; Jonathan Kish; Dhruv Chopra; Djibril Liassou; Solomon J. Lubinga, PhD; John Hartman; Bruce Feinberg; Regulatory - Financial - and Access Considerations Checkpoint blockade; Chemotherapy
732 Poster Presentation Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via a novel CMKRL1-mediated pathway Russell Pachynski, MD; Keith R. Rennier, PhD; Woo Jae Shin; Ethan Krug; Gurpal Virdi, BS; Russell Pachynski, MD; Tumor and Stromal Cell Biology Chemokine; Cytokine; Gene expression; Solid tumors; Tumor evasion
733 Poster Presentation Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy Evisa Gjini, PhD; Jimena Trillo-tinoco; Andrew Browne; Ryan Powles; Tai Wang; Christine Tauras; Ana Lako; Ruben Ferrer-Luna; Zoe Bleicher; timothy consedine; Chensheng Zhou; Evan Kelemen; anne lewin; Catherine King; sumit bhattacharya; harris bell-temin; ashok dongre; David Nelson; Christos Hatzis, PhD; Kenzie Macisaac; Fadi Towfic; Benjamin Chen, MD, PhD; Michaela Bowden, PhD; Evisa Gjini, PhD; Tumor and Stromal Cell Biology Biomarkers; Gene expression; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
734 Poster Presentation A novel NQO1 specific anti-tumor agent, SBSC-S3001, selectively regresses the growth of tumors with high NQO1 expression. Minhyuk Yun; Goo-Young Kim, Ph.D.; Sang Woo Jo; Changhoon In; Gyu-Young Moon; In Seok Ko; Eun Ju Lee; Yong Rae Hong; Whee Seong Lee; Helen Cho; Tumor and Stromal Cell Biology Chemotherapy; Gene expression; Immune monitoring; Metabolism
735 Poster Presentation Impact of reversing an epithelial-to-mesenchymal transition program on tumor metabolism and immune suppression Michelle M. Williams, Ph.D.; Jessica L. Christenson, Ph.D.; Kathleen I. O'Neill; Sabrina A. Hafeez; Nicole S. Spoelstra; Jill E. Slansky, PhD; Jennifer K. Richer, Ph.D.; Tumor and Stromal Cell Biology Immune suppression; Monocyte/Macrophage; Metabolism; Solid tumors; Tumor evasion
736 Poster Presentation MicroRNA expression patterns in melanomas originating from gynecologic sites Mallory J. DiVincenzo, DVM; Lorena Suarez-Kelly, MD; Maribelle Moufawad; Casey Ren; Zoe Barricklow; Paolo Fadda, PharmD; Lianbo Yu, PhD; Sarah Peters, MD; Alejandro A. Gru, MD; William E. Carson, III, MD, FACS; Tumor and Stromal Cell Biology Bioinformatics; Biomarkers; Cytokine; Epigenetics; Gene expression; RNA
737 Poster Presentation A novel humanized murine model to identify neoantigen-specific T cells in pediatric acute megakaryoblastic leukemia. Elizabeth A. Garfinkle, BS; Anthony E. Zamora, PhD; Jeremy C. Crawford, PhD; Paul G. Thomas, PhD; Tanja A. Gruber, MD, PhD; Tumor and Stromal Cell Biology Adoptive immunotherapy; Bioinformatics; Cytokine; Leukemia/Lymphoma; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs)
738 Poster Presentation Establishment and application of a series of genetically engineered mouse derived breast cancer homograft models Yanrui Song; Jessie J. Wang; Likun Zhang; Annie X. An; Henry Q. Li; Davy X. Ouyang, PhD; Tumor and Stromal Cell Biology Carcinogenesis; Immune monitoring; Solid tumors; Tumor microenvironment
739 Poster Presentation Development of Patient-Derived Models of Esophageal Cancer for GUCY2C-Directed Immunotherapeutic Testing Megan Weindorfer, BS; Amanda N. Lisby, MS; Alicja Zalewski, MD; Trevor R. Baybutt, BA; Robert Carlson, BS; Madison Crutcher, MD; David Loren, MD; Ernest Rosato, MD; Nathaniel Evans III, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; Tumor and Stromal Cell Biology Adoptive immunotherapy; CAR T cells; Carcinogenesis; Targeted therapy
740 Poster Presentation Biomarkers Diverging between Tumor Mutation Burden and Microsatellite Instability Jason Ding; Nihir Patel; Tumor and Stromal Cell Biology Bioinformatics; Biomarkers; Carcinogenesis; Epigenetics; Gene expression; Systems biology
741 Poster Presentation High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome Diana Bell; Achim Bell, PhD; Renata Ferrarotto, MD; Ehab Hanna; Diana Bell; Tumor and Stromal Cell Biology Inflammation; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
742 Poster Presentation Phosphopeptides are Increased in the MHC-I Immunopeptidome of Irradiated Human Breast Cancer Cells Samantha J. Van Nest, PhD, MS; Tomer M. Yaron; Martin G. Klatt; Noah Dephoure; Gad Getz, PhD; Laura Santambrogio; Olivier Elemento, PhD; David A. Scheinberg; Sandra Demaria, MD; Lewis C. Cantley; Tumor and Stromal Cell Biology Proteomics; Radiotherapy; Tumor antigens; Post-translational modifications
743 Poster Presentation High levels of stromal tumor infiltrating lymphocytes, CD3, CD8 cells & Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy. Bernardo L. Rapoport, MD, MMed; Jérôme Galon; Simon Nayler; Aurelie Fugon; Isabelle Boquet; Marine Martel; Mlecnik B; Teresa Smit; Carol Ann Benn; Farhana Moosa; Liezl Heyman; Ronald Anderson, Prof; Tumor and Stromal Cell Biology Biomarkers; Chemotherapy; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
744 Oral Presentation Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy Hussein Abbas; Dapeng Hao, Ph.D.; Katarzyna J. Tomczak; Praveen Barrodia; Jin Seon Im; Patrick Reville; Zoe Alaniz; Wei Wang; Ruiping Wang; Feng Wang, PhD; Gheath Al-Atrash; Koichi Takahashi, MD; Jing Ning; Maomao Ding; Jairo Matthews; Latasha Little, BS; Jianhua Zhang; Sreyashi Basu; Marina Konopleva; Guillermo Garcia-Manero, MD; Michael R. Green, PhD; Padmanee Sharma, MD, PhD; James P. Allison, PhD; Steven M. Kornblau, MD; Kunal Rai; Linghua Wang, PhD; Naval Daver, MD; Andrew Futreal; Tumor and Stromal Cell Biology Bioinformatics; Checkpoint blockade; Immune contexture; Immune monitoring; Immune tolerance; Leukemia/Lymphoma; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
745 Poster Presentation High throughput tissue imaging and phenotyping by streamlined 8-plex staining and analysis of complex TMA samples Amanda J. Bares, PhD; Marie Cumberbatch; Lorcan Sherry, PhD; Christopher Womack; Milan Bhagat; Angela Vasaturo, PhD; Mael Manesse, PhD; Tumor and Stromal Cell Biology Antibody; Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
746 Poster Presentation Non Small-Cell Lung Cancer cells and cancer-associated fibroblasts drive macrophage polarization in a novel co-culture model Josiah Flaming, B.S.; Raghav Chandra; Luc Girard, Ph.D.; Debolina Ganguly, M.S.; Jason Toombs, B.S.; John D. Minna, M.D.; Rolf A. Brekken, Ph.D.; Tumor and Stromal Cell Biology Cytokine; Gene expression; Immune suppression; Immune tolerance; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor evasion; Tumor microenvironment; Tumor stroma
747 Poster Presentation Evaluation of immune microenvironment of primary lung cancer and synchronous liver metastasis with multispectral imaging system Hyeonbin Cho; Jae-Hwan Kim, PhD; Ji-Hyun Kim; Tumor and Stromal Cell Biology Biomarkers; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma
748 Poster Presentation Myeloid Cell Infiltration Correlates with Prognosis and Varies Based on Tumor Location in Cholangiocarcinoma Sean C. Dougherty, MD; Paul R. Kunk, MD; Sean C. Dougherty, MD; Tumor and Stromal Cell Biology Antigen presenting cells; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
749 Poster Presentation Spatial profiling of the tumour microenvironment in head and neck cancer to identify biomarkers of response to therapy Arutha J. Kulasinghe, PhD; Tumor and Stromal Cell Biology Biomarkers; Checkpoint blockade; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
750 Poster Presentation Malat1 lncRNA Controls Metastatic Reactivation of Dormant Breast Cancer by Immune Evasion Dhiraj Kumar, PhD; Sreeharsha Gurrapu, PhD; Hyunho Han, MD, PhD; Yan Wang, MD, PhD; Seongyeon Bae, PhD; Hong Chen, PhD; Chang-Jiun Wu, PhD; Filippo Giancotti, MD, PhD; Tumor and Stromal Cell Biology Immune monitoring; Immune toxicity; Inflammation; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; RNA
752 Poster Presentation The impact of grade of differentiation and BRAF mutation status on neoantigen and immune landscape in papillary thyroid cancer Myungwoo Nam, MD; Woojung Yang; Ju Young Lee, MD; Jaeyoun Choi, M.D.; Hansol Choi; Emma Yu; Eugene Kim; Jin Young Hwang; William H. Bae; Chan Mi Jung; Victor Wang; Jeffrey Chuang; Young Kwang Chae; Tumor and Stromal Cell Biology Gene expression; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
753 Poster Presentation The immune landscape of papillary thyroid cancer and its association with neoantigen landscape and DNA repair gene mutations Myungwoo Nam, MD; Woojung Yang; Ju Young Lee, MD; Jaeyoun Choi, M.D.; Hansol Choi; Eugene Kim; Emma Yu; Jin Young Hwang; William H. Bae; Chan Mi Jung; Victor Wang; Jeffrey Chuang; Young Kwang Chae; Tumor and Stromal Cell Biology Gene expression; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
754 Poster Presentation Dysregulation of soluble immune checkpoint proteins in newly - diagnosed early breast cancer patients. Bernardo L. Rapoport, MD, MMed; Helen Steel; Simon Nayler; Teresa Smit; Liezl Heyman; Annette Theron; Nomsa Hlatswayo; Luyanda Kwofie; Carol Ann Benn; Lidia jooste; Ronald Anderson, Prof; Tumor and Stromal Cell Biology Biomarkers; Chemokine; Chemotherapy; Costimulation; Cytokine; Immune suppression; Solid tumors; Tumor microenvironment
755 Oral Presentation CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity Alvaro Teijeira; Saray Garasa, BS; Itziar Migueliz; Assunta Cirella; Ignacio J. Melero, Dr., MD, PhD; Alvaro Teijeira; Tumor and Stromal Cell Biology Chemokine; Granulocyte; Myeloid cells; MDSC; Tumor microenvironment
756 Poster Presentation Assessment of the immune checkpoint landscape in head and neck squamous cell carcinoma by single-cell RNA sequencing and multispectral imaging Lazar Vujanovic, PhD; Aditi Kulkarni; Cornelius Kürten, MD; Anthony R. Cillo, PhD; Patricia M. Santos, PhD; Stephan Lang; Uma Duvvuri, MD PhD.; Seungwon Kim, MD; Heath Skinner; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Riyue Bao, PhD; Robert L. Ferris, MD, PhD; Tumor and Stromal Cell Biology Gene expression; Immune contexture; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma